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Abstract i
Abstract
Gout is a painful form of inflammatory arthritis that is caused by the deposition
of monosodium urate (MSU) crystals in the joints. MSU crystals trigger a local
inflammatory response initiated by resident macrophages followed by a large infil-
tration of leukocytes. The spontaneous resolution of acute gout is associated with
the production of transforming growth factor β1 (TGFβ1). The overall objectives
of this thesis were to investigate mechanisms that lead to TGFβ1 production and
contribute to the resolution of acute gout, the effect of TGFβ1 on the functional
phenotype of differentiated macrophages, and possible changes in surface marker
expression by macrophages in response to MSU crystals.
To determine macrophage-independent sources of TGFβ1 during the resolution of
acute gout and how TGFβ1 production altered MSU crystal-recruited neutrophil
functions, neutrophils were purified from MSU crystal-treated mice when levels of
TGFβ1 were high. MSU crystal-recruited neutrophils and circulating blood neu-
trophils were identified as TGFβ1+ cells. The mechanism for TGFβ1 production by
neutrophils was associated with their ability to phagocytose apoptotic neutrophils.
TGFβ1 produced by canibalising neutrophils inhibited both respiratory burst and
interleukin-1β (IL-1β) production by MSU crystal-activated neutrophils ex vivo.
Importantly, neutrophils from MSU crystal-challenged mice treated with TGFβ1
neutralising antibody in vivo produced elevated levels of superoxide but neutrophil
IL-1β production was unaffected. These results show that TGFβ1 produced by
canibalising neutrophils can actively suppress neutrophil inflammatory functions
and therefore make a significant contribution towards the resolution of gouty in-
flammation.
To investigate the effect of TGFβ1 on macrophage differentiation in vitro, granulo-
cyte macrophage colony-stimulating factor (GM-CSF) bone marrow macrophages
(GM-BMMs) and macrophage colony-stimulating factor (M-CSF) bone marrow
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macrophages (M-BMMs) were generated in the presence of TGFβ1. TGFβ1 was
found to drive a hyper-inflammatory GM-BMM phenotype, while contributing to the
differentiation of a hypo-inflammatory M-BMM phenotype specifically in response
to MSU crystals. Increased IL-1β production by TGFβ1-differentiated GM-BMMs
was associated with enhanced NOD like receptor family, pyrin domain-containing
3 (NLRP3) inflammasome activation and caspase 1/caspase 8 interaction, and a
down-regulation of receptor-interacting serine/threonine-protein kinase 3 (RIP3)
triggered by MSU crystals. At the same, TGFβ1 inhibited antigen-specific T cell
proliferation by GM-BMMs. In contrast, TGFβ1-treated M-BMMs down-regulated
the expression of active IL-1β that correlated with decreased IL-1β production, and
upregulated RIP3 expression in response to MSU crystals. These data indicate that
TGFβ1-treated GM-BMMs exhibited a hyper-inflammatory response to MSU crys-
tal stimulation, whereas M-BMMs were found to be hypo-responsive.
Macrophages were found to upregulate the surface marker NK1.1, which is pri-
marily expressed on natural killer (NK) cells, and occured as a consequence of
phagocytosis. Following phagocytosis of MSU crystals, activated macrophages pro-
duced IL-1β and tumour necrosis factor α (TNFα), which triggered the upregulation
of NK1.1 expression. Macrophage NK1.1 expression is an activation-driven event
specific to MSU crystals. However, phagocytosis of apoptotic neutrophils also trig-
gered the upregulation of NK1.1 by macrophages, a non-inflammatory event that is
characteristic for the resolution of acute inflammation. These findings suggest that
macrophages may develop NK cell-like properties initiated by an activation-driven
or apoptotic cell clearance mechanism.
Taken together, the results of this thesis indicate that canibalising neutrophils self-
regulate their inflammatory functions via TGFβ1 and that TGFβ1 drives a hyper-
inflammatory GM-BMM phenotype, while shutting down inflammatory functions
of M-BMMs. These data highlight a regulatory role for TGFβ1 during acute gouty
inflammation.
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Chapter 1: General Introduction 1
1 Acute Gouty Arthritis, an Autoinflammatory
Disease
1.1 History of gout
Gout is a painful arthritic disease that manifests as episodic and debilitating joint
inflammation. The ancient Egyptian Imhoteb observed and investigated gout as a
distinct disorder in as early as 2640BC [1]. Several centuries later (400BC) Hip-
pocrates, the father of Western medicine, described gout as podagra or the disease
of kings, for it was associated with changes in lifestyle and social wealth [1]. In
the present day, the prevalence of gout is dramatically increasing across all socio-
economic groups in western societies [2; 1; 3]. The incidence of gout in the US
increased from 2.9/1000 in 1990 to 5.2/1000 in 1999 [2; 4] and in 2007 approxi-
mately 8.3 million US adults have had at least one gout attack [5]. In a study based
in England, the prevalence of gout was estimated at 9.5/1000 in 1995 [6]. Previous
sub-national studieshave demonstrated high prevalence of gout in the entire New
Zealand population [7; 8; 9; 10; 11], particularly among Maori and Pacific people
(>7% in all adult males and >30% in older Maori and Pacific men, December 2009)
[12]. These statistics emphasize the rising incidence of gout worldwide. Gout suffer-
ers experience debilitating high morbidity and poor quality of life [13]. This impacts
significantly on their ability to work and the increasing incidence of gout presents a
significant collective burden of disease. A more clear understanding of the inflam-
matory mechanisms in gout is required to treat and manage the disease effectively.
This thesis will provide a significant advance in the understanding of the cellular
events that characterise acute gouty inflammation.
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1.2 Monosodium urate crystals
Monosodium urate (MSU) crystals have been described and observed in affected
joints from gout patients throughout history [11], however it was not until 1962
that Faires and McCarty confirmed MSU crystals as the causative agent in gout
attacks. Using synthetically prepared MSU crystals, they injected crystals into the
synovial space of their own knees resulting in a gout attack [14].
MSU crystals are the biological form of crystalline uric acid. They range in size
from 10 - 25 µm in length, appear needle-like in shape and have the ability to po-
larise light, a quality known as birefringence (Figure 1.1). MSU crystals can be
identified in the synovial fluid of gout patients even after the gout attack has re-
solved and there is no evidence for clinical inflammation [15; 16]. Once uric acid
has crystallised in the joints, it takes a long time for MSU crystals to be redissolved
by the body.
A B
Figure 1.1: Monosodium urate crystals. Monosodium urate (MSU) crystals
as visualised under a microscope in normal (A) and polarised (B) light fields. Pictures
provided by Dr William-John Martin.
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1.3 Acute and chronic gout
Acute gout is characterised by sudden and periodic attacks of inflammation occur-
ring in one or more joints, which cause severe pain. The deposition of MSU crystals
in the joints triggers an acute inflammatory response characterised by swelling, ten-
derness and redness of the affected joints and tissues (Figure 1.2A). Patients often
suffer from fever and chills, which usually takes 6 - 12 hours to develop. These
symptoms are associated with the intense influx of leukocytes into the local area.
An untreated gout attack will spontaneously resolve within 7 - 10 days [17], however
some individuals will never experience complete freedom from the ongoing chronic
pain associated with periodic gout attacks, which are known as gout flares [18].
Over several years, the poor management of acute gout may lead to chronic topha-
ceous gout. This stage is characterised by the accumulation of MSU crystals and
immune cells, collectively called tophi, in the joints or soft tissue (Figure 1.2B). The
formation of tophi leads to polyarticular bone erosions and deformations resulting
in severe tissue and bone damage [19].
A B
Figure 1.2: Acute and chronic gout. Joint/big toe from patients with acute
(A) and chronic tophaceous gout (B). The black arrow indicates the deposition of MSU
crystals (tophus), which ruptured through the skin and caused ulceration. Pictures used
with permission from PHARMAC, NZ.
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1.4 Uric acid
One of the main predictors of gout risk and development is the concentration of
urate in the serum. Uric acid (UA) is the final product of the purine metabolic
pathway in the human body. Purines are an important building block required for
deoxyribonucleic acid (DNA) and energy carrying molecules, nicotinamide adenine
dinucleotide phosphate (NADPH) and adenosine triphosphate (ATP). In humans,
one-third of urate, which is deprotonated uric acid, is excreted via the gastrointesti-
nal tract and two-thirds via the kidneys [20]. About 90% of the uric acid filtered
by the kidneys is reabsorbed and this process is mediated by specific transporters
including urate transporter-1 (URAT-1) [21].
Most mammals, except humans, have uricase or uric acid oxidase, an enzyme re-
sponsible for the regulation and breakdown of uric acid into a more soluble molecule
allantoin [22]. This explains why urate levels are much higher in humans and why
gout is mainly a human disease.
Normal serum urate levels are between 0.14 - 0.36 mM in women and 0.20 - 0.42
mM in men [23]. Clinical hyperuricemia is diagnosed when serum urate levels ex-
ceed 0.42 mM, which is approximately the saturation point for uric acid solubility
[24]. Such high serum uric acid levels means that individuals have a greater risk of
experiencing a gout attack.
1.5 Gout risk factors
1.5.1 Hyperuricemia
Although hyperuricemia is a risk factor for the development of gout, only 25% of
individuals with elevated circulating urate levels develop gout [24; 25; 26; 27]. Some
individuals can be in the state of asymptomatic hyperuricemia for several years
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before suffering a gout attack. These observations suggest that the process from
hyperuricemia to MSU crystal formation to inflammation has additional regulatory
mechanisms, which are still not fully understood.
1.5.2 Gender and age
Gout is the most common cause of inflammatory arthritis among men over 40 years
[28]. In fact, the incidence of gout in men is four times higher than that observed
in women [29]. This is possibly due to the uricosuric effect of estrogen, which may
help the kidneys to excrete uric acid, and is consistent with the observation that
it is rare for women to suffer from gout during menopause [30]. Testosterone has
been shown to increase the expression of the genes URAT-1 and glucose transporter
9 (GLUT9) [31; 32], which indicates that gender differences in serum urate levels
are associated with the renal urate reabsorption transport system and that this is
a possible causative factor for hyperuricemia and gout in males. However, the risk
of gout increases with age due to a decrease in renal functions by the elderly and
is further complicated by some medications commonly used by the elderly to treat
other co-morbid conditions, which have diuretic side effect or can raise serum urate
levels [2; 33].
1.5.3 Diet
Throughout history, gout epidemics have been observed in periods of social wealth.
The consumption of purine-rich food including shellfish, seafood (trout, sardines),
red meat, offal foods (liver, heart, kidney), mushrooms, alcohol and fructose-rich
beverages are associated with the development of gout attacks [34; 35; 36; 37]. For
example, fructose contributes to increased uric acid levels by interfering with ATP
recycling, degrading it to uric acid rather than to ADP then ATP [38; 39]. On the
other hand, the intake of dairy food seems to be protective [40; 41].
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1.5.4 Genetics
Gout is often a familial disease. Studies using a genome-wide search have identi-
fied two genes: URAT-1 and GLUT9, which are linked with urate reabsorption and
have a strong influence on the regulation of renal urate excretion [42; 43; 44; 45].
A particular allele of GLUT9 has been associated with reduced serum urate levels
in Italian, UK, German and Croatian populations suggesting that genetic polymor-
phism or mutations of urate transporters contribute to the development of hyper-
uricemia and gout [46; 47; 48]. Koettgen and colleagues have now identified 18 new
loci (such as VEGFA, NFAT5 or TRIM46) using data from <140.000 individuals
of European ancestry, that are associated with serum urate concentrations, which
may have implications for the treatment and prevention of gout [49].
1.6 Treatment and management of gout
Due to the intensity of the inflammatory response characterising a gout attack, treat-
ments are needed to control acute gouty inflammation and to control hyperuricemia,
the precursor to the formation of MSU crystals. Currently, there are two approaches
for managing gout: anti-inflammatory drugs and urate lowering therapy.
1.6.1 Anti-inflammatory drugs
Due to the intensity of inflammatory reactions characterising a gout attack, anti-
inflammatory agents are primarily used for treating acute gout. This includes the
use of glucocorticoids, although non-steroidal anti-inflammatory drugs (NSAIDs)
such as indomethacin, etoricoxib, naproxen and ibuprofen are the preferred treat-
ment option [26; 50; 51]. NSAIDs provide marked symptomatic relief within the
first 24 hours of administration and are the first drug of choice in gout patients who
do not have contraindications against their use [52; 53; 54].
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Alternative treatment options to NSAIDs are prednisolone or colchicine, which
are used to treat acute gout episodes. The use of oral prednisolone for the treat-
ment of acute gout flares has been shown to be as effective in pain reduction as
NSAIDs [55; 56; 57]. Colchicine has a number of therapeutic activities includ-
ing reducing neutrophil activity and migration by blocking microtubule assembly,
phagocytosis and transport of MSU crystals, and reducing adhesion molecules on
endothelial cells in response to interleukin-1β (IL-1β) and tumor necrosis factor α
(TNFα) [58; 59; 60]. Recently, it has also been demonstrated that colchicine can
suppress MSU crystal-induced NLRP3 inflammasome activation and IL-1β process-
ing [61; 62]. Colchicine, however has a narrow therapeutic window (24 hours) as a
number of complications can occur during treatment, such as diarrhea, fever, gas-
trointestinal toxicity and vomiting [63; 64; 65; 54].
Among new therapies for gout, anti-cytokine agents have been explored by tar-
geting the first step in the inflammatory cascade. Due to the central role of IL-1β
and the inflammasome in gout, drugs such as canakinumab and triamcinolone ace-
tonide have been developed and studied in acute gout patients with successful results
showing pain and inflammation relief as well as reduced risk of new gout flares in
these patients [66]. These drugs have been found to inhibit IL-1β and inflammasome
functions [67; 68], yet although, anti-IL-1 treatment seems to be highly effective, the
main limitation of these drugs is that they are extremely expensive.
1.6.2 Urate lowering therapy
The aim of urate lowering therapy (ULT) is to reduce and maintain serum urate
levels below 0.36 mmol/L, the saturation point at which crystal formation occurs.
ULT drugs accomplish their effect by either lowering the production of uric acid
(uricostatic drugs) or by increasing the renal excretion of uric acid (uricosuric drugs).
The uricostatic drug allopurinol has been widely used as an effective ULT treatment,
however about 20% of patients with gout are intolerant or refractory to this drug
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[69; 70]. For such patients, an appropriate alternative is febuxostat - a drug that
selectively inhibits the xanthine-oxidase breakdown to uric acid [70]. Uricosuric
drugs, such as probenecid, sulfinpyrazone, benzbromarone and lesinurad, prevent
the reabsorption of uric acid by the kidneys and thus increase the excretion of uric
acid [71; 44; 45]. Uricosuric drugs have shown good responses with good tolerability
in patients suffering from gout [72].
1.7 Cellular inflammation in acute gout
Inflammation often results from exposure to external stimuli, however, auto-inflamm-
atory conditions also occur when inflammation is initiated by self danger signals [73].
Such sterile inflammation is triggered by diseases including acute gouty arthritis,
whereby the deposition of MSU crystals in the joints induces a rapid infiltration
of cells. This can lead to chronic inflammation resulting in severe tissue and bone
damage. While some of the important cells and cellular mediators in acute gout
have been identified, much remains unknown. This section will highlight what is
currently known about cellular responses in acute gouty inflammation.
1.7.1 Cell activation in acute inflammation
During the initiation of a gout attack, resident cells recognise and respond to MSU
crystals. The activation of resident cells including macrophages, mast cells and
epithelial cells have been shown to produce pro-inflammatory cytokines (such as IL-
1β, TNFα and IL-6) that amplify the local inflammatory reaction [62; 74; 75; 76].
Complement proteins and various chemoattractants (such as MCP-1, IL-8) are also
thought to be involved in the activation and recruitment of circulating leukocytes
into the joint synovial space [77; 78; 79; 80]. These mediators upregulate adhesion
molecules on both the epithelial cells and responding leukocytes, driving further
infiltration of neutrophils and monocytes to the site of inflammation. Neutrophils,
once recruited may also be directly activated by MSU crystals to recruit more neu-
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trophils through the production of IL-8 and S100 proteins [81; 82].
In addition, natural killer (NK) cells can also interact with cells of the innate immune
system and modulate gouty inflammation [83]. Recently, it has been demonstrated
that the CD56bright subset of NK cells is greatly expanded in the synovial fluid of
patients with inflammatory arthritis [84] and can produce large amounts of both
pro- and anti-inflammatory cytokines. In a reciprocal contact-dependent activation
interface, CD56bright NK cells were capable of engaging with monocytes [85], thus
indicating the existence of a positive feedback loop that could contribute to the am-
plification of the inflammatory response in acute gout [84]. It is not known whether
macrophages develop NK cell-like functions, such as lytic properties or expression
of specific NK cell markers in response to MSU crystals or whether these functions
play a role in augmenting or shutting down acute gouty inflammation.
1.7.2 Recognition of MSU crystals as a danger signal
I: Immune cell recognition of MSU crystals
To promote the generation of an immune response, microbial and yeast cell wall
components or viral RNA typically provide the required signals that alert the im-
mune system to danger [86]. In the absence of such signals, there is often no immune
defence response or tolerance may develop [87]. Therefore, a danger signal or ad-
juvant must be present with the foreign antigen in order to prime the production
of cytokines via signalling through, for example toll like receptors (TLRs) on resi-
dent cells, and to augment an inflammatory response [87; 86]. As a non-infectious
agent, MSU crystals were recently described as an endogenous danger signal or ad-
juvant capable of inducing an inflammatory response. Reports have shown that uric
acid released from locally damaged or dead cells acts as a danger signal to antigen-
presenting cells such as dendritic cells (DCs) to drive T cell proliferation [88; 89; 90].
This adjuvant effect only occured when uric acid was present at a high concentration
consistent with the saturation point for crystallisation. Further studies have shown
Chapter 1: General Introduction 10
that subcutaneous administration of MSU crystals exhibited adjuvant activities by
enhancing the tumor rejection process in vivo [91; 92]. These data indicate that
uric acid and/or MSU crystals have the potential to function as an antigen carrier,
adjuvant and danger signal to initiate and augment inflammatory immune responses.
II: Recognition of MSU crystals by innate cells
In order for inflammation to occur, innate cells need to recognise MSU crystals.
There is evidence that complement found in the synovial fluid plays a role in the
inflammatory response to MSU crystals [93]. In the joints of complement-deficient
rabbits, resident macrophages fail to recognise MSU crystals, which results in de-
creased production of the neutrophil chemoattractant CXCL1 and diminished infil-
tration of neutrophils after MSU crystal administration [78]. In vitro experiments
with human serum have shown that MSU crystals are able to activate a variety of
complement proteins (such as C1, C3, C5); therefore may play a role in the produc-
tion of chemokines by cells in the synovial membrane [79; 77; 94; 95]. In addition,
pre-coating MSU crystals with immunoglobulin G (IgG) can cause an increase in the
production of reactive oxygen species (ROS) in human polymorphonuclear leuko-
cytes in vitro [82]. These data indicate that complement binding to MSU crystals
can activate both resident macrophages and infiltrating neutrophils. However, even
in the absence of serum, MSU crystals are still able to activate immune cells to
produce pro-inflammatory mediators indicating a direct recognition mechanism of
MSU crystals by innate cells [80].
Currently, the receptors responsible for MSU crystal recognition are not defini-
tively defined. There is evidence to suggest that the pattern recognition receptors
TLR2/TLR4 as well as the adaptor molecule CD14 are involved in crystal recog-
nition. Bone marrow-derived macrophages from CD14 knockout mice exhibit im-
paired recognition and phagocytosis of MSU crystals in vitro [96]. In a murine air
pouch model, Scott and colleagues demonstrated that TLR2/TLR4 deficiency re-
sulted in decreased IL-1β production and neutrophil infiltration in response to MSU
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crystals [58]. These data show that MSU crystals can directly bind to CD14 and
TLR2/TLR4 to induce an inflammatory response [58].
In contrast, a recent study has shown that MSU crystal-induced inflammation is
mediated by the IL-1 receptor (IL-1R) and MyD88 signalling pathways rather than
the TLRs on non-hemopoietic cells [97]. This study suggests that even though
CD14 plays a role in MSU crystal recognition by macrophages, CD14-dependent
signalling via MyD88 is essential for the production of pro-inflammatory cytokines
upon MSU crystal stimulation. The expression of IL-1R on non-hemopoietic cells
indicates that the surrounding tissue is important for the amplification of the MSU
crystal inflammatory response.
1.7.3 Cytokines and chemokines in MSU crystal-induced inflammation
During acute gout attacks, innate cells stimulated with MSU crystals produce in-
flammatory mediators. MSU crystal-activated human neutrophils and monocytes
produce large amounts of the chemokine IL-8, responsible for recruitment and prim-
ing of neutrophils via the IL-8 receptor (CXCR-2) [98; 99]. Previous animal stud-
ies have shown that CXCL1 and IL-1β are required for neutrophil recruitment
[97; 61] while other pleiotropic mediators, such as granulocyte macrophage colony-
stimulating factor (GM-CSF) [100], S100 proteins [81] and complement proteins [80],
may also contribute to immune cell recruitment. MSU crystal-stimulated monocytes
have been shown to produce TNFα and IL-1β, which prime neutrophils to produce
reactive oxygen species (ROS) and augment their recruitment by upregulating the
expression of adhesion molecules on endothelial cells [101; 102]. In addition, mono-
cyte recruitment from the bone marrow to the site of inflammation is partially
driven by MCP-1, a chemoattractant produced by resident cells [103; 104; 105].
Hence, there are a number of cytokines contributing to the onset and initiation of
the inflammatory response in gout.
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IL-1β and the inflammasome
MSU crystals stimulate macrophages to secrete the pro-inflamamtory cytokine IL-1β
[61] that has been shown to play a pivotal role in gouty inflammation whereby the
blockade of IL-1β abrogates inflammation [97]. The cleavage of preformed stores
of pro-IL-1β into active IL-1β requires the assembly of a multi-protein complex
referred to as the inflammasome [106]. In macrophages, the inflammasome is com-
prised of the intracellular pattern recognition receptor NACHT-LRR-PYD contain-
ing protein-3 (NLRP3), the accessory protein ASC and pro-caspase 1 [107]. Fol-
lowing activation by MSU crystals, the NLRP3 oligomerises and recruits ASC, then
binds to pro-caspase 1 resulting in autocatalytic processing and activation [108].
Caspase 1 activation leads to pro-IL-1β cleavage and the secretion of active IL-1β
from the cell, as illustrated in Figure 1.3. The pro-inflammatory cascade is further
amplified after binding of IL-1β to IL-1R expressed on macrophages, endothelial
cells, and neutrophils [97; 109; 110].
Recent studies demonstrated that mice deficient in components of the inflammasome
or in IL-1R showed impaired neutrophil recruitment in vivo [97; 61]. Furthermore,
using a combination of mouse knockouts and bone marrow chimeras, MyD88 sig-
nalling induced by IL-1R engagement on non-hematopoietic cells has been shown to
be essential for the activity of IL-1β in neutrophil recruitment [97; 102]. These ob-
servations suggest that it is the non-hematopoietic cells in the peritoneum including
endothelial cells and fibroblasts that respond to IL-1β, while bone marrow-derived
monocytes and macrophages are the primary source of IL-1β. In addition, the
blockade of IL-1β leads to dramatic improvement of symptoms in patients with
gout [67; 68]. Collectively, these in vitro and in vivo animal studies have identified
gout as an IL-1β-dependent auto-inflammatory disease. This has also been con-
firmed by clinical studies, which address the therapeutic effect of IL-1β blockade
[111; 112].
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Figure 1.3: Schematic representation of the inflammasome - IL-1β sig-
nalling cascade. The uptake of MSU crystals by macrophages leads to the activation
of the inflammasome assembly, which triggers active caspase 1 to cleave pro-IL-1β into its
active form followed by IL-1β secretion.
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1.8 Key innate cells in gout
The key cells involved in acute gouty inflammation are proposed to be neutrophils,
monocytes and macrophages. Macrophages and monocytes are the main source of
cytokine and chemokine production in gout, while activated neutrophils produce
inflammatory mediators such as ROS that augment the inflammatory response and
cause tissue damage. Due to their important functional activities, these three cell
types will be the focus of this section.
1.8.1 Neutrophils in acute gout
Neutrophils, which are also referred to as polymorphonuclear leukocytes (PMNs),
comprise 50 - 70% of circulating white blood cells in humans. When released from
the bone marrow under homeostatic conditions, neutrophils have a very short life
span and undergo apoptosis within 6 - 10 hours [113; 114] and are subsequently
cleared from the circulation by liver and splenic macrophages [115].
I. Neutrophil recruitment
Neutrophils are usually the first cells recruited to the site of tissue damage or in-
fection, and accumulate in high numbers, an important event in immune responses
against invading pathogens [116; 117]. Once recruited, their role involves the uptake
of pathogens and debris, and they produce hazardous molecules to kill and digest
foreign organisms [118]. Recently, the formation of extracellular neutrophil traps
(NETs) by neutrophils has been reported as an effective mechanism to trap and
kill microbes to avoid the spreading of potential pathogens, thereby promoting the
defence against infections [119; 120].
The identification of neutrophils in the synovial fluid is a hallmark for the diagnosis
of acute gout. Here, cytokines and chemokines have been shown to strongly partici-
pate in neutrophil recruitment. Animal models of gout have demonstrated that IL-8
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receptor (CXCR-2) [98] and IL-1β [97; 61; 121] are required for neutrophil recruit-
ment, while other molecules such as TNFα, GM-CSF [100], S100A8 and S100A9 [81]
and complement proteins [78; 80] are thought to augment neutrophil mobilisation.
IL-1β and TNFα, mainly produced by MSU crystal-activated resident macrophages
and monocytes, have been shown to upregulate the adhesion molecules E-selectin,
intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1) by human endothelial cells allowing tethering of neutrophils to endothe-
lial cells in vitro [102]. Additionally, a role for E-selectin expressed on endothelial
cells in supporting neutrophil recruitment has also been shown in in vivo animal
models of MSU crystal-induced inflammation [122; 123]. These data indicate that
neutrophil recruitment is dependent on a number of cell types contributing to the
acute inflammatory response.
II. Neutrophil activation
Neutrophil infiltrating the inflamed joints encounter and recognise MSU crystals,
which results in their activation and subsequent amplification of inflammation, as
illustrated in Figure 1.4. Neutrophil activation by MSU crystals has been proposed
to be mediated by FcgRIIIB and the β2-integrin CD11b receptor [124]. On the other
hand, the recognition of MSU crystals via TLR2 or TLR4, as previously shown for
monocytes/macrophages, has not been assessed for neutrophils [96]. In vitro stud-
ies have shown that the tyrosine phosphatidylation pathways are important in the
activation of human neutrophils by MSU crystals [125; 126; 127; 128].
III. Neutrophil function
Neutrophils exert their detrimental role in acute gouty inflammation through the
release of inflammatory mediators including ROS, IL-1β, IL-6, IL-8 and S100A8/A9,
and granule constitutes such as proteolytic enzymes and antimicrobial peptides
[117; 129], as illustrated in Figure 1.4. Recently, a novel function of neutrophils
has been described in gout: the release of NETs [130]. The formation of NETs by
MSU crystal-activated neutrophils in vitro is linked with IL-1β and ROS production
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as well as autophagy [130; 131]. Analysis of synovial fluid and tissue sections from
gout patients revealed that NETs can be formed in vivo, thereby promoting the in-
flammatory response [131; 130]. Within the inflamed tissue, exposure to cytokines
(such as IL-1β, TNFα and IFNγ), growth factors (such as G-CSF and GM-CSF)
and MSU crystals have been shown to activate and subsequently prolong the half-
life of recruited neutrophils from hours to days in vitro [132]. This may result in the
accumulation of neutrophils within the inflamed environment in order to induce a
prolonged pro-inflammatory response. Despite the prolonged lifespan of neutrophils
treated with MSU crystals, a study has reported that phagocytosis of crystals by
neutrophils results in the destabilisation of the phagosome and the leakage of lyso-
somal enzymes into the cytosol, which results in necrotic cell death and subsequent
tissue damage [133] (Figure 1.4). Therefore, a major area of investigation is how
neutrophils fit into the network of an inflammatory response and how their pro-
inflammatory functions can be controlled to shut down acute inflammation.
1.8.2 Monocytes in gout
I. Monocyte populations and functions
Monocytes are phagocytic mononuclear cells and are thought to play a central role in
gout. Two circulating monocyte populations have been identified expressing either
low or high levels of Gr-1 in mice (CD14low or CD14high in humans) [134]. The Gr-
1low monocytes referred to as resident monocytes have the ability to remain within
the bloodstream during homeostasis [134; 135]. Under steady-state conditions, this
population migrates between bloodstream and tissue to sample the environment for
danger signals [135]. The Gr-1high inflammatory monocytes are recruited in large
numbers to the site of inflammation via MCP-1 [134; 135]. In vitro studies have
shown that murine monocyte-macrophage cell lines, which were exposed to MSU
crystals produce TNFα and IL-1β [136; 137]. Freshly isolated human CD14+ blood
monocytes produced TNFα and IL-1β when stimulated with MSU crystals, indi-
cating that monocytes contribute to gouty inflammation [137; 138]. In contrast,
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Figure 1.4: Schematic representation of activated neutrophils by MSU
crystals. Once recruited, activation of neutrophils by MSU crystals induces degranula-
tion and release of proteolytic enzymes, as well as the secretion of cytokines and inflamma-
tory mediators. Autophagy, IL-1β and ROS are required for the formation of extracellular
traps and delivery of neutrophil granular enzymes. Phagocytosis of MSU crystals results
in necrotic cell death, which fuel inflammation. ROS production and neutrophils enzymes
inflict tissue damage and promote inflammation.
Martin and colleagues have shown that early MSU crystal-recruited monocytes did
not respond to MSU crystal stimulation suggesting that they may not be involved
in the amplification of gouty inflammation in vivo [103].
II. Monocyte differentiation
Once monocytes are recruited from the circulation into the peripheral tissues they
have the capacity to differentiate into a number of cell types depending on the lo-
cal environment and tissue type (e.g. joint, skin, bone). Two important growth
factors, GM-CSF and M-CSF have been identified as influencing the differentiation
and functions of monocytes. Monocytes that are cultured in vitro in the pres-
ence of M-CSF will predominantly differentiate into macrophages representing an
anti-inflammatory or tissue-like macrophage phenotype (M2-like cells) [139; 140;
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141; 142]. Monocytes cultured in GM-CSF and IL-4 will become dendritic cells
(DCs) [143], while monocytes cultured with RANKL and M-CSF become osteo-
clasts [144]. In the presence of high concentrations of GM-CSF, Verreck and col-
leagues have shown that human monocytes treated with GM-CSF can differentiate
into pro-inflammatory macrophages in vitro, better known as M1-like macrophages
[140; 141]. Furthermore, in a tumor environment M-CSF and IL-10 drive the differ-
entiation of monocytes into alternative activated macrophages, also known as tumor
associated macrophages (TAMs) [145; 146; 147; 148].
CD14+ monocyte-differentiated macrophages stimulated with MSU crystals in vitro
have been shown to lose their ability to produce pro-inflammatory cytokines and
instead produce transforming growth factor β1 (TGFβ1), a cytokine linked with the
resolution of inflammation. This finding indicated a switch from a pro-inflammatory
into an anti-inflammatory phenotype [137; 138]. In contrast, data from an in vivo
model of gout demonstrated that MSU crystal-recruited monocytes differentiate
into a pro-inflammatory (M1-like) macrophage phenotype [149]. Together, these
findings highlight the complexity and importance of the inflammatory environment
in determining the fate and function of monocytes.
1.8.3 Macrophages in gout
Macrophages are known for their heterogeneity and can be found in most tis-
sues throughout the body, including alveolar macrophages of the lung, serosal
macrophages of the peritoneum, type A cells in the joint synovium and microglia
of the CNS [147]. Although these macrophages are phenotypically and functionally
different depending on their environment, they share common characteristic fea-
tures including phagocytosis, cytokine and chemokine production (IL-1β, TNFα,
IL-6, IL-10, interferon γ (IFNγ), etc.) [150]. Macrophages can be identified by
the expression of the M-CSF receptor (CD115, in mice) [151] and F4/80, a surface
marker used to identify murine macrophages [152].
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Primary and bone marrow-derived marophages have been reported to produce IL-
1β, TNFα, MCP-1, IL-18, IFNγ and inducible nitric oxide synthase (iNOS) upon
MSU crystal stimulation in vitro [61; 97; 153; 154; 155]. During MSU crystal-induced
inflammation in vivo, depletion of resident macrophages resulted in the abrogation
of IL-1β production and neutrophil recruitment [149], thus emphasising a key role
for macrophages in the initiation of gouty inflammation. However, macrophages
are also thought to be involved in the resolution of gout through the phagocytosis
of apoptotic cells, which triggers the production of the anti-inflammatory cytokine
TGFβ1 as well as allowing for the safe disposal of MSU crystals [138; 137]. These
reports highlight the complexity of macrophage responses depending on the in-
flammatory environment and supports the need for further investigation into this
area.
1.9 Mechanisms of spontaneous resolution of acute gouty
inflammation
A characteristic feature of acute gout is its self-resolving nature. In the absence of
clinical intervention, a gouty episode will spontaneously resolve after 7 - 10 days
[17]. Surprisingly, the pathways behind the spontaneous resolution of gout are
not fully understood. There are several regulatory mechanisms that can be linked
with shutting down acute inflammation in gout. These are summarised in this
section.
1.9.1 Protein coating of MSU crystals
The primary event driving a gout attack is the formation of MSU crystals in the
joint. Early studies have described the coating of the MSU crystal surface as an
important factor in regulating the inflammatory response [156]. Immunoglobulin G
(IgG) coating of the crystals has been linked with driving the inflammatory phase
[157], however, MSU crystals isolated during the resolution of inflammation shows
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that this IgG coating is lost. There is evidence that activated neutrophils produce
an, as yet unidentified, soluble mediator(s) that may interfere with the IgG coating of
MSU crystals [158] thereby providing a potential negative feedback loop designed to
limit the crystal-induced inflammation. Instead of IgG, MSU crystals isolated during
the resolution phase of a gout attack are reported to bind the lipoproteins ApoB and
ApoE [156]. ApoB and ApoE coating of MSU crystals has been shown to suppress
MSU crystal-induced neutrophil activation [159; 160]. As such, apolipoproteins may
play a role in masking MSU crystals from detection by local inflammatory cells and
facilitate non-inflammatory crystal uptake and removal (Figure 1.5).
1.9.2 Danger signalling
MSU crystals trigger the release of active IL-1β via the cleavage of pro-IL-1β by the
NLRP3 inflammasome. Classically, the signal for pro-IL-1β production is via pat-
tern recognition receptors (PRRs), such as TLR2/4 (Figure 1.5), which are involved
in driving inflammation by mediating crystal uptake as well as pro-IL-1β priming
[161]. Inflammatory cells appear to shed these molecules during the latter stages of
the inflammatory response to MSU crystals. This shedding would potentially abro-
gate crystal uptake and decrease the ability of cells to replenish stores of pro-IL-1β,
thereby blocking the release of active IL-1β.
1.9.3 Pro-resolution mediators
There is a growing body of evidence linking lipid mediators, such as resolvins, pro-
tectins, lipoxins and maresins to the resolution of inflammation [162]. These bioac-
tive molecules are generated from essential fatty acids such as omega-3 polyunsat-
urated acids and have been shown to limit neutrophil trafficking and survival, and
enhance apoptotic cell clearance by macrophages [163; 164]. Currently there is lit-
tle information on the role of these pro-resolution mediators in shutting down acute
gout attacks, however, omega-3 fatty acids are able to inhibit NLRP3 inflammasome-
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mediated IL-1β secretion and prevent NLRP3-dependent insulin resistance [165]. It
is therefore likely that the local generation of omega-3-derived pro-resolution media-
tors in the joint contribute to the spontaneous resolution of gout (Figure 1.5).
1.9.4 Pro-inflammatory cytokine regulation
IL-1β production is widely accepted as central to the initiation of the inflammatory
cascade that culminates in an attack of gout [61]. Studies have shown that MSU
crystal-induced inflammation is impaired in mice deficient in IL-1β or IL-1R indicat-
ing that IL-1β production and IL-1R signalling play an essential role in driving the
inflammatory response [61]. In vitro studies show that TGFβ1 can down-regulate
IL-1R expression on hemopoietic cells [166; 167] suggesting that TGFβ1 production
may contribute towards gout resolution by limiting IL-1β signalling. It is also pos-
sible that TGFβ1 can down-regulate the expression of IL-1R on the surrounding
synovial tissues (Figure 1.5). This would be particularly important in gout resolu-
tion where amplification of IL-1β signalling is strongly linked to IL-1R expression
on non-hemopoietic cells [97].
IL-1R antagonism is another mechanism used by the immune system to control IL-
1β signalling. IL-1R antagonist (IL-1Ra) is an endogenous mediator that inhibits
the pro-inflammatory effect of IL-1β by functioning as a competitive inhibitor of
IL-1R [168; 169]. Both in vitro and in vivo studies have shown that IL-1Ra has the
ability to block pro-inflammatory activities of the IL-1 cytokine family, thereby in-
dicating a regulatory role for IL-1Ra in acute inflammation [170; 171; 172]. Elevated
levels of IL-1Ra have been found in the synovial fluid from acute gout patients with
resolving inflammation, which indicates a link between IL-1Ra production and the
shutdown of IL-1β-driven inflammation [173]. Previous reports have also demon-
strated that TGFβ1 can induce the secretion of IL-1Ra by human peripheral blood
monocytes [174; 175] and the secretion of IL-1Ra by neutrophils has also been re-
ported [176]. Consistent with IL-1Ra playing a role in gout resolution, a number
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Figure 1.5: Macrophage-specific modulation of inflammatory signalling
pathways in response to MSU crystals. Red arrows indicate increased activity,
and blue lines represent an inhibitory or negative regulatory effect.
of clinical trials show that the recombinant IL-1Ra anakinra is highly effective at
relieving acute gout attacks [67; 177; 178].
Synovial fluids from patients with gouty arthritis have been found to contain higher
levels of soluble TNF receptors I and II (sTNFR-I/II) and IL-10 [47]. In vitro and
in vivo studies show that extracellular release of soluble sTNFR-I/II acts to inhibit
TNFα signalling by sequestering TNFα, whereas IL-10 has been shown to block
MSU crystal-induced inflammation, including suppression of TNFα production in
vivo [54]. This indicates a role for soluble cytokine receptors in the regulation of
acute gout.
There is also evidence that intracellular, negative cytokine regulators could con-
tribute to the resolution of an acute gout attack. Pro-inflammatory cytokine sig-
nalling is tightly controlled by a number of mechanisms including the signal trans-
ducers and activators of transcription (STATs), and suppressors of cytokine sig-
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nalling (SOCS) [173; 179]. Chen and colleagues have shown that mononuclear cells
and synovial tissue isolated from the synovium of gout patients significantly upreg-
ulate the expression of the SOCS family proteins cytokine-inducible SH2 protein
(CISH) and SOCS3 compared to osteoarthritis patients [173]. Increased expression
of CISH and SOCS3 is observed in MSU crystal-stimulated human monocyte-derived
macrophages indicating that macrophage activation switches on these regulatory
pathways. Overexpression of CIS is shown to decrease MSU crystal-induced IL-1β
and TNFα production and, at the same time, enhance STAT3-mediated TGFβ1
transcription [173]. These data show a role for increased intracellular CISH and
SOCS3 expression in the resolution of acute gout through the ability to nega-
tively regulate pro-inflammatory cytokines, while simultaneously switching on anti-
inflammatory cytokine production (Figure 1.5).
1.9.5 Non-inflammatory crystal clearance by macrophages
Previous work has shown that in vitro-generated macrophages can phagocytose
MSU crystals in a non-inflammatory manner [137]. This implicates the differenti-
ation of infiltrating monocytes into macrophages as a mechanism, which supports
the safe removal of MSU crystals during gout as illustrated in Figure 1.6. How-
ever, in vivo data show that resident macrophages are essential for the induction
of inflammation, and in situ differentiation of infiltrating monocytes in fact gener-
ates a highly pro-inflammatory macrophage phenotype [149]. Further research will
be needed to unravel the exact role of this cell population in the progression and
resolution of a gout attack.
1.9.6 Apoptosis, cell clearance and TGFβ1 production
Neutrophils are short-lived cells that undergo spontaneous apoptosis, a form of pro-
grammed cell death, which can be triggered by ROS production, calcium flux, the
activation of caspases, cathepsins and pro-apoptotic proteins, as well as autophagy
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[180; 181]. Neutrophil apoptosis then induces non-inflammatory cell clearance, a
classical mechanism involved in shutting down inflammation. In MSU crystal-
induced inflammation this has been associated with the clearance of apoptotic
neutrophils by macrophages [182; 183], as illustrated in Figure 1.6. The impor-
tance of apoptotic cell clearance in the resolution of inflammation has been recently
illustrated where deficiency of TG2 expression, a receptor shown to facilitate phago-
cytosis of apoptotic neutrophils by macrophages, leads to increased neutrophil ac-
cumulation and enhanced MSU crystal inflammation in vivo [184].
Clearance of apoptotic cells by macrophages is a process strongly linked with the
production of TGFβ1 [182]. In patients with acute gout, TGFβ1 has been demon-
strated to be present at a high level in the synovial fluid during the resolution phase
of the inflammatory response [185; 186]. Gout patients carrying the TT genotype for
the TGFβ1 polymorphism 869T/C have lower levels of TGFβ1 indicating a link be-
tween longer acute gout attacks and impaired TGFβ1 production [187]. Exogenous
administration of TGFβ1 in rodent models of MSU crystal-induced inflammation
has also led to significantly attenuated cellular recruitment [161]. Accordingly, the
induction of TGFβ1 production via apoptotic cell clearance plays an important part
in controlling gouty inflammation.
In vitro studies have shown that in the presence of IL-1β, TNFα and TGFβ1
monocyte-derived macrophages increase their ability to phagocytose apoptotic neu-
trophils [188]. MSU crystal-recruited monocytes display increased phagocytic ac-
tivity as they differentiate in vivo, which indicates that these monocyte-derived
macrophages may play a key role in inflammatory cell clearance in gout resolution
[149]. It is therefore possible that the early inflammatory environment induced by
MSU crystals actively supports clearance of apoptotic inflammatory cells thereby
indirectly programming the shutdown of a gout attack (Figure 1.6).
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1.10 Using research models to investigate gout
In order to study acute gouty inflammation it is necessary to develop research mod-
els. The first animal model for gout was introduced by Faires and McCarty, whereby
they injected synthetic MSU crystals into dog knees [14]. Faires and colleagues were
able to reproduce the same symptoms that they had observed in dogs, after they
self-administered MSU crystals into their own knees, which included pain, swelling
and redness.
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1.10.1 Murine joint model of gout
Over the last decades, mouse and rat models have been developed for studying
gouty inflammation in more detail. Even though using a murine model of joint
inflammation better mimics the human joint synovial space, the small size of murine
joints limits the range of investigations that can be performed. Because of this,
alternative murine models have been established using either the peritoneum or the
subepidermis to follow inflammatory responses to MSU crystals.
1.10.2 Murine peritoneal model of gout
The peritoneal model of gout was first used by Getting and colleagues [75]. The
peritoneal cavity contains cell types similar to those in the joint synovium including
macrophages, epithelial cells, mast cells, fibroblasts and lymphocytes. Injection of
MSU crystals into the peritoneum triggers the recruitment of leukocytes including
neutrophils and monocytes, as well as the production of cytokines and chemokines,
which are known to be associated with acute gouty inflammation. However, limita-
tions of this model include the absence of certain cell types such as osteoclasts and
chondrocytes that are specific to bone niches, as well as the absence of tissue such
as cartilage and bone. Moreover, due to the relatively large space within the peri-
toneum, the cavity is lacking the mechanically induced algesia caused by oedema,
an event that normally occurs within the joint during a gout attack. Despite these
disadvantages, this model has provided relevant immunological data, which has been
verified by numerous clinical studies.
1.10.3 Murine air pouch model
In the air pouch model, a subcutaneous injection of sterile air on the back of rats
(or mice) is performed in order to form an air sac, which mimics the joint synovium.
Injection of MSU crystals into this space triggers the recruitment of leukocytes.
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This particular model has been previously described by Schlitz and colleagues [189].
The limitations of this model are similar to the peritoneal model, whereby there is
an absence of cell subtypes normally found within the bone niche. The formation
of the air pouch may also initiate inflammation, which could cause a background
inflammatory environment altering cell numbers or cell phenotype.
Within this thesis, the peritoneal model was chosen as inflammatory model for gout,
as it induces an unmanipulated inflammatory background with cellular infiltration.
The model also mimics clinical gout and is widely used in the literature.
1.11 Aims of this study
The research summarised in this chapter implicates neutrophils, monocytes and
macrophages as the key cells in acute gout. To date, several mechanisms have been
shown to be involved in the spontaneous resolution of gouty inflammation including
cell clearance, TGFβ1 and monocyte differentiation. This thesis will address and
clarify the role of TGFβ1 in acute gout, especially during the resolution phase and
during monocyte differentiation.
Accordingly, the aims of this study are:
Aim 1: To identifiy macrophage-independent sources of TGFβ1 during the reso-
lution phase of MSU crystal-induced inflammation and to determine the regulatory
effect of TGFβ1 on neutrophil inflammatory functions.
Aim 2: To investigate the effect of TGFβ1 on the functional phenotype of in
vitro differentiated GM-CSF and M-CSF bone marrow-derived macrophages.
Aim 3: To investigate changes in surface marker expression by macrophages in
response to MSU crystals.
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2 Materials and Methods
2.1 Reagents
Buffer/Media
Dulbecco’s phosphate-buffered saline (D-PBS) Life Technologies, NZ
Dulbecco’s modified eagle’s media & F12 nutrient Life Technologies, NZ
mixture (DMEM/F12)
Hanks’ balanced salt solution (HBSS) Life Technologies, NZ
Macrophage-serum free & specialty media (SFM) Life Technologies, NZ
Roswell park memorial institute -1640 media Life Technologies, NZ
(RPMI-1640) media
Chemicals/Miscellaneous materials
10% neutral buffered formalin Sigma-Aldrich, NZ
β-Mercaptoethanol (β-ME) Life Technologies, NZ
Acetone Life Technologies, NZ
Ac-YVAD-CMK (caspase 1 inhibitor) Cayman Chemicals, USA
β-glycerophosphate Sigma-Aldrich, NZ
Biotinylated conjugated annexinV BD Pharmingen, NZ
Blue-fluorescent reactive dye Life Technologies, USA
Bovine serum albumin (Fraction V, IgG free) Life Technologies, NZ
CytochalasinD Life Technologies, NZ
Calcium pyrophosphate dihydrate Sigma-Aldrich, NZ
Dihydrorhodamine (DHR)-123 Life Technologies, NZ
Ethanol BDH Chemicals NZ Ltd.
Fetal bovine serum Sigma-Aldrich, NZ
FITC annexinV BD Bioscience, NZ
Fluospheres fluorescent microspheres Life Technologies, NZ
(0.5 µm, 505.515 nm, 2% solids)
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Glutamax Life Technologies, NZ
Glycine BDH Prolabo, Belgium
GolgiStop BD Bioscience, NZ
4-(2-Hydroxyethyl)piperazine-1 Sigma-Aldrich, NZ
-ethanesulfonic acid (HEPES)
Heparin Hameln Pharmaceuticals
GmbH, Germany
Igepal CA-630 Sigma-Aldrich, NZ
IL-6 neutralising antibody (clone: MP5-20F3) eBioscience, USA
Lipopolysaccharide, E. coli 0111:B4 (LPS) Sigma-Aldrich, NZ
Lympholyte-M cell separation solution Cedarlane, Canada
Lymphoprep Axis-Shield PoC AS, Norway
Recombinant murine GM-CSF PeproTech, USA
Recombinant murine M-CSF PeproTech, USA
Magnesium chloride BDH Laboratory, UK
MES SDS running buffer (20x) Novex, Life Technologies, USA
Methanol BDH Chemicals NZ Ltd.
NuPAGE antioxidant Life Technologies, USA
NuPAGE sample reducing agent (10x) Life Technologies, USA
NuPAGE LDS sample buffer (4x) Life Technologies, USA
NuPAGE 4-12% Bis-Tris gels Life Technologies, USA
Novex sharp pre-stained protein standard Novex, Life Technologies, USA
Penicillin-streptomycin Life Technologies, NZ
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich, NZ
Phorbol myristate acetate (PMA) Sigma-Aldrich, NZ
Prolong gold anti-fade with DAPI Life Technologies, NZ
Propidium iodide BD Bioscience, NZ
Protease inhibitor Roche, Germany
Protein A - sepharose beads BioVision Inc., USA
Puregene RBC lysis buffer QIAGEN Science, Germany
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Potassium chloride Riedel-DE HAEN AG, Germany
PVDF membrane (protein blotting) Bio-Rad, USA
Q-VD-OPh (general caspase inhibitor) R&D Systems, USA
Saponin Sigma-Aldrich, NZ
Sodium Azide Sigma-Aldrich, NZ
Sodium chloride BDH Laboratory, UK
Sodium dodecyl sulfate BDH Chemicals NZ Ltd.
Sodium hydroxide (NaOH) BDH Chemicals NZ Ltd.
TGFβ1 neutralising antibody R&D Systems, USA
TNFα neutralising antibody eBioscience, USA
Trypan blue stain Life Technologies, NZ
Tween20 Sigma-Aldrich, NZ
UltraPure Tris Life Technologies, NZ
Uric acid (UA) Sigma-Aldrich, NZ
WST-1 Dojindo, Kumamoto, Japan
Z-IETD-FMK (caspase 8 inhibitor) R&D Systems, USA
2.1.1 Antibodies for flow cytometry and immunofluorescent labelling
All antibodies used for flow cytometry or immunofluorescent labelling were titrated
before use to determine the ideal concentration. For cell surface marker expression
of fluorescently labelled antibodies, the corresponding isotype antibodies were used
as experimental controls.
Antibodies
AlexaFluor 555-streptavidin (SA) Life Technologies, NZ
AlexaFluor 488 anti-mouse 7/4 AbD Serotec, USA
AlexaFluor 647 anti-mouse Ly49D eBioscience, USA
APC rat anti-mouse CD11c BD Bioscience, NZ
APC rat anti-mouse Gr-1 BD Bioscience, NZ
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APC rat anti-mouse Ly6G BD Bioscience, NZ
Biotinylated anti-mouse CD115 eBioscience, USA
Biotinylated anti-mouse Ly6G BD Bioscience, NZ
Biotinylated anti-mouse NK1.1 eBioscience, NZ
FITC rat anti-mouse CD11b BD Bioscience, NZ
FITC rat anti-mouse MHCII BD Pharmingen, NZ
FITC rat anti-mouse 7/4 AbD Serotec, USA
FITC rat anti-mouse Ly49A BD Pharmingen, NZ
FITC conjugated-streptavidin (SA) eBioscience, NZ
FITC rat anti-mouse NK1.1 eBioscience, NZ
Mouse anti-TGFβ1 antibody (clone 2Ar2) Abcam, UK
PE rabbit anti-active caspase-3 BD Bioscience, NZ
PE rat anti-mouse F4/80 Biolegend, USA
PE rat anti-mouse CD86 BD Bioscience, NZ
PE rat anti-mouse NK1.1 eBioscience, USA
PerCP rat anti-mouse F4/80 Biolegend, USA
PerCP rat anti-mouse Ly6G BD Bioscience, NZ
PerCP Cy5.5 rat anti-mouse CD14 Biolegend, USA
Isotype controls
AlexaFluor 488 goat anti-mouse IgG1 (γ1 chain) BD Bioscience, NZ
APC rat anti-mouse IgG1 eBioscience, NZ
Biotinylated rat anti-mouse IgG2a,κ eBioscience, NZ
FITC rat anti-mouse IgG2b,κ BD Pharmingen, NZ
FITC rat anti-mouse IgG2a,κ eBioscience, NZ
PE rat anti-mouse IgG2a,κ eBioscience, NZ
PerCP Cy5.5 rat anti-mouse IgG2a,κ eBioscience, NZ
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Others
Anti-mouse FcγRII antibody (2.4G2) was kindly provided by Thomas Back-
strom from the Malaghan Institute of Medical Research.
2.1.2 Antibodies for western blotting and immunoprecipitation
All antibodies used for western blotting and immunoprecipitation were polyclonal
antibodies with a mouse and human species reactivity and used at concentrations
recommended by manufacturer’s instructions.
Antibody Molecular weight Source
Anti-ASC/TMS1 22kDa Novus Biologicals,
USA
Anti-cIAP1 69 kDa Abcam, UK
Anti-caspase 1/ICE pro form: 45 kDa Invitrogen, USA
active form: 20 kDa
Anti-CIAS1/NALP3 116 kDa Abcam, UK
Anti-caspase 8 pro form: 54/56 kDa R&D Systems, USA
p41/43 subunit
active form: 18/10 kDa
Anti-hIL-1 pro form: 35 kDa BioVision Inc, USA
active form: 17 kDa
Anti-β-actin 42 kDa Sigma-Aldrich, USA
RIPK1 74 kDa Novus Biologicals,
USA
RIP3 57 kDa ProSci Inc., USA
Goat anti-rabbit IgG-HRP SantaCruz Biotech,
USA
Goat anti-mouse IgG-HRP SantaCruz Biotech,
USA
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2.1.3 Kits
Biotin/Avidin blocking kit Invitrogen, NZ
Bioplex bead array kits Bio-Rad, CA, USA
Diff-Quik kit Dade Behring, Newark, USA
IL-1β ELISA kit R&D Systems, Minneapolis, USA
Limulus amebocyte lysate kit Associates of Cape Cod, Inc.,
Falmouth, MA, USA
TGFβ1 ELISA kit R&D Systems, Minneapolis, USA
2.2 Buffers and Media
AnnexinV binding buffer
The efficient binding of annexinV to phosphatidylserine on the surface of apoptotic
cells requires a high calcium-containing buffer. This buffer was composed of PBS,
10 mM HEPES, 140 mM NaCl and 2.5 mM CaCl2 at pH 7.4 and filtered sterile.
Storage at 4◦C, used within one month of preparation.
FACS buffer
FACS buffer was used as staining media to label cell surface markers with fluores-
cent antibodies. This solution contained 0.1% bovine serum albumin (BSA) and
0.01% sodium azide in PBS (pH 7.4). Storage at 4◦C.
Red Blood Cell (RBC) lysis buffer
Endotoxin-free puregene RBC lysis buffer was used to remove contaminating red
blood cells from blood and bone marrow samples as well as peritoneal lavage fluids
as required. Cells were suspended in 5 ml RBC lysis buffer and incubated for 10
minutes at 37◦C, washed twice in D-PBS and resuspended in the appropriate media.
If RBC lysis was incomplete, the process was repeated.
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Complete media
Endotoxin-free RPMI-1640 and DMEM/F12 media were purchased from Invitrogen.
In all cases in which the term ’complete media’ appears, refers to media supple-
mented with 10% FBS, 100 units/ml penicillin-streptomycin and 2 mM glutamax.
Stored at 4◦C, but used for cell preparation at room temperature.
PBS buffers
There were two sources of PBS used:
1. PBS: PBS powder was purchased from Life Technologies, made up to the appro-
priate volume in distilled water and the pH adjusted to 7.4 according to manufac-
turer’s instruction. This PBS buffer was used for procedures, which did not require
endotoxin-free PBS, such as FACS buffer, annexinV buffer and saponin buffer.
2. D-PBS: Endotoxin-free PBS in liquid form as D-PBS, and used to harvest and
wash cells, which were used in culture.
Saponin buffer
Saponin buffer was used to permeabilise the cell membrane, to allow intracellular
staining with fluorescent antibodies. This buffer was composed of 0.1% saponin,
0.1% BSA and 0.01% sodium azide in PBS buffer and stored at 4◦C.
Blocking buffer for immunofluorescent labelling
Blocking buffer was used to block non-specific binding sites for fluorescent labelling
of cells with antibodies. The blocking buffer was composed of 0.1% saponin, 0.1%
BSA, 0.01% sodium azide and 10% FBS in D-PBS. Stored at 4◦C.
Protein lysis buffer
Isolation buffer was used for isolating cytoplasmic protein from ex vivo cultured
murine cells. The buffer was composed of 10 mM HEPES, 1.5 mM MgCl2, 10 mM
KCl, 10 mM Na2MoO4 in distilled water and stored at 4
◦C. A mix of proteinase
inhibitors, 20 mM β-glycerophosphate, 2 mM Na3VO4 and 1 mM phenylmethylsul-
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fonyl fluoride (PMSF) were added into the isolation buffer and kept on ice before use.
Transfer buffer
Transfer buffer was used to transfer proteins from the gel onto a PVDF membrane.
The transfer buffer was composed of 100 ml of TG stock buffer (containing 3% Tris,
14.4% Glycine in distilled water), 200 ml methanol, 700 ml distilled water and 1 ml
of 10% sodium dodecyl sulfate (SDS). Stored at 4◦C.
Stripping buffer
Stripping buffer was used to disrupt primary and secondary antibody binding on
the western blot membrane. The buffer was composed of 0.1 M Glycine dissolved
in 200 ml PBS buffer (pH 2). Before use, 2% Tween20 was added into buffer.
2.3 Preparation of crystals
Monosodium urate crystals (MSU)
MSU crystals were prepared as follow: 250 mg uric acid was boiled in 45 ml of 30
mM NaOH/MilliQ water until completely dissolved. The uric acid solution was fil-
tered sterile using a 0.2 µm vacuum driven disposable bottle top filter, and stored at
26◦C for 7 days to encourage the formation of crystals. The resulting MSU crystals
were washed with ethanol and acetone and then air-dried under sterile conditions.
The MSU crystals were needle shaped (5 - 25 µm in length) and showed optical
birefringence under the microscope [103]. MSU crystals used were endotoxin free as
determined by Limulus amebocyte lysate (LAL) assay kit (< 0.01 EU / 10 mg).
Other crystal types used for in vitro assays
Magnesium urate (MgU) crystals, calcium urate (CaU) crystals, potassium urate
(KU) crystals and ammonium urate (NH4U) crystals were made and kindly provided
by Henry Hudson, Malaghan Institute of Medical Research. Calcium pyrophosphate
dihydrate (CPPD) was purchased from Sigma-Aldrich, NZ.
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2.4 Endotoxin levels
As bacterial endotoxin can activate innate immune cells, all glassware and reagents
used for cell culture were both sterile and endotoxin free. All plasticware such as
microplates, flasks, culture tubes and pipettes were endotoxin free. All reagents
used were either certified as low endotoxin or tested for endotoxin levels by LAL
assay.
2.4.1 Limulus amebocyte lysate (LAL) assay
The LAL assay kit contains E. coli control endotoxin standard, chromogenic sub-
strate and endotoxin-free water. The chromogenic LAL assay measures the endo-
toxin levels in the samples such as MSU crystals by reading the absorbance at 405
nm. The following were tested for endotoxin levels by LAL assay kit.
MSU crystals < 0.01 EU / 10 mg
MilliQ water < 0.01 EU / ml
Cleaned and autoclaved glassware < 0.01 EU / ml
2.4.2 Purchased reagents
5 M NaCl Sigma-Aldrich, NZ < 0.3 EU / ml
D-PBS Invitrogen, NZ < 0.03 EU / ml
RPMI-1640 Invitrogen, NZ < 0.03 EU / ml
HBSS Invitrogen, NZ < 0.03 EU / ml
Puregene RBC lysis buffer QIAGEN, CA, USA < 0.03 EU / ml
Fetal bovine serum Sigma-Aldrich, NZ < 0.13 EU / ml
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2.5 Animal studies
2.5.1 Maintenance and ethical approvals
All mice were bred and housed in a conventional animal facility at the Malaghan
Institute of Medical Research, Wellington, New Zealand. All animals used for the
experiments were aged between 8 - 10 weeks. The experiments were approved by
the Victoria University Animal Ethics Committee and carried out in accordance
with the Commitee’s guidlines for the care of animals (Ethics approval numbers
2011R19M and 2012R17M).
2.5.2 Mouse strain sources
C57Bl/6J male mice were originally purchased from the Jackson Laboratory (Bar
Harbour, ME, USA).
OTII male mice expressing the transgenic T cell receptor specific for OVA323−339
presented on I-Ab respectively were originally obtained from Professor Frank Car-
bone, Melbourne University (Melbourne, Victoria, Australia).
2.5.3 Murine peritoneal model of MSU crystal-induced inflammation
C57Bl/6J male mice were injected intraperitoneally (i.p.) with 3 mg MSU crystals
suspended in 0.5 ml D-PBS and at different time points mice were sacrificed by
carbon dioxide asphyxiation followed by cervical dislocation.
Blood was then collected by cardiac puncture into 1.5 ml eppendorf tubes con-
taining 50 µl of 125 units/ml heparin in D-PBS and stored on ice.
The peritoneal exudate cells (PECs) were harvested by peritoneal lavage from naive
and MSU crystal-treated mice. 3 ml of D-PBS containing 25 units/ml heparin
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was injected into the peritoneum near the inguinal fat pads. The peritoneum was
then massaged for 10 seconds before the lavage fluid was withdrawn using the same
syringe needle and placed on ice.
2.5.4 In vivo TGFβ1 neutralisation
For TGFβ1 neutralising experiments in vivo, C57Bl/6J mice were injected with 1
mg of the anti-TGFβ1 antibody 30 minutes prior to MSU crystal administration.
After 8 and 18 hours, the mice were euthanised by carbon dioxide asphyxiation
followed by cervical dislocation.
2.6 Processing and isolation of cell types
2.6.1 Preparation of peritoneal lavage cells
PECs from naive and MSU crystal-treated mice were harvested by peritoneal lavage
as described in section 2.5.3. Cells were retrieved from the lavage fluid by centrifuga-
tion (1500 rpm, 5 minutes) and washed twice with D-PBS. The lavage supernatants
were stored for cytokine/chemokine analysis at -20oC (section 2.8) and the pelleted
cells resuspended in complete RPMI-1640 for further analysis.
2.6.2 Preparation of mouse blood
Blood was collected by cardiac puncture from MSU crystal-treated mice. Under
sterile conditions, the red blood cells were lysed by resuspending the blood in 5 ml
RBC lysis buffer and incubated at 37◦C for 15 minutes. Cells were subsequently
washed twice with D-PBS by centrifuging at 1500 rpm for 5 minutes before further
separation steps were performed.
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2.6.3 Preparation of cells from lymph nodes
OTII mice were euthanased by carbon dioxide asphyxiation followed by cervical
dislocation. The inguinal and mesenteric lymph nodes were removed and disrupted
with the back of the plunger of a 1 ml syringe and flushed with complete RPMI-1640
through a 40 µm nylon cell strainer into a 50 ml Falcon tube. The suspension was
then centrifuged at 1500 rpm for 5 minutes and any red blood cells were lysed as
described in section 2.2, if required. Cells were washed twice and resuspended in
complete RPMI-1640, and placed on ice until further use.
2.6.4 Extraction and preparation of bone marrow cells
C57Bl/6J mice were euthanased by carbon dioxide asphyxiation followed by cervical
dislocation. The hind leg bones were detached from the hip, and muscle and con-
nective tissue removed from the femur and tibia. These were placed in RPMI-1640
on ice. Under sterile conditions, the ends of the bones were snipped and the bone
marrow cells flushed into a 50 ml Falcon tube using a 25-gauge needle and a 10 ml
syringe containing DMEM/F12. The cell suspension was strained through a 40 µm
cell strainer and washed once with DMEM/F12. Red blood cells were lysed for blood
(section 2.2) and immediately washed twice and resuspended in 5 ml DMEM/F12.
5 ml of Lymphoprep cell separation media was added below the cell suspension us-
ing a sterile disposable glass pasteur pipette (Poulten + Graf Ltd., Germany) and
centrifuged at 1600 rpm for 20 minutes (with brake off). The cells were gently re-
moved from the interface using a sterile transfer pipette, washed twice with complete
DMEM/F12 and then resuspended at the appropriate concentration.
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2.6.5 Enrichment of MSU crystal-recruited peritoneal and blood neu-
trophils
Peritoneal exudate cells were harvested by lavage from C57Bl/6J mice treated with
MSU crystals for 8 and 18 hours (section 2.5.3) and prepared as described in section
2.6.1. Individual samples were pooled in sterile 15 ml tubes, washed twice in D-PBS
and resuspended in 5 ml D-PBS. 4 ml of Lympholyte-M cell separation media was
added below the cell suspension using a sterile disposable glass pasteur pipette and
the cells were centrifuged for 20 minutes at 2400 rpm at 10◦C. The supernatant was
carefully removed by decanting, and the pelleted neutrophil fraction washed twice
in D-PBS, then resuspended in complete RPMI-1640 and placed on ice until further
use.
The blood cells were processed as described in section 2.6.2. After red blood cell
lysis, cells were resuspended in 5 ml D-PBS and 4 ml of Lympholyte-M cell sep-
aration media was added below the cell suspension following centrifugation for 20
minutes at 2400 rpm at 10◦C. The enriched blood neutrophils were collected from
the bottom of the 15 ml tube, washed twice in D-PBS and resuspended in complete
RPMI-1640. Cells were kept on ice until further use.
2.6.6 Cell counting
Cells were counted by using 10 µl of the cell suspension mixed with 90 µl of 0.4%
Trypan Blue Stain. This mixture was placed on a haemocytometer and the viable
cells that did not contain the dye were counted under 10x magnification with an
Olympus BX40 (Olympus, Central Valley, PA, USA) microscope.
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2.7 Ex vivo and in vitro assays
2.7.1 Ex vivo neutrophil assays
Blood and peritoneal neutrophils from 8 and 18 hour MSU crystal-treated mice were
purfied by density gradient (section 2.6.5) and cultured ex vivo at 2x105 cells/ml,
200 µl per well in 96-well flat-bottom plates (Falcon BD Labware, USA). Cells were
incubated in the presence or absence of MSU crystals (200 µg/ml) for up to 24
hours at 37◦C. At various times, supernatants were collected and stored at -20◦C
until analysis. Neutrophils were then harvested and analysed for the expression of
the surface marker annexinV, CD11b, Ly6G and Gr-1 as well as for intracellular
caspase 3 and TGFβ1 by flow cytometry (section 2.9).
In assays investigating intracellular expression of TGFβ1, neutrophils were cultured
in the presence of GolgiStop (1:1000) to block cytokine secretion.
To investigate the effect of apoptosis, phagocytosis and TGFβ1 on neutrophil func-
tion, purified neutrophils were incubated in the absence or presence of a general
caspase inhibitor Q-VD-OPh (20 µM), the phagocytosis inhibitor CytochalasinD
(20 µg/ml) or with the anti-TGFβ1 antibody (35 µg/ml) over time.
2.7.2 Neutrophil phagocytosis assay
MSU crystal-recruited peritoneal neutrophils were isolated and purified as described
in section 2.6.5. Neutrophils were labelled with PerCP-Ly6G and then incubated
ex vivo for 18 hours in serum free RPMI-1640 to induce apoptosis. Apoptotic
neutrophils (PerCP-Ly6G+) were then co-incubated in RPMI-1640 with freshly iso-
lated MSU crystal-recruited live neutrophils that had been labelled with APC-Ly6G
(apoptotic cell:live cell ratio 5:1) in the presence of GolgiStop (1:1000). After 8
hours, the cells were harvested and analysed by flow cytometry for the expression
of APC-Ly6G, PerCP-Ly6G, and intracellular TGFβ1. Live neutrophils that had
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phagocytosed apoptotic neutrophils were identified as APC-Ly6G+/PerCP-Ly6G+
cells (double positive cells).
2.7.3 Measurement of neutrophil superoxide production
Neutrophil superoxide production was measured using the colorimetric dye water-
soluble tetrazolium 1 (WST-1) as previously described by Tan and colleagues [190].
Purified MSU crystal-recruited neutrophils were suspended in phenol red-free RPMI-
1640 and added to a 96-well flat-bottom plate at 2x105 cells per well with 250 µg/ml
WST-1 and incubated with anti-TGFβ1 antibody (35 µg/ml) or MSU crystals (200
µg/ml) or with a combination of both reagents at 37◦C for 1 hour. After 1 hour,
MSU crystals were removed from the supernatant by centrifugation and 100 µl of
the crystal-free supernatants was transferred into another 96-well flat-bottom plate.
The plate was loaded into a Versamax spectrophotometer (Molecular Devices) and
the absorbance (450 nm) measured.
2.7.4 Differentiation of bone marrow-derived macrophages
Bone marrow cells were obtained as described in section 2.6.4. The viable cells
were adjusted to a concentration of 4x106 cells/ml in complete DMEM/F12 media
containing 50 µM β-ME supplemented with either 1000 units/ml GM-CSF or 5000
units/ml M-CSF, and cultured in T25 culture flasks (5 ml of 4x106 cell suspension
per flask) overnight. On day one, the non-adherent cells were collected and resus-
pended at 1x106 cells/ml in complete DMEM/F12 media containing either GM-CSF
or M-CSF. The GM-CSF and M-CSF cell suspensions were then plated at 1x106
cells/3 ml in six-well plates and treated either with 1 ng/ml or 10 ng/ml recombinant
human TGFβ1, or left untreated. The cells were fed on day three and five, each
time by replacing 1 ml media with 1 ml fresh complete DMEM/F12 containing ei-
ther 1000 units/ml GM-CSF or 5000 units/ml M-CSF and/or 1 ng/ml or 10 ng/ml
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rhTGFβ1. On day seven, supernatants from the cell cultures were collected and
the cells washed twice with D-PBS before fresh complete DMEM/F12 media was
added. The GM-CSF and M-CSF macrophages were then primed with 50 pg/ml
LPS overnight. Following LPS priming, supernatants were collected and BMMs
washed with D-PBS, and complete macrophage-SFM media added to the cell cul-
ture.
In assays investigating the effect of TGFβ1 on bone marrow-derived macrophages
(BMMs) after they have been differentiated with either GM-CSF (1000 units/ml)
or M-CSF (5000 units/ml) for seven days, BMMs were treated with 1 ng/ml or
10 ng/ml rhTGFβ1, or left untreated for one day or for an additional five days.
After treatment with TGFβ1 for one or five days, cells were washed twice with
D-PBS and fresh complete DMEM/F12 media containing 50 pg/ml LPS was added
overnight. Following LPS priming, TGFβ1-differentiated BMMs were washed with
D-PBS and complete M-SFM media added to the cell culture before stimulation
assay was carried out (section 2.7.5).
2.7.5 TGFβ1-differentiated BMM stimulation assay
TGFβ1-differentiated GM-CSF and M-CSF BMMs were obtained as described in
section 2.7.4. After LPS priming, 2 ml of complete M-SFM media was added to the
BMM cell culture (1x106 cells per well in six-well plates) and the cells were either
left unstimulated or treated with 200 µg/ml MSU crystals, 100 ng/ml LPS and/or in
the prescence of the caspase 1 inhibitor YVAD (10 µg/ml) or the caspase 8 inhibitor
IETD (10 µM) or a combination of both inhibitors, and incubated for 18 hours at
37◦C. After incubation, supernatants were collected and stored at -20◦C for cytokine
analysis (section 2.8), and BMMs were harvested and analysed for the expression
of surface markers by flow cytometry (section 2.9). In other experiments, BMMs
were washed with D-PBS and prepared for the isolation of cytoplasmic protein for
western blot analysis (section 2.11).
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Next to stimulation with MSU crystals and LPS, TGFβ1-differentiated BMMs were
also stimulated in vitro with Pam3Cys (100 ng/ml) or left untreated for 18 hours.
Supernatants from the cell culture were collected and analysed for IL-1β by ELISA
(section 2.8).
2.7.6 In vitro T cell proliferation assay
In vitro T cell proliferation assays were performed for CD4+ T cells from OTII mice.
GM-CSF and M-CSF BMMs (section 2.7.4) were incubated with 100 ng/ml LPS
in complete RPMI-1640 for 18 hours. After incubation, LPS-primed BMMs were
washed and harvested using cold D-PBS to detach the cells from the bottom of
the 6-well plates. GM-CSF and M-CSF BMMs were then resuspended in complete
RPMI-1640 and loaded with 1 µM ISQ peptide (OVA323−339 protein) specific for
CD4 T cell cross-presentation. During the 2 hour incubation with peptide, lymph
nodes were harvested from OTII mice and made into cell suspension as described
in section 2.6.3. Following peptide loading, BMMs were washed and resuspended at
1x105 cells/ml in complete RPMI-1640, and serially titrated at 2 fold dilution with a
starting concentration of 1x104 cells per well into 96-well culture plates. BMMs were
either stimulated with 200 µg/ml MSU crystals or left untreated prior to the addition
of T cells, at 1x105 cells/well and the cells were then incubated for 3 days at 37◦C.
After incubation, 1 µCi [3H]-thymidine (GE Healthcare, UK) was added to each
well and incubated for an additional 18 hours. Cells were harvested onto filtermats
(PerkinElmer Life Science, Finland) using an automated cell harvester (Tomtec
Inc., USA). Thymidine incorporation was used to measure T cell proliferation using
a Wallac 1450 MicrobetaPlus Liquid Scintillation Counter (Wallac, USA).
2.7.7 Measurement of intracellular ROS production by BMMs
To measure intracellular ROS production by TGFβ1 differentiated BMMs (section
2.7.7), cells were suspended in HBSS and transfered into a 96-well flat-bottom plate
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at 1x105 cells per well with 10 µM DHR-123 solution and incubated at 37◦C for 5
minutes to allow DHR-123 uptake. After incubation, cells were washed and then
stimulated with MSU crystals (200 µg/ml) or PMA (0.2 µg/ml) at 37◦C for 45
minutes. The reaction was then stopped by placing the cell culture plate on ice. As
controls, BMMs were also incubated with DHR-123 solution following stimulation
with MSU crystals and PMA at 4◦C for 45 minutes. The cells were stained for the
surface marker F4/80, CD11b and CD14 using cold FACS buffer and analysed for
their expression by flow cytometry (section 2.9).
2.7.8 In vitro peritoneal macrophage assays
Peritoneal exudate cells (PECs) from naive mice were obtained as described in sec-
tion 2.6.1. The peritoneal macrophages were resuspended in complete macrophage-
SFM media and cultured at 2x105 cells/ml, 200 µl per well in 96-well flat-bottom
plates.
Stimulation of macrophages
Macrophages were plated as above and stimulated with different crystals MSU,
CPPD, CaU, MgU, NH4U and KU (200 µg/ml) and non-crystalline 100 ng/ml LPS
for up to 24 hours at 37◦C. At different time points, supernatants were collected and
stored at -20◦C for further analysis (section 2.8). Cells were harvested and analysed
for the expression of the surface markers NK1.1, CD11b, F4/80, Ly49A and Ly49D
as well as the apoptotic markers annexinV and caspase 3 by flow cytometry (section
2.9).
Blockade of cytokines and apoptosis
In assays investigating the effect of cytokines on NK1.1 expression, macrophages
were cultured in the absence or presence of anti-IL-1β (5 µg/ml), the caspase 1 in-
hibitor YVAD (10 µg/ml), anti-IL-6 (5 µg/ml), anti-TNFα (5 µg/ml) and caspase
8 inhibitor IETD (10 µM). After 1 hour, macrophages were stimulated with 200
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µg/ml MSU crystals or left untreated, and at different time points supernatants
were collected and cells harvested and prepared for flow cytometry as above.
Phagocytosis assay
In assays investigating the effect of phagocytosis on the expression of NK1.1, macrop-
hages were stimulated with 200 µg/ml MSU crystals or co-cultured with apoptotic
neutrophils (apoptotic neutrophils:macrophages, cell ratio 5:1) or fluorescent beads
for up to 24 hours. Phagocytosis was inhibited using CytochalasinD (10 µg/ml).
At different time points, supernatants were collected for cytokine analysis (section
2.8), and cells harvested and analysed for surface marker expression of NK1.1, F4/80,
CD11b and Ly6G by flow cytometry (section 2.9).
2.8 Cytokine analysis
Cytokine levels from the peritoneal lavage fluid and culture supernatants were as-
sayed either by multiplex bead array (section 2.1.3) and analysed on a Bioplex flow
cytometer, or with ELISA kits (section 2.1.3) and analysed on a Versamax spec-
trophotometer. Each measurement system was used according to manufacturer’s
instructions.
Cytokines Measurement system
IL-1β, TGFβ1 ELISA
IL-1α, TNFα, IL-6, CXCL1, MCP-1 Multiplex bead array
2.9 Flow cytometry
For cell surface labelling, 200 µl of the cell suspension was transfered into a 96-well
round-bottom plate. The cells were centrifuged for 5 minutes at 1500 rpm, the
supernatants decanted and the cells were then incubated with anti-mouse FcγRII
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antibody (2.4G2) (section 2.1.1) in 50 µl FACS buffer for 10 minutes at 4◦C. After
incubation, cells were washed in FACS buffer and incubated with the appropriate 25
µl master mix of fluorophore-labelled antibodies (section 2.1.1) or blue-fluorescent
reactive dye (Life Technologies, USA) for 15 minutes at 4◦C. Isotype-matched anti-
bodies were used as experimental controls. Cells were then washed in 200 µl FACS
buffer, filtered through gauze (20 µm) and transferred into Titertube micro tubes
(Bio-Rad, USA). Flow cytometry analysis was performed on a BD FACSCalibur
(BD, USA) and the data then analysed using the software FlowJo 9.7.4 (Tree Star
Inc., Ashland, OR, USA).
2.9.1 AnnexinV / propidium iodide (PI) staining
Apoptotic and necrotic cell death of cells was determined by using fluorescently
labelled annexinV protein and PI. PI binds to the DNA when the cell membrane be-
comes permeable. The viable cells were identified as double negative cells (annexinV−
/PI−), while annexinV single positives indicated early apoptotic cells and PI single
positive as necrotic cells. Late apoptotic were annexinV+/PI+.
At different time points, cells (200 µl) were transferred into a 96-well plate and
centrifuged (1500 rpm, 5 minutes), the supernatants decanted and the cells resus-
pended in annexinV binding buffer. Non-specific binding was blocked using anti-
mouse FcγRII antibody (2.4G2) for 10 minutes at 4◦C. After incubation, cells were
washed in 200 µl annexinV binding buffer and stained with FITC-annexinV for 15
minutes at 4◦C. Cells were washed and resuspended in annexinV binding buffer. 5
minutes before analysis, 10 µg/ml PI was added to the samples and annexinV/PI
staining determined using a FACSCalibur flow cytometer.
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2.9.2 Intracellular staining of cells
Cells were labelled with the cell surface markers (such as F4/80, CD11b or Ly6G) as
described above in section 2.9 and then fixed with 10% neutral buffered formalin for
10 minutes at room temperature. Cells were then washed and incubated in saponin
buffer for 20 minutes at 4◦C. Following incubation, cells were stained with the
antibodies TGFβ1 - IgG1-AlexaFluor 488, NK1.1-FITC and the apoptosis marker
caspase 3 (section 2.1.1) for 30 minutes at 4◦C. After intracellular antibody staining,
cells were washed and resuspended in FACS buffer, and flow cytometry analysis was
performed on FACSCalibur.
2.10 Histology
2.10.1 Morphological staining of cells
Diff-Quik staining was used to visualise the morphology of cells harvested from the
peritoneal lavage samples. 100 µl of cells (1x106 cells/ml) were centrifuged for 5
minutes at 800 rpm onto glass slides (LabServ, NZ) using a Shandon Cytospin 4
cytocentrifuge (Thermo Scientific, UK) and were air-dried. The cells were then fixed
for 5 seconds in Diff-Quik fixative (1.8 mg/ml Triarylmethane dye methyl alcohol),
stained 10 seconds in Diff-Quik Solution 1 (1 g/l Xanthine dye) following a 7 second
staining in Diff-Quik Solution 2 (0.625 g/l Azure A, 0.625 g/l Methylene blue).
Excess dye was washed off with water. Slides were examined using an Olympus
BX51 microscope (bright field).
2.10.2 Immunofluorescent staining of cells
Purified neutrophils from blood and peritoneum of MSU crystal-treated mice (sec-
tion 2.6.5) and apoptotic neutrophils, which had been cultured ex vivo for 24
hours in the presence of GolgiStop (1:1000) were spun onto glass slides at 500 rpm
Chapter 2: Materials and Methods 50
for 6 minutes. Cells were washed with PBS and then fixed with 200 µl ice-cold
methanol:acetone (50:50). After 10 minutes, cells were washed with PBS and non-
specific binding was blocked by incubation with blocking buffer (section 2.2) for
30 minutes at 37◦C. Slides were washed with PBS and cells stained with the sur-
face marker anti-mouse Ly6G-biotin (section 2.1.1) at 37◦C for 2 hours. After 3
wash steps, the AlexaFluor 555-SA was added, and the cells incubated for 1 hour
at 4◦C. Saponin buffer (section 2.2) was used to permeabilise the cells, which were
then stained for intracellular TGFβ1 using a mouse anti-TGFβ1 monoclonal an-
tibody (section 2.1.1) for 2 hours at 37◦C. Cells were washed with saponin buffer
and treated for 1 hour with the secondary antibody AlexaFluor 488-goat anti-mouse
IgG1 (section 2.1.1). Excess antibody was removed by washing with PBS, and cells
were fixed with 10% neutral buffered formalin (section 2.1) for 10 minutes at room
temperature. One drop of ProLong Gold anti-fade with DAPI was applied. DAPI
was used to stain the cell nuclei. The slides were then mounted with a cover slip
(Paul Marienfeld GmbH & Co., Germany) and imaged using an Olympus BX51
fluorescence microscope.
2.11 Western blot analysis
2.11.1 Cytoplasmic protein extraction
After differentiation of GM-CSF and M-CSF BMMs (section 2.7.4) and stimulation
(section 2.7.5) in vitro, cells were washed twice with cold D-PBS to remove serum
and non-adherent cells. Cells were lysed directly on the plate by adding 50 µl
of the protein lysis buffer (section 2.2). A cell scraper was used to detach the
adherent cells and the cell lysate was transfered into a 1.5 ml Eppendorf tube.
Cells were immediately mixed by pipetting up and down and put on ice for 20
minutes. After incubation, cell lysate was collected to the bottom of the tube
by centrifugation (9000 rpm, 10 seconds) and 3 µl of 10% Igepal CA-630 added,
followed by vortexing for 10 seconds and incubation on ice for 2 minutes. The
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insoluble material was pelleted by centrifugation for 30 seconds at 13000 rpm and the
supernatant, containing the extracted protein, was transferred to a new Eppendorf
tube and stored at -80◦C until further analysis.
2.11.2 Protein quantification
Cytoplasmic protein was obtained as described in section 2.13.1. The protein con-
centrations were quantified by Bradford assay using a Bio-Rad protein assay protocol
as per manufacturer’s instructions. Briefly, each sample was quantified in duplicates
with 5 µl of protein sample, 25 µl of Reagent A + S, and 200 µl of Reagent B, and
incubated for 15 minutes at room temperature. The colour generated was pro-
portional to the amount of protein and the absorbance was measured at 750 nm
wavelength. BSA standards were used to generate a standard curve and the col-
orimetric quantification was carried out using a Versamax microplate reader and
SOFTmax PRO 4.0 software.
2.11.3 Protein sample preparation
The protein concentrations were determined as described in section 2.13.2 and the
required volume of protein samples was added into eppendorf tubes containing the
required amount of MilliQ water, 4x NuPAGE LDS sample buffer and 10x NuPAGE
sample reducing buffer. The protein was denatured by incubation at 95◦C for 6
minutes and then put on ice.
2.11.4 Western blot procedure
NuPAGE 4-12% Bis-Tris gels (Life Technologies, USA) were placed in a NuPAGE
tank and the outer chamber was filled with MES SDS running buffer and the inner
chamber filled with 200 ml MES SDS running buffer and 500 µl NuPAGE Antioxi-
dant. 15 µg of the samples were loaded and in one lane, 6 µl of a sharp pre-stained
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protein standard used as a molecular weight marker/loading control. To allow bet-
ter protein separation, the gels were first run at 120 V for 15 minutes before the
voltage was increased to 150 V for further 60 minutes using a Bio-Rad Powerpac 300.
The gels were placed into a transfer cassette with PVDF membranes (hydrated
in 100% methanol, Bio-Rad, US) and sandwiched, with bubbles removed, between
blotting paper and sponges soaked in transfer buffer. The sandwich transfer cassette
was placed in a Bio-Rad criterion blotter gel box and run for 2 hours at 300 mA.
After the transfer was completed, the membranes were rinsed twice with T-PBS
(PBS buffer with 0.1% Tween20) and non-specific protein binding blocked using 2%
milk powder in T-PBS for 1 hour at room temperature on a shaker.
The primary antibodies (section 2.1.2) were diluted in the appropriate concentration
in blocking buffer and incubated at 4◦C overnight on a rocker. After incubation,
the membranes were washed in T-PBS for 5 minutes on a shaker and incubated
with the appropriate secondary antibody (goat anti-rabbit IgG or goat anti-mouse
IgG - conjugated to the horse radish peroxidase (HRP) enzyme) at 1:2000 at room
temperature for 1 hour on a shaker. The membranes were washed with PBS and
Western Lightning ECL Pro (PerkinElmer Inc., USA) added to detect HRP activity.
Membranes were imaged using a GelLogic 4000 PRO Carestream and pictures were
taken using Carestream Molecular Imaging Software to identify the specific proteins
in the cell lysate samples.
After imaging, the membranes were incubated in stripping buffer (section 2.2) at
70◦C for 45 minutes to remove the primary and secondary antibody from the west-
ern blot membranes. After stripping, membranes were incubated in blocking buffer
for 1 hour at room temperature and reprobed with a second primary antibody and
then incubated at 4◦C overnight on a rocker and so forth. Each membrane was
stripped and reprobed at the most four times.
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2.11.5 Immunoprecipitation
Cytoplasmic protein was collected from in vitro TGFβ1-differentiated GM-BMMs
as described in section 2.11.1. Immunoprecipitation was used to isolate the caspase
1 protein from the cytoplasmic protein fractions of cultured GM-BMMs. 20 µl of
protein A - sepharose beads were incubated with 1 µg/ml of the caspase 1 antibody
(section 2.1.2) at 4◦C for 1 hour. The bead/antibody mix was washed three times
with wash buffer (PBS + 0.02% Tween20) by centrifugating at 13000 rpm for 1
minute and the supernatants discarded. Cytoplasmic protein samples (150 µl) were
then incubated with the bead/antibody mix on a rotating wheel at 4◦C overnight.
After incubation, the samples were washed three times with wash buffer and resus-
pended in PBS buffer. To separate the caspase 1 protein/antibody mix from the
beads, 25 µl of 4x NuPAGE LDS sample buffer was added to the sample and then
incubated at 70◦C for 10 minutes in a shaking heat block (300 rpm). The samples
were spun at 13000 rpm at 4◦C for 1 minute and 20 µl of the supernatants loaded
onto a NuPAGE 4-12% Bis-Tris gel. Western blot procedure was carried out as
described in section 2.11.4. Caspase 8 was used as primary antibody to investigate
whether the caspase 1 protein from the GM-BMM samples was immunoprecipitated
with caspase 8, specifically whether caspase 1 and caspase 8 are associated and
interact.
2.12 Statistical analysis
Statistic analysis was performed using GraphPad Prism (GraphPad software, ver-
sion 5.0., USA). Student’s paired, two-tailed t-test was used to calculate significance
between two groups. Between three or more samples, one-way analysis of variance
(ANOVA) with Tukey’s post test was used. When using two parameters with multi-
ple groups, two-way ANOVA with Bonferroni’s post test was carried out. Statistical
significance was determined when P < 0.05.
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3 The Contribution of Neutrophils in the Resolu-
tion of MSU Crystal-Induced Inflammation
3.1 Introduction
Inflammation is a defensive mechanism against pathogen invasion but it can also
occur in response to the release of danger-associated molecular patterns (DAMPs)
by the body. Included amongst the DAMPs is UA. In high concentrations, UA
forms MSU crystals, the widely recognised inflammatory trigger for gouty arthritis
[73]. This acute inflammatory response is characterised by localised swelling in the
affected joints and periarticular tissues, reddening of the skin, and debilitating pain
in patients having a gout attack. Interestingly, in the absence of clinical interven-
tion, this acute gouty inflammation will spontaneously resolve after 7 - 10 days [17].
A characteristic feature of many auto-inflammatory innate responses including gout
is the infiltration of neutrophils to the site of inflammation. During these responses,
stimulation of neutrophils triggers the production of toxic ROS via the activation of
the NADPH oxidase otherwise known as the respiratory burst [191; 192]. Although
the release of free radicals by activated neutrophils is generally beneficial to host
defences, these processes must be tightly regulated, as inappropriate ROS produc-
tion such as that associated with MSU crystal-induced auto-inflammation in gout
can be cytotoxic, which results in cell and tissue damage [193; 194].
The deposition of MSU crystals triggers a rapid inflammatory infiltration of neu-
trophils and monocytes, the release of pro-inflammatory mediators such as TNFα
and chemokines following phagocytosis and activation of MSU crystals [195; 74; 103;
196]. IL-1β is a pivotal cytokine involved in the auto-inflammatory cascade in re-
sponse to MSU crystals. This cytokine is mainly produced by resident macrophages,
but there is evidence that the infiltrating neutrophils also have the capacity to pro-
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duce IL-1β [197; 198; 198] and could therefore augment local IL-1β levels to drive
inflammation.
In patients suffering a gout attack, the spontaneous resolution of inflammation is
associated with elevated levels of TGFβ1 in the synovial fluid of affected joints [185].
The exogenous administration of TGFβ1 has also been shown to significantly atten-
uate MSU crystal-induced cellular recruitment in vivo [161]. Furthermore, human
TGFβ1 gene polymorphisms have been linked with longer inflammatory attacks and
increased tophus formation in the joints [187]. These findings identify TGFβ1, a
key mediator commonly involved in the resolution and tissue repair [182; 138], as
an important cytokine in MSU crystal-induced inflammation.
A key process in shutting down an inflammatory response is the efficient clearance of
apoptotic cells [183]. At the site of inflammation, neutrophils undergo spontaneous
apoptosis and are phagocytosed by macrophages, a mechanism involved in the res-
olution of acute gouty inflammation and the production of TGFβ1 [182; 184]. To
date, little is known about alternative sources of TGFβ1 other than macrophages,
and the importance of TGFβ1 during the resolution phase of MSU crystal-induced
inflammation and its regulatory effect on respiratory burst and IL-1β production by
MSU crystal-recruited neutrophils.
3.2 Aims
The aims of this chapter were to identify macrophage-independent sources of TGFβ1
during the resolution phase of MSU crystal-induced inflammation. In addition, to
determine the regulatory effect of TGFβ1 on ROS and IL-1β production by MSU
crystal-recruited neutrophils.
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3.3 Results
3.3.1 TGFβ1 profile in MSU crystal-induced inflammation
The resolution of acute gouty inflammation has been associated with the produc-
tion of the anti-inflammatory cytokine TGFβ1 [173]. Elevated levels of TGFβ1
have been found in the synovial fluid of patients suffering from gout [185; 186]. To
determine how the levels of TGFβ1 changed during the inflammatory response in
a murine peritoneal model of acute gout in vivo, peritoneal lavage fluids from MSU
crystal-treated mice were collected over time (section 2.6.1) and analysed for secreted
TGFβ1 by enzyme-linked immunosorbent assay (ELISA) (section 2.8). As shown
in Figure 3.1A, TGFβ1 levels increased in the peritoneum of MSU crystal-treated
mice within 4 hours, peaking at 8 hours and remained elevated for up to 72 hours
after MSU crystal administration, before returning to background level after 7 days.
Previous time course experiments have shown that following in vivo MSU crystal
administration, pro-inflammatory cytokine levels peak in the peritoneum between
4 - 8 hours [103]. To confirm that this was also the case in this study, IL-1β levels
were measured in the peritoneal fluid from mice at 8 and 18 hours post MSU crys-
tal administration (section 2.8). As expected, the pro-inflammatory cytokine levels
of IL-1β peaked at 8 hours and were significantly decreased by 18 hours (Figure
3.1B). Together, these findings showed that the levels of TGFβ1 induced by MSU
crystals mirrored the classical pro-inflammatory cytokine profile and that TGFβ1
was produced early during the inflammatory response.
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Figure 3.1: Profile of TGFβ1 and IL-1β in response to MSU crystals
in vivo. Mice were injected with MSU crystals (3 mg, i.p.) and at different time
points, peritoneal lavage fluid was collected in 3 ml PBS, and TGFβ1 (A) and IL-1β (B)
levels analysed by ELISA. Values are the mean -/+ SEM (n = 5 mice per group) and
representative of up to three experiments. * = P < 0.05, *** = P < 0.001, **** =
P < 0.0001 by one-way ANOVA with Tukey’s post test.
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3.3.2 Neutrophils are a source of TGFβ1
A hallmark feature of gout is the early infiltration of neutrophils and monocytes
to the site of inflammation. To determine which cells could be producing TGFβ1
in response to MSU crystal administration, MSU crystal-recruited peritoneal cells
were isolated (section 2.6.1) and analysed by flow cytometry (section 2.9) to identify
TGFβ1+ cells. Based on the TGFβ1 profile (Figure 3.1A) and the high number of
neutrophils [103] at the site of inflammation, 18 hours after MSU crystal adminis-
tration was chosen as the time point of interest.
To identify the infiltrating cells during the period of high TGFβ1 levels, peritoneal
cells were harvested by lavage from mice 18 hours after MSU crystal administration
(section 2.6.1). The peritoneal exudate cells were stained with fluorescent antibod-
ies for cell surface markers (Clone 7/4, Gr-1, Ly6G, CD11b, F4/80). MSU crystal-
recruited neutrophils were identified as Gr-1high 7/4+ Ly6Ghigh CD11b+ (Figure
3.2A, G1) and monocytes as Gr-1intermediate 7/4+ Ly6G− CD11b+ (Figure 3.2A,
G2). In naive mice, the resident cell population of macrophages were 7/4intermediate
Gr-1− F4/80+ CD11b+ (Figure 3.2B, G3).
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Figure 3.2: Identification of infiltrating cells in response to MSU crystals
in vivo. Mice were injected intraperitoneally with MSU crystals (3 mg). 18 hours
post MSU crystal administration, the peritoneal exudate cells were harvested by lavage
with 3 ml PBS and the cells were identified by flow cytometry. A Neutrophils were
identified as Gr-1high 7/4+ Ly6Ghigh CD11b+ (G1), and monocytes identified as Gr-
1intermediate 7/4+ Ly6G− CD11b+ (G2). B Macrophages harvested from naive mice were
identified as 7/4intermediate Gr-1− F4/80+ CD11b+ (G3). Results are representative of
three independent experiments.
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As shown in Figure 3.3A, there was a significant monocyte and neutrophil infiltra-
tion within the first 18 hours after challenge with MSU crystals. Analysis of the
different infiltrating cell populations for intracellular TGFβ1 expression showed that
both infiltrating monocytes and neutrophils expressed TGFβ1 (Figure 3.3B). The
production of TGFβ1 by monocytes/macrophages during an inflammatory response
is well documented [199]. However, the ability of neutrophils to produce TGFβ1
has not been previously reported. To confirm the results obtained by flow cytome-
try (Figure 3.3B), MSU crystal-recruited neutrophils were isolated and stained for
intracelluar TGFβ1 using fluorescence microscopy. In order to carry out this ex-
periment, an efficient purification method was required to get a pure neutrophil
population.
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Figure 3.3: Expression of TGFβ1 by monocytes and neutrophils Mice were
injected with MSU crystals (3 mg, i.p.), and after 8 and 18 hours peritoneal exudate cells
were harvested by lavage (3 ml PBS). A Number of infiltrating monocytes and neutrophils
from 8 and 18 hours MSU crystal-treated mice. B Peritoneal monocytes and neutrophils
were stained for intracellular TGFβ1 and analysed by flow cytometry. Values are the
mean -/+ SEM (n = 4 mice per group) and the results are representative of two separate
experiments. **** = P < 0.0001 (two-way ANOVA with Bonferroni’s post test).
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Firstly, it was necessary to obtain a pure neutrophil population. Peritoneal exudate
cells were harvested from mice that had been treated with MSU crystals for 18 hours
and the neutrophils were purified using a Lympholyte-M density gradient (section
2.6.5). The neutrophil population was then analysed for the expression of the sur-
face marker CD11b and the specific neutrophil marker Ly6G by flow cytometry. As
shown in Figure 3.4A, neutrophils were identified as CD11b+ Ly6G+ cells with a pu-
rity of greater than 90%. These cells also exhibited classical neutrophil morphology
with multi-lobed nuclei (hypersegmented), as shown in Figure 3.4B. These findings
confirmed that this purification method efficiently purified the CD11b+ Ly6G+ cells
from the peritoneum of MSU crystal-treated mice.
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Figure 3.4: Purification of neutrophils from MSU crystal-treated mice
in vivo. Mice were injected with MSU crystals (3 mg, i.p.). After 18 hours, peritoneal
cells were harvested by lavage (3 ml PBS) and neutrophils purified using a Lympholyte-M
density gradient. A The purified neutrophil population was identified as CD11b+ Ly6G+
by flow cytometry. B Purified neutrophils were stained using a hematoxylin and eosin
(H&E) staining method and examined microscopically. Original magnification 40x. Scale
bar represents 100 µm. Results are representative of three separate experiments.
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After the initiation of acute inflammation, the pro-inflammatory cytokine levels
of IL-1β returned to background within 18 hours after MSU crystal administra-
tion indicating a switch towards resolution (Figure 3.1B). To confirm that TGFβ1
levels were elevated at that time, peritoneal lavage fluid from 18 hour MSU crystal-
challenged mice was collected and analysed for TGFβ1 by ELISA. Consistent with
the clinical inflammatory profile, TGFβ1 levels in the lavage fluid from MSU crystal-
treated mice were significantly higher than those in the lavage fluid from naive mice
(Figure 3.5A). Neutrophils are present in high numbers 18 hours after MSU crys-
tal administration; therefore neutrophils from 18 hours MSU crystal-treated mice
were purified and stained for the surface marker Ly6G and intracellular TGFβ1.
Immunofluorescent histology (section 2.10.2) showed that Ly6G+ neutrophils (red)
expressed intracellular TGFβ1 (green) (Figure 3.5B). This finding identified MSU
crystal-recruited neutrophils as a potential source of TGFβ1 production in vivo.
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Figure 3.5: Neutrophils are a source of TGFβ1 in vivo. Mice were injected
with MSU crystals (3 mg, i.p.). After 18 hours, the peritoneal cells were harvested by
lavage (3 ml PBS). A TGFβ1 levels in peritoneal lavage fluid were analysed by ELISA.
B Fluorescence microscopy of purified neutrophils from the peritoneum (Ly6G+, red)
expressing intracellular TGFβ1 (green). Scale bars represent 100 µm. Values are the
mean -/+ SEM of three independent experiments. **** = P < 0.0001 by Student’s
t-test.
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3.3.3 TGFβ1 production in ex vivo cultured peritoneal neutrophils
To determine whether freshly isolated TGFβ1+ neutrophils were also secreting
TGFβ1 during ex vivo culture, MSU crystal-recruited neutrophils from 18 hour
treated mice were purified, as previously shown and cultured ex vivo under serum
free conditions for 24 hours. The culture supernatants were collected and analysed
for TGFβ1 (section 2.8). Interestingly, cultured neutrophils secreted significantly
higher levels of TGFβ1 compared to freshly isolated neutrophils from the peritoneum
(Figure 3.6A). Ex vivo cultured neutrophils were also stained for the surface marker
Ly6G (red) and intracellular TGFβ1, and analysed by immunofluorescent histol-
ogy (section 2.10.2). As shown in Figure 3.6B, ex vivo cultured Ly6G+ neutrophils
were positive for TGFβ1 (green). These results showed that ex vivo cultured neu-
trophils secreted more TGFβ1 compared to freshly isolated MSU crystal-recruited
neutrophils.
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Figure 3.6: TGFβ1 production by ex vivo cultured peritoneal neu-
trophils. Mice were treated with MSU crystals (3 mg, i.p.). After 18 hours, peritoneal
neutrophils were purified and cultured in serum free media ex vivo for 24 hours. A Cul-
ture supernatants were analysed for secreted levels of TGFβ1 by ELISA. B Fluorescence
microscopy of purified cultured neutrophils from the peritoneum (Ly6G+, red) expressing
TGFβ1 (green). Scale bars represent 100µm. Values are the mean -/+ SEM and are
representative of two independent experiments. *** = P < 0.001 by Student’s t-test.
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3.3.4 TGFβ1 production by apoptotic peritoneal neutrophils
Having confirmed that neutrophils were a source of TGFβ1 in MSU crystal-induced
inflammation, the mechanism which triggers neutrophil TGFβ1 production was in-
vestigated. Neutrophils are known to have a very short life span and undergo spon-
taneous apoptotic cell death [200; 201]. To identify a possible link between TGFβ1
and apoptosis, neutrophils were purified 18 hours following MSU crystal adminis-
tration (section 2.6.5) and cultured ex vivo for 24 hours. The neutrophils (CD11b+
Ly6G+) were then stained with the apoptosis marker annexinV and analysed by flow
cytometry (section 2.9). As shown in Figure 3.7A, the percentage of annexinV+ neu-
trophils following ex vivo culture significantly increased compared to freshly isolated
MSU crystal-recruited neutrophils indicating that neutrophils underwent apoptotic
cell death.
Neutrophils were also cultured ex vivo in the presence of GolgiStop to prevent the
release of TGFβ1 for 24 hours. Ex vivo cultured neutrophils, as well as freshly iso-
lated neutrophils, were then stained for the intracellular apoptosis marker caspase
3 in combination with intracelluar TGFβ1, and their expression determined by flow
cytometry (section 2.9). As shown in Figure 3.7B, the percentage of apoptotic neu-
trophils (caspase 3+) increased when neutrophils were cultured ex vivo for 24 hours
(red box) compared to the freshly isolated neutrophils (black box). Importantly,
only apoptotic neutrophils upregulated TGFβ1 (Figure 3.7C, red line).
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Figure 3.7: TGFβ1 production by apoptotic peritoneal neutrophils. Mice
were treated with MSU crystals (3 mg, i.p.). After 18 hours, peritoneal neutrophils were
purified and cultured ex vivo for 24 hours. A Percentage of freshly isolated neutrophils
from the peritoneum and 24 hour cultured neutrophils (CD11b+ Gr-1+) expressing the
apoptotic marker annexinV, as determined by flow cytometry. B, C Purified peritoneal
neutrophils were cultured ex vivo in the presence of GolgiStop (1:1000) for 24 hours.
Freshly isolated and cultured neutrophils co-expressing the apoptotic marker caspase 3 and
TGFβ1 (B), and the TGFβ1+ expression by caspase 3+ neutrophils (C) as determined by
flow cytometry. Values are the mean -/+ SEM and are representative of two independent
experiments. * = P < 0.05 by Student’s t-test.
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The previous results in Figure 3.7 were conducted for a single time point only. To
determine the association between TGFβ1 and apoptosis over a period of 24 hours,
MSU crystal-recruited neutrophils were purified and cultured ex vivo. The levels of
secreted or intracellular TGFβ1 were analysed in the absence or presence of Gol-
giStop by flow cytometry respectively (section 2.9). As shown in Figure 3.8A and
3.8B, the ex vivo cultured neutrophils exhibited an increase in both the percentage
of TGFβ1+ neutrophils and the levels of secreted TGFβ1 over time. Neutrophil
TGFβ1 generation was also associated with an upregulation of the apoptotic mark-
ers annexinV and caspase 3 (Figure 3.8C and 3.8D). In summary, these findings
showed that an increase in neutrophil TGFβ1 production was associated with in-
creased neutrophil apoptosis indicating a possible link between neutrophil TGFβ1
production and apoptotic cell death.
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Figure 3.8: Increased TGFβ1 production in ex vivo cultured peritoneal
neutrophils. Mice were treated with MSU crystals (3 mg, i.p.). After 18 hours,
peritoneal neutrophils were purified and cultured ex vivo for up to 24 hours. A Neutrophils
were cultured in the presence of GolgiStop (1:1000) and at respective time points, the
percentage of Ly6G+ TGFβ1+ neutrophils was determined by flow cytometry. B The
levels of TGFβ1 in the culture supernatants (in the absence of GolgiStop) were measured
by ELISA. C, D Percentage of Ly6G+ neutrophils expressing the apoptotic markers
annexinV (C) and caspase 3 (D), as determined by flow cytometry. Values represent the
mean -/+ SEM of three independent experiments. * = P < 0.05, ** = P < 0.01, *** =
P < 0.001 by one-way ANOVA with Tukey’s post analysis.
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3.3.5 Neutrophil TGFβ1 production is linked to neutrophil apopto-
sis
Neutrophils are the shortest lived cells among circulating leukocytes and have been
shown to rapidly undergo apoptotic cell death [182; 200]. This process of neutrophil
apoptosis can be regulated via a number of different caspases, including caspase 1,
3, 4 and 8 [202; 203; 204]. To confirm the relationship between neutrophil apoptosis
and TGFβ1 production, neutrophil apoptosis was inhibited using a general caspase
inhibitor Q-VD-OPh (20µM), and the production of TGFβ1 was monitored for up
to 24 hours (section 2.7.1). At different time points, the supernatants from ex vivo
cultured neutrophils were collected and the levels of secreted TGFβ1 measured by
ELISA (section 2.8). Neutrophils were stained for the apoptotic markers annexinV
and caspase 3, and analysed by flow cytometry (section 2.9). To determine intra-
cellular TGFβ1 by flow cytometry, neutrophils were treated with GolgiStop during
the ex vivo culture. As shown in Figure 3.9A and 3.9B, the number of annexinV+
and caspase 3+ neutrophils were significantly decreased when the cells were treated
with the caspase inhibitor Q-VD-OPh indicating that neutrophil apoptosis was suc-
cessfully inhibited. The blockade of neutrophil apoptosis resulted in fewer TGFβ1+
neutrophils (Figure 3.9C) and correlated with a decrease in the levels of secreted
TGFβ1 (Figure 3.9D). These findings indicated that neutrophil apoptosis was re-
quired for the production of TGFβ1 by neutrophils.
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Figure 3.9: Neutrophil TGFβ1 production is linked to neutrophil apop-
tosis. Mice were injected with MSU crystals (3 mg, i.p.). After 18 hours, MSU
crystal-recruited neutrophils were purified from the peritoneal lavage and cultured in the
presence of the general caspase inhibitor Q-VD-OPh (20µM) ex vivo for 24 hours. To
measure intracellular TGFβ1, cells were also treated with GolgiStop (1:1000). A, B The
percentage of Ly6G+ neutrophils expressing the apoptotic marker annexinV (A) and cas-
pase 3 (B) was measured by flow cytometry. C The percentage of TGFβ1+ neutrophils
was determined by flow cytometry. D The levels of TGFβ1 in the culture supernatants
were measured by ELISA. Values represent the mean -/+ SEM. Results are representative
of two independent experiments. * = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** =
P < 0.0001 (two-way ANOVA with Bonferroni’s post test).
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3.3.6 TGFβ1 production by apoptotic blood neutrophils
In MSU crystal-induced inflammation, neutrophils infiltrate into a highly pro-inflam-
matory microenvironment where they become activated by MSU crystals, and pro-
duce cytokines and chemokines. In order to examine whether the phenomenon of
neutrophil TGFβ1 production was a general function of neutrophils rather than
an effect of their activation status, circulating blood neutrophils were collected by
cardiac puncture from MSU crystal-treated mice after 18 hours (section 2.6.2) and
purified using a Lympholyte-M density gradient (2.6.5). Between 60 - 70% of the
white blood cells were identified as Gr-1+ neutrophils by flow cytometry (Figure
3.10A). Purified circulating blood neutrophils were stained for the surface marker
Ly6G and intracellular TGFβ1, and examined under a fluorescence microscope (sec-
tion 2.10.2). As shown in Figure 3.10B, a small number of Ly6G+ blood neutrophils
were identified as TGFβ1+. These findings demonstrated that like MSU crystal-
recruited peritoneal neutrophils, circulating neutrophils were also able to produce
TGFβ1. This raised the question of whether the process of apoptosis by circulating
neutrophils is also required for the production of TGFβ1.
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Figure 3.10: TGFβ1+ blood neutrophils. Mice were treated with MSU crystals
(3 mg, i.p.). After 18 hours, blood neutrophils were collected by cardiac puncture and
purified using a Lympholyte-M density gradient. A Blood neutrophils were analysed by
flow cytometry to determine their purity (Gr-1+ cells). B Fluorescence microscopy stain-
ing of purified blood neutrophils (Ly6G+, red) expressing intracellular TGFβ1 (green).
Scale bars represent 100µm.
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In order to investigate whether TGFβ1 production by blood neutrophils was also
the result of apoptotic cell death, blood neutrophils were purified 18 hours following
MSU crystal administration and cultured ex vivo in the presence of GolgiStop for
up to 24 hours. The blood neutrophils were analysed for the expression of caspase
3 and intracellular TGFβ1 as well as secreted levels of TGFβ1 in the culture su-
pernatants. As shown in Figure 3.11A, the percentage of caspase 3+ cells increased
when the blood neutrophils (Gr-1+) were cultured ex vivo for 24 hours (red box)
compared to the freshly isolated neutrophils (blue box). Approximately 48% of these
caspase 3+ blood neutrophils were identified as TGFβ1+ illustrated by an increase
in the expression of TGFβ1 by ex vivo cultured neutrophils compared to uncultured
neutrophils (Figure 3.11B). This was consistent with an increase in the levels of se-
creted TGFβ1 in ex vivo cultured blood neutrophils over time (Figure 3.11C). In
summary, these data indicated that apoptosis of circulating naive neutrophils was
required for TGFβ1 production and that apoptosis-driven TGFβ1 production was
not dependent on MSU crystal activation of neutrophils in vivo.
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Figure 3.11: TGFβ1 production by apoptotic blood neutrophils. Mice
were injected with MSU crystals (3 mg, i.p.). After 18 hours, blood neutrophils were
purified and cultured ex vivo for 24 hours. A, B Percentage of Gr-1+ blood neutrophils co-
expressing the apoptotic marker caspase 3 and TGFβ1 (A), and the TGFβ1+ expression
by caspase 3+ neutrophils (B) as determined by flow cytometry. C TGFβ1 levels from
supernatants of cultured blood neutrophils were measured by ELISA. Values represent
the mean -/+ SEM of two independent experiments. ** = P < 0.01, *** = P < 0.001 by
one-way ANOVA with Tukey’s post analysis.
Chapter 3: Neutrophils in the Resolution of Acute Inflammation 79
3.3.7 TGFβ1 production by neutrophils is linked to neutrophil self-
clearance
Studies have shown that the process of recognition and clearance of apoptotic neu-
trophils by macrophages is an important mechanism involved in the generation of
macrophage TGFβ1 and the resolution of acute inflammation [182; 183; 199]. How-
ever, neutrophils are also professional phagocytes [191] and they are present in high
numbers at sites of acute inflammation whereas the macrophages are rare.
This led to the hypothesis that neutrophil phagocytosis of apoptotic cells triggers the
generation of TGFβ1.
To test this hypothesis, MSU crystal-recruited peritoneal neutrophils were purified
and cultured ex vivo in the presence of CytochalasinD (section 2.7.1), a phagocyto-
sis inhibitor which has been widely used to block the uptake of apoptotic cells by
macrophages [205; 206; 207]. At different time points, intracellular TGFβ1 produc-
tion by neutrophils was analysed by flow cytometry and the TGFβ1 levels in culture
supernatants measured by ELISA. As shown in Figure 3.12A, the blockade of neu-
trophil phagocytosis resulted in a decrease in the percentage of TGFβ1+ neutrophils.
In contrast, ex vivo culture of neutrophils in the presence of CytochalasinD caused
an increase in the secreted levels of TGFβ1 (Figure 3.12B) over time. CytochalasinD
has been shown to have effects on neutrophil morphology, exocytosis and disrup-
tion of the actin cytoskeleton [208; 209; 210]; therefore the viability of neutrophils
was investigated. As shown in Figure 3.12C, the percentage of necrotic neutrophils
(PI+) in the presence of CytochalasinD had increased over time. These data indi-
cated that CytochalasinD was inducing membrane disruption in neutrophils thus
causing non-specific release of TGFβ1 as a result of necrotic cell death. Based on
the evidence that CytochalasinD caused necrotic cell death of neutrophils, an alter-
native approach was employed to investigate the association between phagocytosis
of apoptotic cells and TGFβ1 production by neutrophils.
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Figure 3.12: TGFβ1 production by neutrophils is linked to neutrophil
self-clearance. Mice were injected with MSU crystals (3 mg, i.p.). After 18 hours,
MSU crystal-recruited neutrophils were purified from the peritoneal cavity and cultured in
the presence of the phagocytosis inhibitor CytochalasinD (20 µg/ml) ex vivo for 24 hours.
A The percentage of TGFβ1+ neutrophils was analysed by flow cytometry. B The levels
of TGFβ1 in culture supernatants were measured by ELISA. C The percentage of PI+
neutrophils was analysed by flow cytometry respectively. Values represent the mean -/+
SEM of two independent experiments. * = P < 0.05, ** = P < 0.01, **** = P < 0.0001
(two-way ANOVA with Bonferroni’s post test).
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3.3.8 Phagocytosis of apoptotic neutrophils induces neutrophil TGFβ1
production
As CytochalasinD caused necrosis, an alternative approach was used to determine
if phagocytosis of apoptotic neutrophils was inducing neutrophil TGFβ1 produc-
tion. First, MSU crystal-recruited neutrophils were purified and cultured ex vivo
overnight to induce apoptosis. These apoptotic neutrophils were then incubated ex
vivo with freshly isolated MSU crystal-recruited neutrophils at a cell ratio of 5:1
(apoptotic cell:live cell) for 8 hours. The TGFβ1 levels in supernatants from the
single cell culture of live or apoptotic neutrophils, and the co-culture consisting of
both live and apoptotic cells were measured by ELISA. As shown in Figure 3.13A,
the levels of secreted TGFβ1 from co-incubation of live and apoptotic neutrophils
were significantly higher than in the supernatants from the single cell cultures of live
or apoptotic neutrophils. This indicated that phagocytosis of apoptotic neutrophils
by live neutrophils could be the primary trigger for neutrophil TGFβ1 production.
To confirm that phagocytosis was triggering TGFβ1 production, freshly isolated
MSU crystal-recruited neutrophils labelled with the surface marker APC-Ly6G were
incubated with apoptotic neutrophils labelled with PerCP-Ly6G (apoptotic cell:live
cell, ratio 5:1) in the presence of GolgiStop ex vivo for 8 hours (section 2.7.2) and
then stained for intracellular TGFβ1. Flow cytometry analysis of the cell culture
confirmed that live neutrophils (APC-Ly6G+, green box) were able to phagocytose
apoptotic neutrophils (PerCP-Ly6G+, black box) as shown in the double positive
population (APC-Ly6G+ / PerCP-Ly6G+, red box) in Figure 3.13B. Interestingly,
the expression of TGFβ1 was greatest in live cells that had phagocytosed apoptotic
cells (red line) compared to the single cell populations, apoptotic neutrophils (black
line) or live neutrophils (green), as shown in Figure 3.13C. Taken together, these
results confirmed that the clearance of apoptotic cells by neutrophils was a primary
trigger for inducing TGFβ1 production.
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Figure 3.13: Phagocytosis of apoptotic neutrophils induces neutrophil
TGFβ1 production. Mice were injected with MSU crystals (3 mg, i.p.). After 18
hours, neutrophils were purified and cultured for 8 hours ex vivo. A Supernatants from
apoptotic neutrophils, live neutrophils or the co-culture were analysed for TGFβ1 by
ELISA. B, C Apoptotic neutrophils (PerCP-Ly6G+) and live neutrophils (APC-Ly6G+)
were co-cultured for 8 hours ex vivo. The cell culture was analysed by flow cytometry
to compare the levels of TGFβ1 expression in the single positive neutrophil populations
versus the live cell population that had phagocytosed apoptotic neutrophils (APC-Ly6G+
/ PerCP-Ly6G+). Values represent the mean -/+ SEM of two independent experiments.
* = P < 0.05 (one-way ANOVA with Tukey’s post test).
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3.3.9 TGFβ1 production suppresses neutrophil respiratory burst and
IL-1β production ex vivo
Previous studies have shown that phagocytosis of apoptotic neutrophils can sup-
press pro-inflammatory responses to external stimuli, including the production of
cytokines and reactive oxygen species (ROS) [199; 211]. IL-1β is a primary signal
for the inflammatory cascade, and ROS production by neutrophils is an important
effector function that can directly contribute to cell and tissue damage [193; 212].
To investigate whether neutrophil TGFβ1 production could be modulating super-
oxide and IL-1β production, MSU crystal-recruited neutrophils were purified and
incubated ex vivo with either an anti-TGFβ1 antibody (35 µg/ml), or stimulated
with MSU crystals (200 µg/ml) or a combination of both (section 2.8.1). Superoxide
production was measured immediately using the colorimetric dye WST-1 (section
2.7.3). To measure IL-1β levels, supernatants were collected from the neutrophil
culture after 4 hours and analysed by ELISA (section 2.8).
Restimulation of the neutrophils ex vivo resulted in an increase in the production
of both neutrophil superoxide (Figure 3.14A) and IL-1β (Figure 3.14B) compared
to untreated neutrophils. Interestingly, in the presence of the neutralising TGFβ1
antibody, the neutrophils exhibited a significant increase in both the production of
superoxide (Figure 3.14A) and IL-1β (Figure 3.14B), with or without MSU crys-
tals.
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Figure 3.14: TGFβ1 production suppresses neutrophil respiratory burst
and IL-1β production ex vivo. Mice were injected with MSU crystals (3 mg, i.p.).
After 18 hours, neutrophils were purified from the peritoneal cavity. Freshly isolated
MSU crystal-recruited neutrophils were cultured ex vivo -/+ MSU crystal stimulation
(200 µg/ml) and -/+ anti-TGFβ1 antibody (35 µg/ml) and A superoxide production and
B IL-1β production measured by ELISA after 4 hours in culture. Values represent the
mean -/+ SEM of two independent experiments. * = P < 0.05, ** = P < 0.01 (two-way
ANOVA with Bonferroni’s post test).
Chapter 3: Neutrophils in the Resolution of Acute Inflammation 85
Neutrophils were also tested for their ability to regulate other pro-inflammatory
cytokines such as TNFα, IL-6 and the neutrophil chemokine (C-X-C motif) ligand
1 (CXCL1). As shown in Figure 3.15A - C, ex vivo restimulation of neutrophils
with MSU crystals, the anti-TGFβ1 antibody or the combination of both had no
effect on the production of TNFα, IL-6 or CXCL1. Taken together, these results
indicated that neutrophil phagocytosis and TGFβ1 production were important for
regulating neutrophil respiratory burst and IL-1β production ex vivo.
A
TN
Fα
 [p
g/
m
L]
α-TGFβ1
B
0
5
10
15
20
- -+ +
0
5
10
15
20
-
C
0
2
4
6
8
10
untreated MSU
+
untreated MSU
- +
IL
-6
 [p
g/
m
L]
α-TGFβ1 - +
untreated MSU
- +α-TGFβ1
C
X
C
L1
 [p
g/
m
L]
Figure 3.15: Neutrophil TGFβ1 production does not alter the cytokines
TNFα, IL-6 or the chemokine CXCL1. Mice were injected with MSU crystals
(3 mg, i.p.). After 18 hours, neutrophils were purified from the peritoneal cavity. Freshly
isolated MSU crystal-recruited neutrophils were cultured ex vivo -/+ MSU crystal stim-
ulation (200 µg/ml) and -/+ anti-TGFβ1 antibody (35 µg/ml) for 4 hours. The levels of
the cytokines (A) TNFα, (B) IL-6 and (C) CXCL1 in culture supernatants were mea-
sured by multiplex bead array. Values represent the mean -/+ SEM of two independent
experiments.
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3.3.10 TGFβ1 production suppresses neutrophil respiratory burst in
vivo
Finally, the effect of TGFβ1 on MSU crystal-induced neutrophil superoxide and IL-
1β production was investigated in vivo. Mice were injected intraperitoneally with
the anti-TGFβ1 antibody (1 mg) 30 minutes prior to MSU crystal treatment (3 mg)
(section 2.5.4). After 8 and 18 hours, MSU crystal-recruited neutrophils were har-
vested and purified, and superoxide production was measured immediately (section
2.7.3). Neutrophils were also cultured ex vivo for 4 hours, and the culture super-
natants collected and analysed for IL-1β (section 2.8). As shown in Figure 3.16A,
neutrophils that were isolated 18 hours after MSU crystal administration produced
more superoxide than neutrophils isolated 8 hours after MSU crystal administration.
TGFβ1 neutralisation did not alter superoxide production by neutrophils, isolated
8 hours after MSU crystal treatment. However, TGFβ1 neutralisation caused a sig-
nificant increase in superoxide production by neutrophils 18 hours following MSU
crystal administration.
In contrast, MSU crystal-recruited neutrophils from the 18 hour time point produced
less IL-1β compared to neutrophils isolated 8 hours after MSU crystal administration
(Figure 3.16B). Interestingly, TGFβ1 neutralisation did not affect IL-1β production
by neutrophils isolated at 8 and 18 hours. These findings showed that neutralisation
of TGFβ1 resulted in an increase in superoxide production by neutrophils without
altering IL-1β production in vivo.
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Figure 3.16: TGFβ1 production suppresses neutrophil respiratory burst
in vivo. Mice were injected with the anti-TGFβ1 antibody (1 mg, i.p.) 30 minutes prior
MSU crystal administration (3 mg, i.p.). After 8 and 18 hours, MSU crystal-recruited
peritoneal neutrophils were harvested and purified, and A superoxide production was
measured. B Purified peritoneal neutrophils were cultured for 4 hours ex vivo and IL-1β
production in culture supernatants measured by ELISA. Values represent the mean -/+
SEM of two independent experiments. ** = P < 0.01 (two-way ANOVA with Bonferroni’s
post test).
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3.4 Summary
The process of phagocytosis of apoptotic neutrophils and TGFβ1 production is a
characteristic feature of the spontaneous resolution of acute inflammation and it
is traditionally attributed to macrophage function [199; 183]. Like macrophages,
neutrophils are professional phagocytes [191]. Previous research has shown that
phagocytosis of apoptotic neutrophils can suppress pro-inflammatory responses via
cytokines and ROS [199; 211]. The results presented in this chapter show that
the process of phagocytosis of apoptotic neutrophils by neutrophils triggers the
production of TGFβ1, which further leads to the suppression of superoxide and
IL-1β production by MSU crystal-activated neutrophils in vitro. However, although
neutralising TGFβ1 in vivo resulted in an increase in superoxide production by neu-
trophils, it did not alter IL-1β production. This indicated that neutrophil-derived
TGFβ1 may only be one mechanism involved in regulating active IL-1β during a
neutrophil-driven inflammatory response in vivo.
The results presented in this chapter show that the process of neutrophil cani-
balism triggers neutrophil TGFβ1 production, which leads to the suppression of
neutrophil respiratory burst and acts as a non-essential moderator of IL-1β pro-
duction, as shown in Figure 3.17. This indicated that neutrophils also contribute
to the spontaneous resolution of acute gouty inflammation via phagocytosis-driven
TGFβ1 production.
Chapter 3: Neutrophils in the Resolution of Acute Inflammation 89
IL-1β
O2˙MSU crystals
TGFβ1
21
3
4
Figure 3.17: Neutrophils and the resolution of inflammation. Neutrophils
undergo apoptosis (1) and are phagocytosed by live neutrophils (2) leading to the produc-
tion of TGFβ1 (3) and the suppression of MSU crystal-induced neutrophil inflammatory
responses (4). O2- = superoxide; IL-1β = interleukin-1 beta.
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4 The Effect of TGFβ1 on GM-BMMs and M-
BMMs in Response to MSU Crystals
4.1 Introduction
Macrophages are known for their heterogeneity and diversity depending on the in-
flammatory microenvironment. Two major cytokines that influence the differen-
tiation and function of macrophages are GM-CSF and M-CSF; well documented
growth factors. Recent reports have shown that human monocytes treated with
GM-CSF differentiate into a pro-inflammatory macrophage subset in vitro, bet-
ter known as M1-like macrophages [140; 141]. In the presence of M-CSF, human
monocyte-derived macrophages can be differentiated into an anti-inflammatory or
tissue-resident macrophage phenotype (M2-like cells) [140; 141; 142].
One study has now shown that in a peritoneal model of acute inflammation, MSU
crystal-recruited monocytes differentiate into hyper-inflammatory macrophages in
vivo [149]. The polarisation of this pro-inflammatory macrophage phenotype is de-
pendent on the growth factor GM-CSF [unpublished data, manuscript submitted].
Results presented previously in Figure 3.1A show that this phenotype also develops
in the presence of high levels of TGFβ1. However, the effect of TGFβ1 on the
development of GM-CSF and M-CSF macrophages in acute gouty inflammation in
vivo remains unknown. To gain more insight into how both CSFs (GM-CSF and
M-CSF) and TGFβ1 contribute to macrophage differentiation and inflammatory
responses, the current study focused on the effect of TGFβ1 on the function of in
vitro generated bone-marrow derived macrophages (BMMs).
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4.2 Aim
The aim of this chapter was to investigate the effect of TGFβ1 on the functional
phenotype of in vitro generated GM-CSF and M-CSF BMMs.
4.3 Results
4.3.1 Differentiation of GM-CSF and M-CSF BMMs
To investigate the effect of TGFβ1 on the functional properties of GM-CSF-different-
iated macrophages (GM-BMMs) and M-CSF-differentiated macrophages (M-BMMs),
murine bone marrow cells were harvested (section 2.6.4) and cultured in vitro with
either GM-CSF (1000 units/ml) or M-CSF (5000 units/ml) in the absence or pres-
ence of recombinant human TGFβ1 (1 ng/ml or 10 ng/ml) for seven days (sec-
tion 2.7.4). The concentrations of GM-CSF and M-CSF for the differentiation of
macrophages were used according to the literature [213; 214]. As illustrated in Fig-
ure 4.1, the cells were fed with the appropriate media containing the growth factors
GM-CSF and M-CSF, and/or rhTGFβ1 on day one, three and five.
On day seven, the non-adherent cells were removed by extensive washing and the
adherent BMMs were primed with 50 pg/ml lipopolysaccharide (LPS) overnight
(section 2.7.4). Unlike monocytes and due to the sterile in vitro culture environ-
ment, macrophages need a co-stimulating or priming signal first, for example LPS,
to induce the synthesis of cytokine gene expression, including inactive pro-IL-1β
[215; 216; 217; 218]. Following LPS priming, TGFβ1-differentiated GM-BMMs and
M-BMMs were then stimulated with MSU crystals (200 µg/ml) or LPS (100 ng/ml)
or left untreated (control) for 18 hours (section 2.7.5). After stimulation, culture
supernatants were collected and analysed for different cytokines and chemokines by
ELISA or multiplex bead array (section 2.8), and/or cells were harvested for flow
cytometry analysis (section 2.9) or cytoplasmic protein collected for western blot
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analysis (section 2.11).
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Figure 4.1: Experimental layout of in vitro TGFβ1-differentiated GM-
CSF and M-CSF bone marrow-derived macrophages.
4.3.2 TGFβ1 drives a pro-inflammatory GM-BMM phenotype
Cytokine analysis showed that after MSU crystal stimulation, GM-BMMs produced
the pro-inflammatory cytokines IL-1α and IL-1β (Figure 4.2). Interestingly, in re-
sponse to TGFβ1 MSU crystal-stimulated GM-BMMs significantly increased the
production of IL-1β and IL-1α. TGFβ1 treatment had no effect on the cytokine
levels of TNFα and IL-6, or the chemokines MCP-1 and CXCL1 produced by MSU
crystal-stimulated GM-BMMs. In response to LPS, GM-BMMs produced low levels
of IL-1β but high levels of TNFα, MCP-1 and CXCL1, that were unaffected by
TGFβ1.
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Figure 4.2: Cytokine production by in vitro stimulated TGFβ1-
differentiated GM-BMMs. Bone marrow cells were harvested and cultured in vitro
with the growth factor GM-CSF (1000 units/ml) in the presence of recombinant human
TGFβ1 (1 ng/ml or 10 ng/ml) for 7 days following priming with 50 pg/ml LPS overnight.
GM-BMMs were then stimulated with MSU crystals (200 µg/ml) or LPS (100 ng/ml) or
left untreated (control) for 18 hours. Supernatants from cell culture were collected and
analysed for IL-1β, IL-1α, TNFα, IL-6, MCP-1 and CXCL1 by ELISA and multiplex
bead array. Values are the mean -/+ SEM and representative of three experiments. ** =
P < 0.01, **** = P < 0.0001 (two-way ANOVA with Bonferroni’s post test).
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The non-adherent GM-BMMs were also tested for their functional properties. After
priming with LPS, the cells were stimulated with MSU crystals (200 µg/ml) or
LPS (100 ng/ml) for 18 hours and the supernatants collected for cytokine analysis
(section 2.8). The MSU crystal-stimulated non-adherent cells produced significantly
lower levels of IL-1β than the adherent GM-BMMs that decreased further with
TGFβ1 treatment (Figure 4.3). The non-adherent cells failed to produce TNFα, IL-
6, MCP-1 and secreted only low levels of CXCL1. TGFβ1 treatment had no effect on
LPS-stimulated cells apart from decreased MCP-1 levels. These results confirmed
that only the adherent TGFβ1-differentiated GM-BMMs exhibited an enhanced
inflammatory phenotype in response to MSU crystals similar to that identified in
vivo [103]. Therefore, all further experiments carried out within this chapter focused
on the adherent macrophage population.
Chapter 4: The Effect of TGFβ1 on GM-BMMs and M-BMMs 96
IL
-1
α 
[p
g/
m
l]
control MSU LPS
control MSU LPS
IL
-6
 [p
g/
m
l]
control MSU LPS
TN
Fα
 [p
g/
m
l]
M
C
P
-1
 [p
g/
m
l]
control MSU LPS control MSU LPS
IL
-1
β 
[p
g/
m
l]
control MSU LPS
untreated 1 ng/ml rhTGFβ1 10 ng/ml rhTGFβ1
C
X
C
L1
 [p
g/
m
l]
0
50
100
150
200
***
0
50
100
150
0
100
200
300
1500
2000
2500
0
50
100
100000
200000
300000
400000
0
100
200
300
1000
2000
3000
****
****
0
50
100
150
200
2000
4000
6000
8000
10000
150
Figure 4.3: Cytokine production by in vitro stimulated non-adherent
TGFβ1-differentiated GM-BMMs. Bone marrow cells were harvested and cultured
in vitro with GM-CSF (1000 units/ml) in the presence of rhTGFβ1 (1 ng/ml or 10 ng/ml)
for 7 days. Non-adherent cells were removed and transfered into new 6-well plates (1x106
cells/ml) following priming with 50 pg/ml LPS overnight. Non-adherent GM-BMMs were
then stimulated with MSU crystals (200 µg/ml) or LPS (100 ng/ml) or left untreated
(control) for 18 hours. Supernatants from cell culture were collected and analysed for IL-
1β, IL-1α, TNFα, IL-6, MCP-1 and CXCL1 by ELISA and multiplex bead array. Values
are the mean -/+ SEM and representative of two experiments. *** = P < 0.001, **** =
P < 0.0001 (two-way ANOVA with Bonferroni’s post test).
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As shown in Figure 4.4, MSU crystal-stimulated M-BMMs produced significantly
reduced levels of IL-1β following TGFβ1 treatment, whereas the levels of IL-1α,
TNFα, IL-6, MCP-1 and CXCL1 were unaffected. Unlike GM-BMMs, TGFβ1 treat-
ment significantly increased the production of all cytokines and chemokines by LPS
stimulated M-BMMs. During the 7 day in vitro culture of M-BMMs, non-adherent
cells were not observed in the culture plates; therefore, only the adherent M-BMMs
were characterised within this chapter. Taken together, these findings showed that,
with respect to MSU crystal stimulation, TGFβ1 was driving a hyper-inflammatory
GM-BMM phenotype, but a hypo-inflammatory M-BMM phenotype.
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Figure 4.4: Cytokine production by in vitro stimulated TGFβ1-
differentiated M-BMMs. Bone marrow cells were harvested and cultured in vitro
with M-CSF (5000 units/ml) in the presence of rhTGFβ1 (1 ng/ml or 10 ng/ml) for 7
days following priming with 50 pg/ml LPS overnight. M-BMMs were then stimulated with
MSU crystals (200 µg/ml) or LPS (100 ng/ml) or left untreated (control) for 18 hours.
Supernatants from cell culture were collected and analysed for IL-1β, IL-1α, TNFα, IL-6,
MCP-1 and CXCL1 by ELISA and multiplex bead array. Values are the mean -/+ SEM
and representative of two experiments. *** = P < 0.001, **** = P < 0.0001 (two-way
ANOVA with Bonferroni’s post test).
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4.3.3 The effect of TGFβ1 on BMM polarisation
In the preceeding experiments, GM-BMMs and M-BMMs were differentiated in the
presence of TGFβ1 for seven days following stimulation. To investigate whether
TGFβ1 had the same effect on fully differentiated GM-BMMs and M-BMMs, both
macrophage populations were differentiated with GM-CSF or M-CSF for seven days
prior to the culture in the absence or presence of TGFβ1 (1 ng/ml or 10 ng/ml)
for one or five days (section 2.7.4). LPS-primed BMMs were stimulated with either
MSU crystals (200 µg/ml) or LPS (100 ng/ml) for 18 hours, and the IL-1β levels
in the culture supernatants measured by ELISA (section 2.8). IL-1β production by
MSU or LPS-stimulated GM-BMMs was not affected by one or five days TGFβ1
treatment (Figure 4.5A and B).
In comparison to GM-BMMs, one and five day TGFβ1 treatment resulted in a sig-
nificant decrease in the production of IL-1β by MSU crystal-stimulated M-BMMs
(Figure 4.5C and D). Interestingly, TGFβ1 treatment for one day had no significant
effect on the IL-1β levels by LPS-stimulated M-BMMs (Figure 4.5A) that was sig-
nificantly reduced after five days of TGFβ1 treatment (Figure 4.5B). These results
were in contrast to the IL-1β production obtained in Figure 4.4 showing that LPS-
stimulated M-BMMs produced significantly more IL-1β when differentiated in the
presence of TGFβ1.
Together, these findings indicated that TGFβ1 was required during the differen-
tiation process to drive the hyper-inflammatory GM-BMM phenotype in response
to MSU crystals. In addition, TGFβ1 induced a hypo-inflammatory M-BMM phe-
notype after MSU crystal stimulation that was independent of whether M-BMMs
were treated with TGFβ1 during or after differentiation.
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Figure 4.5: TGFβ1 required during differentiation to drive pro-
inflammatory GM-BMMs. Bone marrow cells were harvested and cultured in vitro
with GM-CSF (1000 units/ml) or M-CSF (5000 units/ml) for 7 days. After 7 days,
rhTGFβ1 (1 ng/ml or 10 ng/ml) was added into the GM-BMM or M-BMM culture for 1
day or 5 days, respectively. BMMs were then primed with 50 pg/ml LPS overnight fol-
lowing stimulation with MSU crystals (200 µg/ml) or LPS (100 ng/ml), or left untreated
(control) for 18 hours. Supernatants from the 1 day (A, C) or 5 days (B, D) cultures were
collected and analysed for IL-1β by ELISA. Results are representative of two experiments.
** = P < 0.01, *** = P < 0.001 (two-way ANOVA with Bonferroni’s post test).
Chapter 4: The Effect of TGFβ1 on GM-BMMs and M-BMMs 101
4.3.4 TGFβ1 induces pro-inflammatory GM-BMM phenotype indepen-
dent of stimuli
In addition to MSU crystals, TLR agonists such as LPS and Pam3Cys have been
shown to trigger an inflammatory response in monocytes and macrophages, leading
to the activation of the NLRP3 inflammasome and the production of IL-1β [219].
To determine whether the hyper-inflammatory GM-BMM phenotype and the hypo-
inflammatory M-BMM phenotype emerging in the presence of TGFβ1 were also
triggered in response to different inflammatory stimuli, LPS-primed GM-BMMs and
M-BMMs were stimulated with LPS (100 ng/ml), Pam3Cys (100 ng/ml) or MSU
cystals (200 µg/ml) for 18 hours (section 2.7.5). After stimulation, supernatants
from the cell cultures were collected and analysed for IL-1β by ELISA (section 2.8).
Consistent with the previous results in Figure 4.2, TGFβ1-differentiated GM-BMMs
produced significantly more IL-1β upon MSU crystal stimulation compared to un-
treated GM-BMMs (Figure 4.6A). Similarly, stimulation of GM-BMMs with LPS
and Pam3Cys also triggered the production of IL-1β, which significantly increased
upon TGFβ1 treatment. TGFβ1 treatment induced a significant decrease in the
levels of IL-1β in MSU crystal-stimulated M-BMMs (Figure 4.6B) consistent with
previous data obtained in Figure 4.4. Interestingly, TGFβ1 treatment significantly
increased the production of IL-1β by LPS or Pam3Cys-stimulated M-BMMs.
These results confirmed that TGFβ1 contributed to the differentiation of a hyper-
inflammatory GM-BMM phenotype, whereas M-CSF-differentiated macrophages
were pushed towards a less responsive M-BMM phenotype specifically in response
to MSU crystals. Based on the differential effect of TGFβ1 on GM-BMMs vs M-
BMMs, the remainder of this chapter focused on investigating the effect of TGFβ1
on MSU crystal-stimulated GM-BMMs and M-BMMs.
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Figure 4.6: TGFβ1 induced pro-inflammatory response by GM-BMMs
independent of stimuli. Bone marrow cells were harvested and cultured in vitro with
GM-CSF (1000 units/ml) and M-CSF (5000 units/ml) in the presence of rhTGFβ1 (1
ng/ml or 10 ng/ml) for 7 days following priming with 50 pg/ml LPS overnight. After
priming, GM-BMMs and M-BMMs were stimulated with MSU crystals (200 µg/ml), LPS
(100 ng/ml) or Pam3Cys (100 ng/ml) for 18 hours. Supernatants from the GM-BMM (A)
and M-BMM (B) culture were collected and analysed for IL-1β by ELISA. Results are
representative of two separate experiments. ** = P < 0.01, **** = P < 0.0001 (two-way
ANOVA with Bonferroni’s post test).
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4.3.5 TGFβ1 suppresses T cell proliferation by GM-BMMs
Macrophages have been shown to play a role in bridging innate and adaptive im-
mune responses. They have the ability to act as antigen presenting cells (APCs)
initiating T cell responses, and to maintain tolerance [220; 221]. APCs express
major histocompatibility complex class II (MHCII) molecules on their cell surface,
therefore they are able to present antigen to CD4 T cells [222; 223]. For the acti-
vation of naive CD4 T cells, two signals are required: the first signal is provided by
the recognition of MHCII on APCs and the second signal is a co-stimulatory signal
via CD86, which is expressed on activated APCs. Recent studies have shown that
GM-BMMs can activate and present antigen to T cells [224], whereas M-BMMs are
defective in APC functions [225]. There is also evidence showing that TGFβ1 has
immunosuppressive activities by inhibiting T cell proliferation [226]. In order to
confirm the functional differences between GM-BMMs and M-BMMs and the effect
of TGFβ1 on their APC function, GM-BMMs and M-BMMs were primed with LPS
(100 ng/ml) for 18 hours (section 2.7.6) and then analysed for the expression of
CD86 and MHCII by flow cytometry (section 2.9).
Mature GM-BMMs expressed high levels of CD86 and MHCII (Figure 4.7A). The
expression of both CD86 and MHCII was down-regulated upon TGFβ1 treatment.
This was consistent with previous reports showing that TGFβ1 down-regulates
CD86 and MHCII expression on GM-CSF-differentiated BMMs [227; 228]. On the
other hand, M-BMMs expressed low levels of CD86 and MHCII compared to GM-
BMMs (Figure 4.7B, red line). TGFβ1 treatment induced the upregulation of CD86
but decreased the expression of MHCII by M-BMMs.
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Figure 4.7: TGFβ1 down-regulates antigen-presenting capacity of LPS-
primed GM-BMMs and M-BMMs. Bone marrow cells were harvested and
cultured in vitro with the growth factor GM-CSF (1000 units/ml) and M-CSF (5000
units/ml) in the presence of recombinant human TGFβ1 (1 ng/ml or 10 ng/ml) for 7 days
following priming with 100 ng/ml LPS overnight. The TGFβ1-differentiated GM-BMMs
(A) and M-BMMs (B) were analysed for the expression of the surface marker MHCII and
CD86 by flow cytometry. Results are representative of two independent experiments.
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Next, in vitro T cell proliferation assays were performed to assess the effect of
TGFβ1 on the ability of GM-BMMs and M-BMMs to induce OVA-specific CD4+
T cell proliferation. Mature GM-BMMs and M-BMMs were pulsed with OVA pep-
tide and at varying cell numbers co-incubated for three days with T cells harvested
from lymph nodes of OTII transgenic mice. After incubation, 1 µCi [3H]-thymidine
was added to each well and cells were incubated for an additional 18 hours. As a
measure of T cell proliferation, the amount of [3H]-thymidine incorporated into the
cellular DNA was determined by liquid scintillation counting (section 2.7.6).
As shown in Figure 4.8A, GM-BMMs efficiently induced antigen-dependent CD4
T cell proliferation that was significantly inhibited upon TGFβ1 treatment. This
indicated an immunosuppressive effect of TGFβ1 on antigen presenting capacity,
consistent with down-regulated expression of MHCII (Figure 4.7A). In contrast, M-
BMMs failed to induce CD4 T cell proliferation independent of TGFβ1 treatment
(Figure 4.7C) confirming the inability of M-BMMs to act as APCs to induce T cell
proliferative responses.
Recent reports have also shown that MSU crystals exhibit adjuvant activities and
are able to augment the proliferation of T cells by dendritic cells (DCs) [88; 90; 89].
De-En Hu and colleagues have also shown that in a murine tumour model, adminis-
tration of MSU crystals enhanced the tumour rejection process [91]. To investigate
the adjuvant effect of MSU crystals on TGFβ1-differentiated BMMs, OVA-loaded
GM-BMMs and M-BMMs were activated with MSU crystals (200 µg/ml) and pro-
liferation assays were carried out (section 2.7.6).
MSU crystal-activated GM-BMMs were less efficient stimulators of CD4 T cell prolif-
eration (Figure 4.8B, red line) compared to unstimulated GM-BMMs (Figure 4.8A,
red line). TGFβ1 treatment further inhibited the low T cell stimulatory activ-
ity. This indicated that MSU crystal activation of GM-BMMs did not rescue the
inhibitory antigen-presenting effect of TGFβ1. As expected, TGFβ1-differentiated
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M-BMMs did not induce CD4 T cell proliferation upon MSU crystal activation (Fig-
ure 4.8D). Taken together, these findings demonstrated that TGFβ1 suppressed the
antigen presenting and T cell proliferative capability of GM-BMMs indicating that
TGFβ1 switched off the adaptive immune response but promoted the innate im-
mune response by driving a hyper-inflammatory GM-BMM phenotype. In contrast,
M-BMMs were defective in functioning as APCs. Based on these interesting results,
a more detailed phenotypic analysis on TGFβ1-treated GM-BMMs and M-BMMs
was carried out.
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Figure 4.8: TGFβ1 suppresses CD4 T cell proliferation by GM-BMMs.
Bone marrow cells were harvested and cultured in vitro with the growth factor GM-
CSF (1000 units/ml) and M-CSF (5000 units/ml) in the presence of recombinant human
TGFβ1 (1 ng/ml or 10 ng/ml) for 7 days following priming with 100 ng/ml LPS overnight.
Mature GM-BMMs and M-BMMs were loaded with 1 µM ISQ peptide (OVA323−339 pro-
tein) for 2 hours. Unstimulated GM-BMMs (A) or M-BMMs (C) and MSU crystal-
stimulated (200 µg/ml) GM-BMMs (B) and M-BMMs (D) were then co-incubated at
various numbers with T cells harvested from lymph nodes of OTII mice for 3 days. After
incubation, 1 µCi [3H]-thymidine was added to each well and incubated for an additional
18 hours. T cell proliferation was measured by thymidine incorporation using a liquid
scintillation counter. Values are the mean -/+ SEM and representative of three indepen-
dent experiments. ** = P < 0.01, **** = P < 0.0001 (two-way ANOVA with Bonferroni’s
post test).
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4.3.6 Morphology of TGFβ1-differentiated BMMs
First, the effect of TGFβ1 on the morphology of differentiated GM-BMMs and
M-BMMs was investigated. LPS-primed GM-BMMs showed classical macrophage
round shape-like morphology (Figure 4.9A), whereas M-CSF induced a majority
of more elongated tissue-resident macrophage morphology (Figure 4.9B). TGFβ1
treatment, however had no effect on the morphology of GM-BMMs, but induced
more elongated M-BMMs.
untreated 1ng rhTGFβ1 10ng rhTGFβ1
A
B
untreated 1ng rhTGFβ1 10ng rhTGFβ1
GM-BMMs
M-BMMs
Figure 4.9: Morphology of in vitro TGFβ1-differentiated GM-BMMs and
M-BMMs. Bone marrow cells were harvested and cultured in vitro with the growth
factors GM-CSF (1000 units/ml) or M-CSF (5000 units/ml) in the presence of recombinant
human TGFβ1 (1 ng/ml or 10 ng/ml) for 7 days. The differentiated GM-BMMs (A) and
M-BMMs (B) were primed with 50 pg/ml LPS overnight and then examined under a
microscope. Original magnification 40x. Results are representative of three independent
experiments.
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4.3.7 Phenotyping of primed TGFβ1-differentiated BMMs
To determine how TGFβ1 affected the surface phenotype during the differentiation
of GM-BMMs and M-BMMs, LPS-primed GM-BMMs and M-BMMs were anal-
ysed for the expression of a variety of surface markers by flow cytometry (section
2.9). GM-BMMs expressed the common macrophage surface marker F4/80, CD14
and CD11b, and low levels of the M-CSF receptor CD115 and the activation marker
CD86 (Figure 4.10A, red line). Since GM-CSF is widely used to generate monocyte-
derived dendritic cells (DCs) in vitro, the adherent GM-BMMs were also stained
with the DC surface markers CD11c and MHCII. As shown in Figure 4.10A, GM-
BMMs expressed both CD11c and MHCII (red line). TGFβ1 treatment resulted
in the upregulation of the activation marker CD86 and the macrophage matura-
tion marker F4/80 but in the down-regulation of CD11b, CD11c and MHCII (Fig-
ure 4.10A, blue and black line) indicating that TGFβ1-differentiated GM-BMMs
lost their DC-like phenotype and differentiated towards a mature and activated
macrophage phenotype.
LPS-primed M-BMMs also expressed the macrophage surface marker F4/80, CD14
and CD11b (Figure 4.10B, red line). In contrast to GM-BMMs, M-BMMs expressed
low levels of CD11c and MHCII (red line). Previous reports have shown that the
M-CSF receptor CD115 is expressed on macrophages and that signalling through
the CD115 pathway upon activation with M-CSF is involved in regulating growth,
survival and differentiation by monocytes and macrophages [229; 230; 231]. As ex-
pected, M-CSF-differentiated BMMs expressed high levels of the M-CSF receptor
CD115 (Figure 4.10B, red line). TGFβ1 treatment caused the down-regulation of
CD115 expression. TGFβ1 had only minor effects on the expression of F4/80, CD14
and CD11b by M-BMMs. These findings showed that TGFβ1 treatment induced
a less differentiated M-CSF macrophage phenotype (M-BMMs) as indicated by a
down-regulation of CD115.
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Figure 4.10: Surface marker expression by in vitro primed TGFβ1-
differentiated GM-BMMs and M-BMMs. Bone marrow cells were harvested and
cultured in vitro with GM-CSF (1000 units/ml) or M-CSF (5000 units/ml) in the presence
of recombinant human TGFβ1 (1 ng/ml or 10 ng/ml) for 7 days following priming with 50
pg/ml LPS overnight. The TGFβ1-differentiated GM-BMMs (A) and M-BMMs (B) were
analysed for the expression of the surface marker F4/80, CD14, CD11b, CD115, CD11c,
MHCII and CD86 by flow cytometry. Results are representative of three independent
experiments.
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4.3.8 The effect of TGFβ1 on MSU crystal-stimulated GM-BMMs and
M-BMMs
To investigate the effect of TGFβ1 on phenotypic surface changes by stimulated
GM-BMMs and M-BMMs, LPS-primed GM-BMMs and M-BMMs were treated with
MSU crystals (200 µg/ml) for 18 hours and then analysed for the expression of a
variety of surface markers by flow cytometry (section 2.9). TGFβ1 treatment in-
duced the upregulation of the surface marker F4/80, CD14, CD11c and TGFβRII by
unstimulated GM-BMMs (Figure 4.11). MSU crystal-stimulated GM-BMMs signif-
icantly down-regulated the expression of F4/80 and CD11b upon TGFβ1 treatment
but increased the expression of CD11c compared to unstimulated GM-BMMs (con-
trol).
In contrast, TGFβ1 treatment induced a significant down-regulation of the surface
marker F4/80, CD11b, CD115 and TGFβRII on M-BMMs, whereas an upregulation
in CD14 expression (Figure 4.12). MSU crystal-stimulated M-BMMs significantly
down-regulated the expression of F4/80 and CD115 upon TGFβ1 treatment but
increased the expression of CD14, CD11c and CD11b compared to unstimulated
M-BMMs (control). In particular, the abrogation of CD115 expression by TGFβ1-
differentiated M-BMMs indicated the development of a less differentiated M-CSF
macrophage phenotype.
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Figure 4.11: Surface marker expression by MSU crystal-stimulated
TGFβ1-differentiated GM-BMMs. Bone marrow cells were harvested and cul-
tured in vitro with GM-CSF (1000 units/ml) in the presence of rhTGFβ1 (1 ng/ml or
10 ng/ml) for 7 days following priming with 50 pg/ml LPS overnight. After priming,
GM-BMMs were stimulated with MSU crystals (200 µg/ml) or left untreated (control)
for 18 hours. The TGFβ1-differentiated GM-BMMs were analysed for the expression of
the surface marker F4/80, CD14, CD11c, CD11b, CD115 and TGFβRII by flow cytom-
etry. Values are the mean -/+ SEM and representative of up to three experiments. * =
P < 0.05, ** = P < 0.01, **** = P < 0.0001 (two-way ANOVA with Bonferroni’s post
test).
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Figure 4.12: Surface marker expression by MSU crystal-stimulated
TGFβ1-differentiated M-BMMs. Bone marrow cells were harvested and cultured
in vitro with M-CSF (5000 units/ml) in the presence of rhTGFβ1 (1 ng/ml or 10 ng/ml)
for 7 days following priming with 50 pg/ml LPS overnight. After priming, M-BMMs
were stimulated with MSU crystals (200 µg/ml) or left untreated (control) for 18 hours.
The TGFβ1-differentiated M-BMMs were then analysed for the expression of the surface
marker F4/80, CD14, CD11c, CD11b, CD115 and TGFβRII by flow cytometry. Values
are the mean -/+ SEM and representative of up to three separate experiments. * =
P < 0.05, ** = P < 0.01, *** = P < 0.001, **** = P < 0.0001 (two-way ANOVA with
Bonferroni’s post test).
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4.3.9 Enhanced NLRP3 inflammasome activity in TGFβ1-differentiated
GM-BMMs is not induced via ROS
Recent reports have shown that reactive oxygen species (ROS) can also activate
the NLRP3 inflammasome leading to the production of IL-1β after exposure to
different danger signals such as asbestos, silica or MSU crystals [232; 233; 234].
To test whether TGFβ1 was driving this hyper-inflammatory GM-BMM (M1-like)
phenotype via ROS production, LPS primed TGFβ1-differentiated GM-BMMs and
M-BMMs were incubated with the fluorescent dye DHR-123 to measure intracellu-
lar ROS for 5 minutes (section 2.7.7) and then stimulated with either MSU crystals
(200 µg/ml) or phorbol myristate acetate (PMA, control) at 37oC for 45 minutes.
After stimulation, BMMs were placed on ice to stop the reaction, and the expression
of DHR-123 was determined by flow cytometry (section 2.9).
The data in Figure 4.13A and B showed that TGFβ1 treatment did not trigger
an upregulation of the expression of intracellular ROS (DHR-123) by GM-BMMs
independent of whether these cells were stimulated with MSU crystals or PMA or
left untreated. However, M-BMMs treated with 1 ng/ml TGFβ1 significantly down-
regulated the expression of intracellular ROS (DHR-123), which was not observed
at a concentration of 10 ng/ml TGFβ1 (Figure 4.13C and D). This partial effect
of TGFβ1 on intracellular ROS was independent of the stimuli. Collectively, these
results demonstrated that TGFβ1 was driving the hyper-inflammatory GM-BMM
phenotype independent of ROS.
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Figure 4.13: Intracellular ROS production by TGFβ1-differentiated GM-
BMMs and M-BMMs. Bone marrow cells were harvested and cultured in vitro
with the growth factor GM-CSF and M-CSF in the presence of rhTGFβ1 (1 ng/ml or
10 ng/ml) for 7 days following priming with 50 pg/ml LPS overnight. GM-BMMs and
M-BMMs were then incubated with DHR-123 (10 µM) for 5 minutes at 37oC, washed with
D-PBS and stimulated with MSU crystals (200 µg/ml) or PMA (0.2 µg/ml) for 45 minutes
at 37oC. As control, untreated BMMs were incubated at 4oC. After stimulation, cells were
placed on ice to stop the reaction and analysed for the expression of DHR-123 by flow
cytometry. The expression of intracellular ROS (DHR-123) by MSU crystal-activated
or control GM-BMMs (A) and M-BMMs (C) shown as histogram. The expression of
intracellular ROS (DHR-123) by MSU crystal and PMA-stimulated GM-BMMs (B) and
M-BMMs (D). Results are representative of two independent experiments. ** = P < 0.01,
**** = P < 0.0001 (two-way ANOVA with Bonferroni’s post test).
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4.3.10 TGFβ1 does not induce apoptotic cell death by GM-BMMs and
M-BMMs
Recent studies have shown that TGFβ1 can induce apoptotic cell death [235; 236;
237] and that apoptosis by stimulated macrophages can also result in the release of
IL-1β, a form of cell death termed pyroptosis [238; 239; 240]. To determine whether
TGFβ1 was inducing apoptotic cell death in cultured GM-BMMs and M-BMMs
leading the pro-inflammatory response by GM-BMM, TGFβ1-differentiated GM-
BMMs and M-BMMs were stimulated with MSU crystals (200 µg/ml) for 18 hours.
After stimulation, BMMs were harvested and stained with PI to identify live (PI−)
and dead (PI+) cells by flow cytometry (section 2.9). As shown in Figure 4.14,
TGFβ1 treatment did not induce a significant change in the percentage of PI+ cells
upon stimulation indicating that TGFβ1 treatment did not trigger cell death in
GM-BMMs (Figure 4.14A) or M-BMMs (Figure 4.14B).
To further confirm the cell survival data, stimulated GM-BMMs and M-BMMs were
harvested and stained with trypan blue stain. The number of viable cells that did
not contain the dye (trypan blue−) and the dead cells (trypan blue+) were counted
under a microscope and the percentage of live and dead BMMs calculated from the
total cell numbers (section 2.6.6). TGFβ1 treatment did not induce a significant
increase in the percentage of dead GM-BMMs (Figure 4.15A, trypan blue+) or M-
BMMs (Figure 4.15B, trypan blue+). These findings confirmed that the effect of
TGFβ1 in driving this hyper-inflammatory GM-BMM phenotype was independent
of cell death.
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Figure 4.14: Cell viability by TGFβ1-differentiated GM-BMMs and M-
BMMs. Bone marrow cells were harvested and cultured in vitro with the growth factor
GM-CSF (1000 units/ml) and M-CSF (5000 units/ml) in the presence of rhTGFβ1 (1
ng/ml or 10 ng/ml) for 7 days following priming with 50 pg/ml LPS overnight. After
priming, BMMs were stimulated with MSU crystals (200 µg/ml) or left untreated (control)
for 18 hours. GM-BMMs (A) and M-BMMs (B) were stained with PI and the percentage
of live (PI−) and dead (PI+) cells determined by flow cytometry. Results are representative
of two separate experiments.
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Figure 4.15: Cell viability by TGFβ1-differentiated GM-BMMs and M-
BMMs. Bone marrow cells were harvested and cultured in vitro with the growth factor
GM-CSF (1000 units/ml) and M-CSF (5000 units/ml) in the presence of rhTGFβ1 (10
ng/ml) for 7 days following priming with 50 pg/ml LPS overnight. After priming, BMMs
were stimulated with MSU crystals (200 µg/ml) or left untreated (control) for 18 hours.
The percentage of live (trypan blue−) and dead (trypan blue+) GM-BMMs (A) and
M-BMMs (B) determined by trypan blue exclusion under a microscope. Results are
representative of two separate experiments.
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Recent studies have also shown that the process of apoptotic cell death by macropha-
ges can be regulated by a number of different caspases including active caspase
3 [241; 242]. Therefore, another approach was used to prove that the hyper-
inflammatory GM-BMM phenotype was not driven via TGFβ1-induced cell death.
To do so, LPS-primed GM-BMMs and M-BMMs were treated with GolgiStop fol-
lowing stimulation with MSU crystals (200 µg/ml) for 18 hours. The cells were then
stained for intracellular caspase 3 and the percentage of caspase 3+ cells determined
by flow cytometry (section 2.9.2). The percentage of caspase 3+ GM-BMMs did not
significantly change upon TGFβ1 treatment in response to MSU crystals indicating
that TGFβ1 was not inducing cell death (Figure 4.16A). This was also the case for
TGFβ1-treated M-BMMs upon stimulation (Figure 4.16B).
Using three different cell viability approaches, the findings confirmed that TGFβ1
treatment did not result in apoptotic cell death in MSU crystal-stimulated GM-
BMMs and M-BMMs, and therefore suggested that the hyper-inflammatory GM-
BMM phenotype occuring was not a consequence of TGFβ1-mediated cell death via
pyroptosis.
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Figure 4.16: Cell viability by TGFβ1-differentiated GM-BMMs and M-
BMMs. Bone marrow cells were harvested and cultured in vitro with the growth factor
GM-CSF (1000 units/ml) and M-CSF (5000 units/ml) in the presence of recombinant
human TGFβ1 (1 ng/ml or 10 ng/ml) for 7 days following priming with 50 pg/ml LPS
overnight. After priming, BMMs were stimulated with MSU crystals (200 µg/ml) or left
untreated (control) for 18 hours. GM-BMMs (A) and M-BMMs (B) were then stained
for intracellular caspase 3 and the percentage of caspase 3+ BMMs determined by flow
cytometry. Results are representative of two independent experiments.
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4.3.11 TGFβ1-differentiated GM-BMMs require caspase 1 and caspase
8 for IL-1β production
IL-1β production is a tightly regulated cellular process. The cleavage of IL-1β is
triggered by danger signals such as MSU crystals, ROS and LPS [232; 233; 243]
leading to the formation and activation of the NLRP3 inflammasome. The NLRP3
inflammasome consisting of NLRP3, ASC and pro-caspase 1 then activates caspase
1, which triggers the cleavage of pro-IL-1β to release active IL-1β. Whilst the in-
flammasome components contribute to IL-1β processing, it is not clear whether the
production of IL-1β could also occur via a NLRP3-independent pathway in response
to MSU crystal stimulation. Recent reports have shown that caspase 8 exerts non-
apoptotic functions including the suppression of necrotic cell death (necroptosis), in-
hibition of the transcription factor NF-κB and the production of IL-1β [244; 245]. To
determine whether caspase 1 and caspase 8 were regulating MSU crystal-induced IL-
1β production by TGFβ1-differentiated BMMs, primed GM-BMMs and M-BMMs
were treated with the caspase 1 inhibitor YVAD (10 µg/ml) or the caspase 8 in-
hibitor IETD (10 µM), or a combination of both for 30 minutes prior to MSU crystal
stimulation (200 µg/ml) for 18 hours (section 2.7.5). Supernatants from the cell cul-
tures were collected and analysed for IL-1β by ELISA (section 2.8).
TGFβ1 treatment significantly increased the levels of IL-1β by GM-BMMs stim-
ulated with MSU crystals (Figure 4.17A). This IL-1β production significantly di-
minished when GM-BMMs were treated with either the caspase 1 inhibitor (YVAD)
or the caspase 8 inhibitor (IETD) or a combination of both inhibitors. Consistent
with previous results, MSU crystal-stimulated M-BMMs significantly decreased the
levels of IL-1β upon TGFβ1 treatment (Figure 4.17B). These results demonstrated
that the blockade of both caspases effectively blocked M-BMMs IL-1β production
and that both caspase 1 and caspase 8 were required for the production of IL-1β by
MSU crystal-stimulated BMMs.
Chapter 4: The Effect of TGFβ1 on GM-BMMs and M-BMMs 122
A
MSU YVAD IETD
untreated
1 ng/ml rhTGFβ1
10 ng/ml rhTGFβ1
control
IL
-1
β 
[p
g/
m
l]
0
50
100
150
200
YVAD 
      + IETD
****
****
****
MSU
GM-BMMs
B M-BMMs
0
30
60
90
120
IL
-1
β 
[p
g/
m
l]
MSU YVAD IETDcontrol YVAD 
      + IETD
MSU
untreated
1 ng/ml rhTGFβ1
10 ng/ml rhTGFβ1
****
****
****
Figure 4.17: Caspase 1/caspase 8 are involved in IL-1β processing by
TGFβ1-differentiated GM-BMMs. Bone marrow cells were harvested and cultured
in vitro with GM-CSF (1000 units/ml) and M-CSF (5000 units/ml) in the presence of
recombinant human TGFβ1 (1 ng/ml or 10 ng/ml) for 7 days following priming with 50
pg/ml LPS overnight. After priming, BMMs were treated with the caspase 1 inhibitor
YVAD (10 µg/ml) or the caspase 8 inhibitor IETD (10 µM) or a combination of both
for 30 minutes prior to MSU crystal stimulation (200 µg/ml) for 18 hours. IL-1β levels
were measured from the GM-BMM (A) and M-BMM (B) culture supernatants by ELISA.
Results are representative of two independent experiments. **** = P < 0.0001 (two-way
ANOVA with Bonferroni’s post test).
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IL-1β processing via the NLRP3 inflammasome
To investigate the impact of TGFβ1 on the regulation of the NLRP3 inflamma-
some and the generation of IL-1β by MSU crystal-stimulated BMMs as illustrated
in Figure 4.18 (red arrows), cytoplasmic protein from unprimed, LPS-primed and
MSU crystal-stimulated GM-BMMs and M-BMMs were collected and western blot
analysis on the expression of NLRP3, pro-/active caspase 1, ASC, pro-/active IL-1β
and β-actin (used as loading control) performed (section 2.11).
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Figure 4.18: IL-1β signalling pathway in response to MSU crystals. MSU
crystals induce the formation and activation of the NLRP3 inflammasome (NLRP3, ASC,
pro-caspase 1) leading to the activation of caspase 1. Active caspase 1 triggers the cleavage
of pro-IL-1β into active IL-1β for secretion.
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As expected, LPS priming of GM-BMMs induced the upregulation of NLRP3, ASC,
pro-/active caspase 1 and pro-IL-1β compared to unprimed GM-BMMs (Figure 4.19,
red box). In primed GM-BMMs, TGFβ1 treatment caused a decrease in NLRP3,
ASC and pro-IL-1β expression but an increase in pro-caspase 1. Following MSU
crystal stimulation, TGFβ1 treatment increased the expression of pro-caspase 1,
pro-/active IL-1β by GM-BMMs (Figure 4.19, green box).
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Figure 4.19: IL-1β signalling cascade by TGFβ1-differentiated GM-
BMMs. Bone marrow cells were harvested and cultured in vitro with GM-CSF (1000
units/ml) in the presence of rhTGFβ1 (10 ng/ml) for 7 days following priming with 50
pg/ml LPS overnight. After priming, GM-BMMs were stimulated with MSU crystals
(200 µg/ml) or left untreated (control) for 18 hours. From each culture step, cytoplasmic
protein was collected and western blot analysis on NLRP3 (116 kDa), pro-caspase 1 (45
kDa), active caspase 1 (20 kDa), ASC (22 kDa) and pro-IL-1β (35 kDa), active IL-1β (17
kDa) including β-actin (42 kDa) as loading control carried out (section 2.11). Results are
representative of two separate experiments.
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TGFβ1 treatment increased the expression of NLRP3, ASC, pro-/active caspase
1 by LPS-primed M-BMMs (Figure 4.20, red box). In response to MSU crystals,
TGFβ1 treatment triggered an increase in the expression of pro-caspase 1 and pro-
IL-1β by M-BMMs but decreased the expression of active IL-1β (Figure 4.20, green
box) that was consistent with decreased IL-1β levels in culture supernatants (Figure
4.17B).
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Figure 4.20: IL-1β signalling cascade by TGFβ1-differentiated M-BMMs.
Bone marrow cells were harvested and cultured in vitro with M-CSF (5000 units/ml) in
the presence of rhTGFβ1 (10 ng/ml) for 7 days following priming with 50 pg/ml LPS
overnight. After priming, M-BMMs were stimulated with MSU crystals (200 µg/ml) or
left untreated (control) for 18 hours. From each culture step, cytoplasmic protein was
collected and western blot analysis on NLRP3 (116 kDa), pro-caspase 1 (45 kDa), active
caspase 1 (20 kDa), ASC (22 kDa) and pro-IL-1β (35 kDa), active IL-1β (17 kDa) including
β-actin (42 kDa) as loading control carried out (section 2.11). Results are representative
of two separate experiments.
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Taken together, western blot analysis of the NLRP3-dependent signalling pathway
confirmed that TGFβ1 was driving a hyper-inflammatory GM-BMM phenotype by
augmenting active IL-1β expression (Figure 4.19). In contrast, TGFβ1 was con-
tributing to the differentiation of a hypo-inflammatory M-BMM phenotype demon-
strated by down-regulation of active IL-1β (Figure 4.20).
IL-1β processing via caspase 8 and the ripoptosome
The results obtained in Figure 4.17 showed that caspase 8 was also required for IL-
1β production by MSU crystal-stimulated BMMs. Recent reports have shown that
the generation of IL-1β via caspase 8 is associated with the inhibitor of apoptosis
(IAP) proteins [246] and that IAPs can be regulated by TGFβ1 [247]. Caspase 8 is
known to be activated by a complex called the ripoptosome containing pro-caspase
8, FADD, RIPK1 [248] leading to the activation of RIP3, which can cleave IL-1β
[246; 249; 250; 251]. Therefore, it was of interest to investigate the effect of TGFβ1
on caspase 8 activation and further upstream events by MSU crystal-stimulated
BMMs, as illustrated in Figure 4.21. To do so, cytoplasmic protein from unprimed,
LPS-primed and MSU crystal-stimulated GM-BMMs and M-BMMs were collected
and western blot analysis on the expression of pro-/active caspase 8, cIAP1, RIP3,
RIPK1 and β-actin performed (section 2.11).
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Figure 4.21: Signalling cascade via caspase 8 by TGFβ1-differentiated
BMMs. Upon MSU crystal stimulation, BMMs also require caspase 8 for the production
of IL-1β. This involves the association of cIAP1 with the ripoptosome containing RIPK1,
pro-caspase 8 and RIP3, which leads to the activation of caspase 8. Active caspase 8
triggers the cleavage of pro-IL-1β into the active IL-1β form for secretion.
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As shown in Figure 4.22, LPS-primed GM-BMMs expressed pro-caspase 8, cIAP1,
RIP3 and RIPK1 that did not differ from the unprimed cells (red box). TGFβ1
treatment decreased the expression of RIP3 but increased cIAP1, whereas no dif-
ference was observed in the expression of caspase 8 or RIPK1. Upon MSU crystal
stimulation, GM-BMMs down-regulated cIAP1 and active caspase 8 (p18) but the
amounts of active RIP3 or RIPK1 did not change (Figure 4.22, green box). In-
terestingly, MSU crystal stimulation by TGFβ1-treated GM-BMMs triggered the
upregulation of RIP3 compared to unstimulated TGFβ1-treated GM-BMMs. How-
ever, TGFβ1 treatment did not change the expression of caspase 8, cIAP1 or RIPK1
by MSU crystal-stimulated GM-BMMs (green box).
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Figure 4.22: Ripoptosome involved in IL-1β signalling by TGFβ1-
differentiated GM-BMMs. Bone marrow cells were harvested and cultured in vitro
with GM-CSF (1000 units/ml) in the presence of rhTGFβ1 (10 ng/ml) for 7 days following
priming with 50 pg/ml LPS overnight. After priming, GM-BMMs were stimulated with
MSU crystals (200 µg/ml) or left untreated (control) for 18 hours. From each culture step,
cytoplasmic protein was collected and western blot analysis on cIAP1 (70 kDa), RIPK1
(75 kDa), RIP3 (57 kDa), pro-caspase 8 (54/56 kDa), caspase 8 subunits (p41/43), active-
caspase 8 (p18 and p10) including β-actin (42 kDa) as loading control carried out (section
2.11). Results are representative of three separate experiments.
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LPS-primed M-BMMs expressed more pro-/active-caspase 8 and RIPK1 but down-
regulated the expression of RIP3 and cIAP1 compared to the unprimed cells (Fig-
ure 4.23, red box). TGFβ1 treatment increased the expression of RIPK1, RIP3
and cIAP1 in primed M-BMMs. MSU crystal stimulation resulted in the upreg-
ulation of RIP3 and cIAP1, whereas caspase 8 or RIPK1 did not change (Figure
4.23, green box). Interestingly, TGFβ1 treatment triggered the upregulation of
RIP3 and RIPK1 by MSU crystal-stimulated M-BMMs but had no effect on the
expression of caspase 8 or cIAP1 (green box). These findings showed that TGFβ1
treatment down-regulated the expression of RIP3 in GM-BMMs but upregulated
RIP3 expression in M-BMMs.
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Figure 4.23: Ripoptosome involved in IL-1β signalling by TGFβ1-
differentiated M-BMMs. Bone marrow cells were harvested and cultured in vitro
with M-CSF (5000 units/ml) in the presence of rhTGFβ1 (10 ng/ml) for 7 days follow-
ing priming with 50 pg/ml LPS overnight. After priming, M-BMMs were stimulated with
MSU crystals (200 µg/ml) or left untreated (control) for 18 hours. From each culture step,
cytoplasmic protein was collected and western blot analysis on cIAP1 (70 kDa), RIPK1
(75 kDa), RIP3 (57 kDa), pro-caspase 8 (54/56 kDa), caspase 8 subunits (p41/43), active-
caspase 8 (p18 and p10) including β-actin (42 kDa) as loading control carried out (section
2.11). Results are representative of two separate experiments.
Chapter 4: The Effect of TGFβ1 on GM-BMMs and M-BMMs 132
4.3.12 Caspase 8 and caspase 1 interaction in MSU crystal-stimulated
GM-BMMs
The previous results showed that caspase 8 was involved in processing IL-1β by
MSU crystal-stimulated BMMs. However, it remained unclear whether caspase
8 was acting on the processing of IL-1β via the NLRP3-independent pathway or
whether caspase 8 was directly associated with the NLRP3 inflammasome e.g. cas-
pase 1 leading to the generation of a TGFβ1-driven hyper-inflammatory GM-BMM
phenotype. To investigate a possible link between caspase 8 and caspase 1 by
TGFβ1-differentiated GM-BMMs, immunoprecipitation experiments were carried
out. Therefore, GM-BMMs were stimulated with MSU crystals (200 µg/ml) or left
untreated for 18 hours and cytoplasmic protein was collected. Immunoprecipita-
tion (IP) for caspase 1 with protein A - sepharose beads was carried out (section
2.11.5) and the cell lysates as well as the IP samples were co-immunoprecipitated
with the caspase 8 and caspase 1 antibodies by western blot analysis (section 2.11.4)
Immunoprecipitation of caspase 1 in GM-BMMs demonstrates that pro-caspase 1
associated with pro-caspase 8, which was shown by the presence of pro-caspase 8
in the IP caspase 1 samples (Figure 4.24, top red box). Pro-caspase 8 was also
observed in the cytoplasmic protein samples confirming the expression of caspase
8 by GM-BMMs (top blue box). These findings identified an association between
caspase 8 and caspase 1 in GM-BMMs that was enhanced by TGFβ1 treatment.
This indicated that caspase 8 might enhance caspase 1 activity to drive the hyper-
inflammatory GM-BMM response to MSU crystals.
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Figure 4.24: The association between caspase 8 and caspase 1 by TGFβ1-
differentiated GM-BMMs. Bone marrow cells were harvested and cultured in vitro
with GM-CSF (1000 units/ml) in the presence of rhTGFβ1 (10 ng/ml) for 7 days following
priming with 50 pg/ml LPS overnight. After priming, GM-BMMs were stimulated with
MSU crystals (200 µg/ml) or left untreated (control) for 18 hours and cytoplasmic protein
was then collected. Caspase 1 was immunoprecipitated (IP) with protein A - sepharose
beads (section 2.11.5) and co-immunoprecipitated with the caspase 8 and caspase 1 an-
tibodies detected by western blot analysis (section 2.11.4). Results are representative of
one experiment.
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4.4 Summary
In vivo studies have shown that the differentiation of monocytes into a hyper-
inflammatory macrophage phenotype in response to MSU crystals in vivo is driven
by GM-CSF [149][unpublished data, manuscript submitted]. The data herein demon-
strated that TGFβ1 further enhances the hyper-inflammatory GM-BMM phenotype
when present during the differentiation process. Interestingly, TGFβ1 had the op-
posite effect on M-BMMs resulting in suppression of the MSU crystal response.
Activation of IL-1β by GM-BMMs and M-BMMs required both caspase 8 and cas-
pase 1. Western blot analysis showed that TGFβ1 enhanced the hyper-inflammatory
activity of GM-BMMs, which was associated with an upregulation of pro-caspase
1 and pro-/active IL-1β expression. In addition, TGFβ1-treated M-BMMs down-
regulated the expression of active IL-1β that was consistent with decreased IL-1β
production. MSU crystal-stimulated GM-BMMs down-regulated the expression of
RIP3 upon TGFβ1 treatment. The opposite pattern was observed for RIP3 in
TGFβ1-treated M-BMMs indicating that TGFβ1 has a differential effect on the
ripoptosome in GM-BMMs and M-BMMs. Finally, immunoprecipitation on GM-
BMMs showed enhanced caspase 1/caspase 8 interaction in activated cells support-
ing co-dependency of caspase 1/caspase 8 on increased IL-1β production in GM-
CSF-differentiated macrophages.
Together, the findings highlighted the differential effect of TGFβ1 on macrophage
differentiation in acute gouty inflammation. It appeared that TGFβ1 suppresses M-
CSF differentiated macrophages, which are representative of tissue-resident macrop-
hages (M2-like cells) primarily present during the initiation of MSU crystal-induced
inflammation. In contrast, TGFβ1 was driving a pro-inflammatory GM-CSF macro-
phage phenotype (M1-like cells) towards hyper-responsiveness to ongoing inflamma-
tory insults.
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5 The Expression of NK1.1 by Macrophages
5.1 Introduction
During the course of this thesis, macrophages were found to upregulate NK1.1 ex-
pression in response to MSU crystals. NK1.1 is a surface marker, identified by the
PK136 monoclonal antibody [252], that is expressed on other innate cells includ-
ing natural killer T (NKT) cells and natural killer (NK) cells [253; 254; 255]. NK
cells have been reported to interact with cells of the innate immune system such as
monocytes and macrophages with a potential role in modulating gouty inflamma-
tion [83]. A recent study demonstrated that the CD56bright subset of NK cells is
greatly expanded in the synovial fluid of patients with inflammatory arthritis [84]
and can produce large amounts of both pro-inflammatory and anti-inflammatory
cytokines. In a reciprocal contact-dependent activation interface, CD56bright NK
cells were capable of engaging with monocytes [85], indicating the existence of a
positive feedback loop, which could contribute to the amplification of the inflamma-
tory response in acute gout [84].
Data on the functional role of NK1.1 expression is limited. However, previous
studies indicate that signalling through NK1.1 can trigger NK cells to apoptose,
and can activate NKT cells to produce IL-4 [256]. In addition, CD11c+ NK1.1+
dendritic (NKDC) cells have been described as capable of cytotoxic killing of target
cells [257]. To date, the upregulation of NK1.1 by macrophages (F4/80+ CD11b+)
has not been previously reported.
5.2 Aim
The aim of this chapter was to investigate the phenomenon of the upregulation of
the NK1.1 surface expression by macrophages in response to MSU crystals.
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5.3 Results
5.3.1 MSU crystal-stimulated macrophages express NK1.1
The activation of resident macrophages by MSU crystals plays a pivotal role in the
initiation of the inflammatory response driving the production of pro-inflammatory
mediators and cell recruitment [103]. However, little is known about changes in
surface marker expression on MSU crystal-activated macrophages. To confirm MSU
crystal-induced NK1.1 expression, peritoneal macrophages were harvested by lavage
from naive mice (section 2.6.1) and cultured in vitro in the presence of MSU crystals
(200 µg/ml) for 24 hours (section 2.7.8). After incubation, the cells were stained
with fluorescent antibodies for the cell surface marker F4/80, CD11b and NK1.1
and analysed by flow cytometry (section 2.9). Resident peritoneal macrophages were
identified as F4/80+ CD11b+ (Figure 5.1A). Macrophages that had been stimulated
with MSU crystals upregulated the surface marker NK1.1 (red line) compared to
freshly isolated macrophages (black line) and unstimulated cultured macrophages
(blue line) (Figure 5.1B). These results showed for the first time that MSU crystal-
stimulated macrophages upregulate the surface marker NK1.1.
Chapter 5: The Expression of NK1.1 by Macrophages 138
100 101 102 103 104
0
20
40
60
80
100
% of Max
A
%
 o
f M
ax
 In
te
ns
ity
FL2-H: NK1.1-PE
B
FL4-H: CD11b-APC
FL
3-
H
: F
4/
80
-P
er
C
P isotype control
MSU 24hr
untreated 0hr
untreated 24hr
100 101 102 103 104
100
101
102
103
104
FL3-H
66.10.501 69.1
17.113.4
Figure 5.1: NK1.1 expression by MSU crystal-stimulated macrophages.
Peritoneal lavage fluid from naive mice was collected by lavage (3 ml PBS). A Peritoneal
macrophages were identified as F4/80+ CD11b+ by flow cytometry. B Peritoneal cells
were cultured in vitro in the presence of MSU crystals (200 µg/ml) for 24 hours and the
expression of NK1.1 by macrophages (F4/80+ CD11b+) determined by flow cytometry.
Results are representative of eight separate experiments.
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To determine whether NK1.1 upregulation was a general feature of macrophage ac-
tivation, peritoneal macrophages from naive mice were harvested (section 2.6) and
stimulated with 200 µg/ml MSU crystals or 100 ng/ml LPS (section 2.7.8) in vitro
for up to 24 hours. Only MSU crystal-stimulated macrophages exhibited a signifi-
cant and rapid increase in both the percentage of NK1.1+ cells and the expression
of NK1.1 compared to untreated or LPS-stimulated macrophages over time (Figure
5.2A).
Macrophages produce the pro-inflammatory cytokine IL-1β in response to MSU
crystals via the activation of the NLRP3 inflammasome, a pivotal event in MSU
crystal-induced inflammation [97; 61]. Accordingly, supernatants from the cell cul-
ture of MSU crystal and LPS-stimulated macrophages were also collected and anal-
ysed by ELISA for secreted levels of IL-1β (section 2.8). As shown in Figure 5.2B,
the activation of macrophages with MSU crystals induced a significantly stronger
IL-1β response compared to LPS stimulation. These results indicated that the up-
regulation of NK1.1 by MSU crystal-activated macrophages might be linked to IL-1β
production.
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Figure 5.2: Increased NK1.1 expression by macrophages stimulated with
MSU crystals. Peritoneal fluid from naive mice was collected by lavage (3 ml PBS) and
peritoneal macrophages cultured in vitro in the presence of MSU crystals (200 µg/ml) or
LPS (100 ng/ml) for up to 24 hours. At different time points, A the percentage of NK1.1+
macrophages and the expression of NK1.1 determined by flow cytometry, and B culture
supernatants were collected and analysed for IL-1β by ELISA. Values are the mean -/+
SEM and representative of three separate experiments. ** = P < 0.01, **** = P < 0.0001
(two-way ANOVA with Bonferroni’s post test).
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5.3.2 NK1.1 expression by MSU crystal-stimulated macrophages is par-
tially dependent on IL-1β and TNFα
To investigate whether MSU crystal-induced NK1.1 upregulation was linked to IL-
1β production, peritoneal macrophages were harvested (section 2.6) and cultured
in vitro in the prescence of the anti-IL-1β antibody (5 µg/ml) prior to stimulation
with MSU crystals (200 µg/ml) for up to 24 hours (section 2.7.8). At different time
points, supernatants from the cell culture were analysed for the levels of IL-1β by
ELISA and the percentage of NK1.1+ macrophages was determined by flow cytom-
etry. As shown in Figure 5.3A, IL-1β by MSU crystal-stimulated macrophages was
successfully neutralised using an IL-1β neutralising antibody. IL-1β neutralisation
resulted in a decrease in the percentage of NK1.1+ macrophages upon MSU crystal
stimulation (blue line) compared to MSU crsytal-activated macrophages (red line)
(Figure 5.3C).
The activation of macrophages by MSU crystals initiates a signalling cascade via
the stimulation of the NLRP3 inflammasome, which triggers the activation of cas-
pase 1, an enzyme responsible for the cleavage of pro-IL-1β into the active IL-1β
form [121]. To identify a possible link between NK1.1 upregulation and caspase 1,
macrophages were treated with the caspase 1 inhibitor YVAD (5 µg/ml) prior to
MSU crystal stimulation. As shown in Figure 5.3B, inhibition of caspase 1 caused
a significant decrease in the levels of IL-1β by MSU crystal-activated macrophages
that correlated with a decrease in the percentage of NK1.1+ MSU crystal-activated
macrophages (Figure 5.3D). These findings indicated that the NK1.1 upregulation
by MSU crystal-activated macrophages was partially dependent on IL-1β production
via activation of the NLRP3 inflammasome.
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Figure 5.3: NK1.1 expression by MSU crystal-stimulated macrophages
partially dependent on IL-1β. Peritoneal lavage fluids were harvested from naive
mice and macrophages cultured in vitro in the presence of anti-IL-1β antibody (5 µg/ml)
or the caspase 1 inhibitor YVAD (5 µg/ml) prior MSU crystal stimulation (200 µg/ml) for
up to 24 hours. A, B At different time points, culture supernatants from anti-IL-1β (A)
and YVAD (B) treated cells were collected and analysed by ELISA. C, D At different
time points, macrophages were harvested and the percentage of NK1.1+ macrophages from
anti-IL-1β (C) and YVAD (D) treated cells was determined by flow cytometry. Values
are the mean -/+ SEM and representative of two independent experiments. * = P < 0.05,
** = P < 0.01, *** = P < 0.001, **** = P < 0.0001 (two-way ANOVA with Bonferroni’s
post test).
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Macrophages also produce the cytokines IL-6 and TNFα during the initiation phase
of MSU crystal-induced inflammation [103]. To investigate whether IL-6 and TNFα
could modulate MSU crystal-induced NK1.1 expression, macrophages were har-
vested (section 2.6) and cultured in vitro in the presence of anti-IL-6 antibody
(5 µg/ml) or anti-TNFα antibody (5 µg/ml), then stimulated with MSU crystals
(200 µg/ml) (section 2.7.8). As shown in Figure 5.4A, the percentage of NK1.1+,
MSU crystal-activated macrophages was not significantly altered by neutralising IL-
6. However, neutralisation of TNFα resulted in fewer NK1.1+ macrophages upon
MSU crystal stimulation (Figure 5.4B). These findings indicated that NK1.1 up-
regulation by MSU crystal-stimulated macrophages was also partially dependent on
TNFα.
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Figure 5.4: NK1.1 expression by MSU crystal-stimulated macrophages
partially dependent on TNFα. Peritoneal lavage fluids were harvested from naive
mice and macrophages cultured in vitro in the presence of anti-IL-6 antibody (5 µg/ml)
(A) and anti-TNFα antibody (5 µg/ml) (B) prior stimulation with MSU crystals (200
µg/ml) for 24 hours. A, B At different time points, macrophages were harvested and
the percentage of NK1.1+ macrophages from anti-IL-6 (A) and anti-TNFα (B) treated
cells determined by flow cytometry. Values are the mean -/+ SEM and representative of
two independent experiments. * = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** =
P < 0.0001 (two-way ANOVA with Bonferroni’s post test).
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5.3.3 NK1.1 expression by macrophages is specific to MSU crystals
In order to investigate whether changes in urate crystal composition could affect
NK1.1 expression by macrophages, peritoneal macrophages were harvested (section
2.6) and cultured in vitro in the presence of urate crystals with different cations for
24 hours. Macrophage were treated with MSU, calcium urate (CaU), ammonium
urate (NH4U), potassium urate (KU) or magnesium urate (MgU) crystals (section
2.3). In addition to urate crystals, macrophages were also stimulated with cal-
cium pyrophosphate dehydrate (CPPD) crystals, the causative agent in pseudogout
[258; 259]. At different time points, macrophages were harvested, and the percentage
of NK1.1+ cells and the expression of NK1.1 determined by flow cytometry. Only
MSU crystals induced an increase in both the percentage of NK1.1+ macrophages
and the expression of NK1.1 by macrophages (Figure 5.5A).
Macrophages were also tested in vitro for their ability to produce IL-1β in response
to MSU, CPPD, CaU, MgU, NH4U and KU crystals (200 µg/ml). As shown in
Figure 5.5B, only macrophages that had been activated with MSU crystals pro-
duced significant levels of IL-1β. These findings indicated that the phenomenon
of macrophage NK1.1 upregulation was only induced by MSU crystals and not in
response to any other crystal types, and that NK1.1 upregulation was linked with
the production of IL-1β by macrophages.
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Figure 5.5: Macrophage NK1.1 upregulation induced by MSU crys-
tals requires sodium. Peritoneal lavage fluids were harvested from naive mice and
macrophages cultured in vitro in the presence of different crystals (MSU, CPPD, CaU,
MgU, NH4U and KU) at a concentration of 200 µg/ml for up to 24 hours. A At different
time points, cells were collected and the percentage of NK1.1+ macrophages and the ex-
pression of NK1.1 determined by flow cytometry. B Culture supernatants were collected
and IL-1β levels analysed by ELISA. Values are the mean -/+ SEM and representative of
two separate experiments. **** = P < 0.0001 (two-way ANOVA with Bonferroni’s post
test).
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5.3.4 Expression of NK1.1 by MSU crystal-stimulated macrophages is
independent of caspase 8
Macrophages produce IL-1β via the activation of NLRP3 inflammasome leading to
the cleavage of caspase 1 and the maturation of pro-IL-1β into active IL-1β, also
known as the canonical signalling pathway [61; 121; 260]. However, a recent study
describes the involvement of a non-canonical IL-1β activation pathway via caspase
8 activation [245; 261].
To determine whether caspase 8 was involved in the IL-1β signalling cascade and the
upregulation of NK1.1 expressed by MSU crystal-activated macrophages, peritoneal
macrophages were harvested (section 2.6) and cultured in vitro in the presence of
the caspase 8 inhibitor IETD (20 µM and 30 µM) prior to MSU crystal stimulation
(200 µg/ml) for 8 and 24 hours (section 2.7.8). After incubation, supernatants from
the cell culture were collected and analysed for IL-1β by ELISA. As shown in Figure
5.6A, macrophages that were stimulated with MSU crystals produced significantly
more IL-1β compared to untreated macrophages. Consistent with findings in chap-
ter 4, the inhibition of caspase 8 significantly blocked the production of IL-1β by
MSU crystal-activated macrophages. Despite lowering IL-1β production, flow cy-
tometry analysis of macrophages showed that the inhibition of caspase 8 did not
significantly alter the percentage of NK1.1+ macrophages after MSU crystal treat-
ment (Figure 5.6B). These findings showed that the upregulation of NK1.1 by MSU
crystal-activated macrophages was independent of caspase 8.
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Figure 5.6: NK1.1 expression by MSU crystal-stimulated macrophages is
caspase 8-independent. Peritoneal lavage fluids were harvested from naive mice and
macrophages cultured in vitro in the presence of the caspase 8 inhibitor IETD (20 µM and
30 µM). After 1 hour, macrophages were stimulated with MSU crystals (200 µg/ml) or
left untreated. At different time points, supernatants from the cell culture were collected
and the levels of IL-1β (A) analysed by ELISA, and the cells were harvested and the
percentage of NK1.1+ macrophages (B) determined by flow cytometry. Values are the
mean -/+ SEM and representative of two independent experiments. ** = P < 0.01, ***
= P < 0.001, **** = P < 0.0001 (one-way ANOVA with Bonferroni’s post test).
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5.3.5 Peritoneal macrophages express the NK inhibitory receptor Ly49A
Human natural killer (NK) cells and NKT cells have been shown to express recep-
tors specific for major histocompatibility complex class I molecules (MHC class I)
[262; 263] that either activate or inhibit NK cell activities. The ability of NK cells
to kill depends on the balance between the activating killer cell-Ig (KAR) and the
inhibitory killer cell Ig-like (KIR) receptor. In mice, these receptors are defined as
Ly49 NK cell receptors [264; 265]. The Ly49A NK cell receptor has an inhibitory
effect on NK cells and has been shown to bind to self MHC class I molecules on
other cells to stop NK cell killing [266; 267; 268]. The Ly49D activating receptor
on the other hand binds to non-self molecules that are upregulated on stressed or
transformed cells resulting in NK cell-mediated lysis [269; 270; 271; 272; 273]. The
ability of macrophages to express these specific NK cell receptors has not been pre-
viously reported.
To look at Ly49A and Ly49D expression, peritoneal macrophages were harvested
(section 2.6) and cultured in vitro in the presence of MSU crystals (200 µg/ml) for
up to 24 hours (section 2.7.8). At different time points, cells were analysed by flow
cytometry and the percentage of macrophages expressing the NK cell inhibitory re-
ceptor Ly49A and the NK cell activating receptor Ly49D were determined (section
2.9). As shown in Figure 5.7A, the percentage of Ly49A+ macrophages increased
overtime regardless of their activation status. The NK cell activating receptor Ly49D
was not expressed on macrophages (Figure 5.7B). These results showed that the NK
cell inhibitory receptor Ly49A was expressed by cultured macrophages independent
of their activation status, which indicated that macrophages may develop the ability
to recognise MHC class I on other cells.
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Figure 5.7: NK inhibitory receptor expression by macrophages. Peritoneal
lavage fluid was harvested from naive mice and macrophages stimulated in vitro with 200
µg/ml MSU crystals for up to 24 hours. At different time points, macrophages (F4/80+
CD11b+) were harvested and the percentage of NK1.1− and NK1.1+ cells expressing the
NK inhibitory receptor Ly49A (A) and the NK activating receptor Ly49D (B) determined
by flow cytometry. Values are the mean -/+ SEM and representative of two independent
experiment.
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5.3.6 Upregulation of surface NK1.1 by macrophages upon MSU crystal
stimulation but not intracellular NK1.1
The upregulation of NK1.1 by MSU crystal-stimulated macrophages occured rapidly
within the first hour (Figure 5.2A), possibly due to a translocation of an existing
pool of intracellular NK1.1 to the cell surface. To test this, peritoneal macrophages
were harvested (section 2.6) and cultured in vitro in the presence of MSU crystals
(200 µg/ml) for 1 hour. After incubation, macrophages were first stained for sur-
face NK1.1-PE, fixed with formalin and then stained for intracellular NK1.1-FITC
(intracellular staining of cells, section 2.9.2), and analysed by flow cytometry. As
shown in Figure 5.8A, macrophages expressed intracellular NK1.1 (black line). The
intracellular NK1.1 levels did not change upon MSU crystal stimulation (red line)
despite upregulation of extracellular NK1.1 expression by activated macrophages
(red line, Figure 5.8B). These results showed that MSU crystal-induced upregula-
tion of NK1.1 expression by macrophages did not result from the translocation of
NK1.1 from an intracellular store to the extracellular membrane surface.
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Figure 5.8: MSU crystals upregulate surface NK1.1 expression by
macrophages but not intracellular NK1.1. Peritoneal lavage fluid from naive
mice was harvested and macrophages cultured in vitro in the absence (black line) or in the
presence of MSU crystals (200 µg/ml) (red line) for 1 hour. After incubation, macrophages
(F4/80+ CD11b+) were harvested and the percentage of intracellular NK1.1-FITC+ (A)
and surface NK1.1-PE+ (B) determined by flow cytometry. Values are the mean -/+
SEM and representative of two independent experiments.
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5.3.7 NK1.1 expression by MSU crystal-activated macrophages
Macrophages are professional phagocytes [183]. Previous data have shown that
phagocytosis of MSU crystals by macrophages is a primary mechanism involved in
the initiation of MSU crystal-induced inflammation [121]. To determine whether
phagocytosis of MSU crystals was required for NK1.1 expression by macrophages,
peritoneal macrophages were harvested and cultured in vitro in the presence of
the phagocytosis inhibitor CytochalasinD (section 2.7.8), which has been widely
used to block the uptake of apoptotic cells by macrophages [205; 206; 207]. Pre-
vious studies and results in chapter 3 (Figure 3.12C) showed that CytochalasinD
can cause neutrophil membrane disruption and cell death [208; 209; 210]; therefore
the viability of CytochalasinD-treated macrophages was investigated. Treatment of
macrophages with 10 µg/ml CytochalasinD had no effect on the percentage of live
cells (annexinV−, Figure 5.9A) or apoptotic cells (annexinV+, Figure 5.9B) com-
pared to untreated macrophages after 24 hours in culture. Based on these findings,
10 µg/ml CytochalasinD was used to investigate the association between phagocy-
tosis of MSU crystals and NK1.1 upregulation by macrophages.
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Figure 5.9: CytochalasinD does not induce cell death by macrophages.
Peritoneal lavage fluids were harvested from naive mice and macrophages cultured in the
presence of the phagocytosis inhibitor CytochalasinD (10 µg/ml) in vitro for 24 hours.
The percentage of live macrophages (annexinV−) (A) and the percentage of apoptotic
macrophages (annexinV+) (B) was determined by flow cytometry. Values are the mean
-/+ SEM and representative of two independent experiments. *** = P < 0.001 (two-way
ANOVA with Bonferroni’s post test).
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To investigate a possible link between phagocytosis of MSU crystals and NK1.1 up-
regulation by macrophages, peritoneal macrophages were harvested and cultured in
vitro in the presence of the phagocytosis inhibitor CytochalasinD (10 µg/ml) prior to
MSU crystal stimulation (200 µg/ml) (section 2.7.8). After incubation, macrophages
were stained for NK1.1 and culture supernatants analysed for IL-1β by ELISA. As
shown in Figure 5.10A and B, both the percentage of NK1.1+ macrophages and
the NK1.1 expression by macrophages increased in response to MSU crystals (black
bars) compared to untreated macrophages (white bars). The blockade of phagocy-
tosis of MSU crystals resulted in a significant decrease in both the percentage of
NK1.1+ cells as well as NK1.1 expression by macrophages (red bars).
Stimulation with MSU crystals triggered the production of high levels of IL-1β
by macrophages. As expected IL-1β production was significantly decreased when
phagocytosis of MSU crystals was inhibited confirming that the internalisation of
MSU crystals was required for inducing macrophage IL-1β (Figure 5.10C). These
findings confirmed that NK1.1 upregulation by macrophages required phagocytosis
of MSU crystals.
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Figure 5.10: Macrophage NK1.1 upregulation is dependent on phagocy-
tosis of MSU crystals. Peritoneal lavage fluids were harvested from naive mice and
macrophages cultured in vitro in the presence of the phagocytosis inhibitor CytochalasinD
(10 µg/ml) prior MSU crystal stimulation (200 µg/ml) or left untreated for 8 and 24 hours.
A The percentage of NK1.1+ macrophage (F4/80+) from the 24 hour culture was deter-
mined by flow cytometry. B After 8 and 24 hours, the cell culture was analysed for the
percentage of NK1.1+ macrophages and the expression of NK1.1 by flow cytometry. C
Supernatants from the cell culture were analysed for levels of IL-1β by ELISA. Values are
the mean -/+ SEM and representative of two independent experiments. ** = P < 0.01,
**** = P < 0.0001 (two-way ANOVA with Bonferroni’s post test).
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5.3.8 Phagocytosis of apoptotic neutrophils triggers NK1.1 expression
by macrophages
Since the observed upregulation of NK1.1 by MSU crystal-activated macrophages
was a phagocytosis-driven event, it was hypothesised that other phagocytosis events
might also trigger NK1.1 expression. The clearance of apoptotic neutrophils by
macrophages has been reported as a key mechanism involved in the resolution of
MSU crystal-induced inflammation [182; 183; 199]. Therefore, the process of phago-
cytosis of apoptotic neutrophils as a possible mechanism for triggering NK1.1 ex-
pression was investigated. MSU crystal-recruited neutrophils were purified (section
2.6.5) and cultured ex vivo overnight to induce apoptosis as described in section
3.3.4. These apoptotic neutrophils were then co-cultured in vitro with peritoneal
macrophages (apoptotic neutrophils:macrophages, cell ratio 5:1) for 24 hours (sec-
tion 2.7.8). After incubation, macrophages were stained for the surface marker
F4/80, Ly6G and NK1.1, and the percentage of F4/80+ Ly6G+ cells determined by
flow cytometry.
As shown in Figure 5.11A, macrophages that were co-cultured with apoptotic neu-
trophils (F4/80+ Ly6G+) exhibited an increase in both the percentage of NK1.1+
cells and the expression of NK1.1 compared to the single cell population of macroph-
ages (F4/80+ NK1.1+, white bars). It was noted that NK1.1 expression and the
percentage of NK1.1+ cells by macrophage phagocytosis of apoptotic neutrophils
were significantly greater (80 - 90%) than that induced in macrophages stimulated
with MSU crystals (20 - 30%) (Figure 5.10B). The co-culture of macrophages with
apoptotic neutrophils (black bars) did not induce a significant increase in the levels
of IL-1β compared to macrophages only (white bars) (Figure 5.11B). These findings
showed that phagocytosis of apoptotic neutrophils by macrophages was triggering
NK1.1 upregulation and that IL-1β was not essential for increased macrophage
NK1.1 expression.
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Figure 5.11: Phagocytosis of apoptotic neutrophils induces upregulation
of NK1.1 by macrophages. Mice were injected with MSU crystals (3 mg, i.p.). After
18 hours, neutrophils were purified and cultured ex vivo overnight to induce apoptosis.
Apoptotic neutrophils were co-cultured in vitro with naive peritoneal macrophages (cell
ratio 5:1) for 1, 8 and 24 hours. A The percentage of NK1.1+ cells and the expression of
NK1.1 from the single cell populations of macrophages (F4/80+) or the double positive
cells (F4/80+ Ly6G+) determined by flow cytometry. B Supernatants from the cell culture
were analysed for IL-1β by ELISA. Values are the mean -/+ SEM and representative of
two independent experiments. **** = P < 0.0001 (two-way ANOVA with Bonferroni’s
post test).
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To confirm that phagocytosis of apoptotic neutrophils by macrophages was the
primary trigger for NK1.1 upregulation, MSU crystal-recruited neutrophils were
purified (section 2.6.5) and cultured ex vivo overnight to induce apoptosis as de-
scribed above. These apoptotic neutrophils were stained with the neutrophil marker
Ly6G and then co-cultured in vitro with peritoneal macrophages (apoptotic neu-
trophils:macrophages, cell ratio 5:1) in the presence of the phagocytosis inhibitor
CytochalasinD (10 µg/ml). The percentage of macrophages that had phagocytosed
apoptotic neutrophils (F4/80+ Ly6G+) significantly decreased with CytochalasinD
treatment (red bars) compared to the untreated co-culture of macrophages with
apoptotic neutrophils (black bars) (Figure 5.12A).
As demonstrated in Figure 5.12B, blocking phagocytosis with CytochalasinD re-
sulted in a significant decrease in both the percentage of NK1.1+ cells and the
levels of NK1.1 expression by macrophages (F4/80+ Ly6G+, red bars). The IL-1β
levels from the cell culture supernatants showed that the inhibition of phagocyto-
sis of apoptotic neutrophils by macrophages (red bars) did not alter the produc-
tion of IL-1β compared to the untreated co-culture of apoptotic neutrophils and
macrophages (black bars) (Figure 5.12C). Together, these results confirmed that
phagocytosis of apoptotic neutrophils was required to trigger the upregulation of
NK1.1 by macrophages.
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Figure 5.12: Phagocytosis of apoptotic neutrophils is required for NK1.1
expression by macrophages. Mice were injected with MSU crystals (3 mg, i.p.).
After 18 hours, neutrophils were purified and cultured ex vivo overnight to induce apop-
tosis. Apoptotic neutrophils were co-cultured in vitro with naive peritoneal macrophages
(cell ratio 5:1) in the presence of CytochalasinD (10 µg/ml) for 1, 8 and 24 hours. A The
percentage of macrophages that had phagocytosed apoptotic neutrophils (F4/80+ Ly6G+)
determined by flow cytometry. B The percentage of NK1.1+ cells and the expression of
NK1.1 from the single cell populations of macrophages (F4/80+) or apoptotic neutrophils
(Ly6G+) versus the double positive cells (F4/80+ Ly6G+) determined by flow cytometry.
C Supernatants from the cell culture were analysed for IL-1β by ELISA. Values are the
mean -/+ SEM and representative of two independent experiments. **** = P < 0.0001
(two-way ANOVA with Bonferroni’s post test).
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5.3.9 Uptake of fluorescent beads does not induce NK1.1 upregulation
by macrophages
The previous section demonstrated that phagocytosis of MSU crystals and apoptotic
neutrophils triggers macrophage NK1.1 expression. To determine whether NK1.1
upregulation could be triggered by non-specific phagocytic activity, macrophages
were harvested (section 2.6) and incubated with fluorescent beads for 1, 8 and 24
hours (section 2.7.8). After incubation, the phagocytic ability was measured as the
percentage of F4/80+ bead+ macrophages by flow cytometry, and the supernatants
were collected for IL-1β by ELISA. As shown in Figure 5.13A, approximately 40%
of the macrophages (at 1 hour) displayed bead uptake (F4/80+ bead+), which sig-
nificantly increased (up to 90%) after 24 hours.
Phagocytosis of fluorescent beads by macrophages (F4/80+ bead+, black bars)
did not cause a change in the percentage of NK1.1+ macrophages compared to
macrophages cultured alone (F4/80+ bead−, white bars) (Figure 13B). While there
was no difference in the percentage of NK1.1+ macrophages, the expression of NK1.1
decreased to a low background level in the macrophage population that had phago-
cytosed fluorescent beads (F4/80+ bead+, black bars) compared to macrophages
only (F4/80+, white bars). The uptake of fluorescent beads by macrophages did
not induce the production of IL-1β by macrophages, indicating that fluorescent
beads were not able to activate the NLRP3 inflammasome to trigger the release of
IL-1β (Figure 5.13C). These findings showed that phagocytosis of fluorescent beads
by macrophages had no effect on either the expression of NK1.1 or the production
of IL-1β. This indicated that the upregulation of NK1.1 did not occur simply as a
result of general phagocytosis.
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Figure 5.13: Uptake of fluorescent beads has no effect on macrophage
NK1.1 expression. Peritoneal lavage fluids were harvested from naive mice and
macrophages cultured in vitro in the presence of fluorescent beads for 1, 8 and 24 hours.
A The percentage of macrophages (F4/80+) that had phagocytosed fluorescent beads
(F4/80+ bead+) was determined by flow cytometry. B The percentage of NK1.1+ cells
and the expression of NK1.1 in the single macrophage population (F4/80+) and double
positive population (F4/80+ bead+) determined by flow cytometry. C Supernatants from
the cell culture were analysed for IL-1β by ELISA. Values are the mean -/+ SEM and rep-
resentative of two independent experiments. ** = P < 0.01, **** = P < 0.0001 (one-way
ANOVA with Tukey’s post test and two-way ANOVA with Bonferroni’s post test).
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5.4 Summary
The data in this chapter showed that the upregulation of the surface marker NK1.1
by macrophages was a phagocytosis-dependent event occurring via two distinct
mechanisms (Figure 5.14):
A. In acute gouty inflammation, macrophages play an essential role during the ini-
tiation phase, where they become activated through phagocytosis of MSU crystals
leading to the production of pro-inflammatory cytokines such as IL-1β and TNFα.
The findings here indicated that MSU crystal-activated macrophages produce IL-1β
and TNFα, which triggers the upregulation of NK1.1 expression. Therefore, it ap-
pears that the upregulation of NK1.1 by macrophages is an activation-driven event
occurring via an autocrine cell signalling loop.
B. One characteristic feature of the resolution of MSU crystal-induced inflammation
is the clearance of apoptotic neutrophils by macrophages. The results presented in
this chapter demonstrated that the second mechanism triggering the upregulation
of NK1.1 expression is a consequence of phagocytosis of apoptotic neutrophils by
macrophages. This phagocytosis-driven NK1.1 upregulation by macrophages occurs
independently of pro-inflammatory cytokine production and therefore represents a
non-inflammatory event.
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Figure 5.14: NK1.1 expression by macrophages. A Macrophage NK1.1 up-
regulation that is triggered via a phagocytosis-driven MSU crystal-induced inflammatory
response. B Apoptotic neutrophils are phagocytosed by macrophages leading to the up-
regulation of macrophage NK1.1 expression in a cytokine independent manner. TNFα =
tumor necrosis factor alpha; IL-1β = interleukin-1 beta.
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6 General Discussion
6.1 Overview
There have been many studies that have explored the involvement of monocytes,
neutrophils and macrophages in acute gouty inflammation. This thesis provides
further insights into the mechanisms involved in TGFβ1 production during the
spontaneous resolution of MSU crystal-induced inflammation, the effect of TGFβ1
on macrophage differentiation and changes in surface marker expression by MSU
crystal-stimulated macrophages.
6.2 Neutrophils driving the resolution of acute gouty in-
flammation
TGFβ1 has been identified in the synovial fluid of gout patients highlighting a po-
tential role for TGFβ1 in the resolution phase of gout [185; 186]. Consistent with
the clinical observation, the data in chapter 3 also showed elevated levels of TGFβ1
during MSU crystal-induced inflammation in vivo. The clearance of apoptotic neu-
trophils by macrophages leading to the generation of TGFβ1 is considered to be a
characteristic event in the resolution of inflammation [138; 137; 136], including the
shutdown of MSU crystal-induced inflammation [199]. The results of the current
work now identify neutrophil phagocytosis of apoptotic neutrophils as a trigger for
neutrophil TGFβ1 production. This indicates that as well as being involved in the
pro-inflammatory phase of gouty inflammation through the production of ROS and
IL-1β [198; 176], neutrophils contribute to the resolution of acute inflammation via
TGFβ1 production.
Neutrophils are professional phagocytes and recent literature reports that neu-
trophils have the capacity to affect non-inflammatory phagocytosis of apoptotic
neutrophils in vitro and in vivo [211; 274]. Interestingly, the literature reports that
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neutrophil canibalism is a non-inflammatory event [211]. The data herein provide
evidence that TGFβ1 produced by phagocytosing neutrophils suppresses both neu-
trophil respiratory burst and IL-1β production ex vivo. This indicates that rather
than being a passive non-inflammatory neutrophil event, neutrophil canibalism ac-
tively suppresses neutrophil inflammatory functions via TGFβ1.
Neutrophils are known for their ability to produce ROS upon MSU crystal stim-
ulation [82]. It has been shown that ROS can activate the NLRP3 inflammasome
leading to the production of IL-1β in response to MSU crystals indicating a possible
link between ROS and IL-1β [275; 276; 243]. In this study, neutrophil TGFβ1 pro-
duction was shown to suppress both neutrophil ROS and IL-1β production in vitro
indicative of a link between respiratory burst and IL-1β release. However, in vivo
studies showed that although TGFβ1 played a part in suppression of ROS produc-
tion, TGFβ1 was not essential for limiting IL-1β production in MSU crystal-induced
inflammation. This indicates that neutrophil TGFβ1 can control neutrophil ROS
but may be only one of a number of independent mechanisms involved in regulating
the generation of active IL-1β in vivo.
Interestingly, the data show that circulating blood neutrophils can also produce
TGFβ1 upon phagocytosis of apoptotic cells (Figure 3.11). This indicates that
rather than being an inflammatory event, neutrophil clearance and TGFβ1 produc-
tion is most likely a general function of neutrophils. A recent study has shown that
TGFβ1 can be found in detectable concentrations in the human blood of healthy
volunteers [277]. As neutrophils are found in high numbers in the blood, neutrophil
self-clearance and TGFβ1 production may play a passive role in neutrophil turnover
to maintain homeostasis. This mechanism may also play an important role in lim-
iting systemic inflammation where high neutrophil cell death would be present.
Neutrophils are considered to be primarily pro-inflammatory in nature [117; 133;
191]. The data within this thesis show evidence that neutrophils can also exhibit
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anti-inflammatory characteristics through regulating neutrophil inflammatory func-
tions. Together, TGFβ1 produced by canibalising neutrophils has the capacity to
drive the spontaneous resolution of inflammation in gout, and may also play a role
in neutrophil turnover and systemic homeostasis.
Future investigations are needed to unravel the mechanism by which TGFβ1 con-
trols inflammatory functions, such as ROS production by neutrophils. Reports have
shown that upon LPS or fMLP stimulation, neutrophils activate the NADPH oxi-
dase, which leads to the generation of ROS [278; 192; 190]. This raises the question:
Does TGFβ1 regulate the NADPH oxidase leading to suppression of ROS production
by MSU crystal-recruited neutrophils? NADPH oxidase is a multiprotein complex
that consists of membrane-bound subunits (such as NOX2, p22phox, p91phox) and
cytosolic subunits (such as p47phox, p40phox) that upon activation triggers the
production of ROS [243]. Herein, only extracellular ROS production (superoxide)
by neutrophils was measured, therefore it would be also of interest to investigate
the effect of TGFβ1 on intracellular NADPH oxidase activity. One way to inves-
tigate intracellular NADPH oxidase activity by MSU crystal-recruited neutrophils
could be to use a p47phox antibody and measure the expression of p47phox by
western blot analysis, microscopy or flow cytometry [192]. This may provide insight
into the mechanism by which neutrophils self-regulate inflammatory functions via
TGFβ1.
6.3 The effect of TGFβ1 on GM-BMMs and M-BMMs
Macrophages have been shown to play an important role in the initiation and pro-
gression of MSU crystal inflammation in gouty arthritis. Resident tissue macrophages
have been identified to initiate and drive the early inflammatory response [103],
whereas MSU crystal-recruited monocyte/macrophage differentiation has been found
to play an important role in clearance of apoptosing cells and TGFβ1 production
[138], alongside the development of hyper-inflammatory macrophage phenotypes in
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vivo [149]. The results of this study now provide insight into how TGFβ1 levels
may influence these macrophage phenotypes.
TGFβ1 was found to be elevated during both the initiation and resolution phase
of the in vivo inflammatory response to MSU crystals. As the initiation phase of
the inflammatory response is reliant on the resident macrophage phenotype, these
findings suggest that TGFβ1 may influence the inflammatory function of resident
macrophages. The tissue-resident macrophage phenotype is predominantly under
the control of M-CSF [279; 280; 281]. The in vitro data in chapter 4 demonstrate
that TGFβ1 decreases the in vitro production of IL-1β by M-CSF differentiated
(M2-like) macrophages in response to MSU crystals. In vivo administration of
TGFβ1 before or during the early phase of the inflammatory response has been
shown to suppress the inflammatory response to MSU crystals and this suppressive
effect could be reversed by TGFβ1 neutralisation in vivo [161]. Combined with the
findings of the current study, early TGFβ1 production may act to suppress MSU
crystal-induced activation of the resident macrophage phenotype. Interestingly, the
opposite effect was observed when TGFβ1-differentiated M-CSF macrophages were
stimulated with LPS indicating that TGFβ1 induces a M-CSF macrophage pheno-
type tuned for stimulus-specific inflammatory responses.
The presence of TGFβ1 either during or after M-CSF macrophage differentiation
showed that M-BMMs were a less differentiated macrophage phenotype as illustrated
by the down-regulation of the M-CSF receptor CD115, and F4/80. CD115 receptor
expression is important for M-CSF-mediated differentiation and function of M-CSF
macrophages [213; 282]. M-CSF signalling through CD115 has been shown to facil-
itate the activation of signalling pathways including Erk1/2, Akt, and STAT3 that
are involved in the production of inflammatory cytokines by BMMs [283; 284] and
MSU crystal-stimulated macrophages [155]. Accordingly, it is possible that TGFβ1-
mediated down-regulation of CD115 signalling could be associated with the observed
hypo-inflammatory responsiveness of MSU crystal-stimulated M-BMMs.
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A recent study has reported that MSU crystal-recruited monocytes differentiate into
a hyper-inflammatory macrophage phenotype in vivo [149]. Combined with this, re-
search within our group has identified that GM-CSF is required for the development
of this M1-like macrophage phenotype [unpublished data, manuscript submitted].
There is one report showing that TGFβ1 may prime macrophages to express par-
ticulate β1,3-glucan-induced inflammatory gene expression of the platelet-derived
growth factor-B (PDGF-B) transcript [285]. The in vitro data in chapter 4 now show
that TGFβ1 specifically enhances the development of the GM-CSF macrophage in-
flammatory cytokine response to MSU crystals, including release of active IL-1β,
without affecting the response to LPS.
GM-CSF is commonly used in the generation of antigen presenting function in
dendritic cells (DCs) [214; 286; 140; 287]. In the presence of TGFβ1, DCs lose
their ability to present antigen and drive T cell expansion [226; 288]. Here, GM-
CSF macrophages also exhibited APC function that was lost in the presence of
TGFβ1. At the same time, the TGFβ1-generated GM-CSF macrophages increased
the expression of maturation (F4/80) and activation (CD86) markers consistent with
the development of a more mature macrophage phenotype [220; 221; 224]. These
data indicate that TGFβ1 switches off APC functions by GM-BMMs and promotes
the innate immune response to MSU crystals as demonstrated by increased IL-1β
production by MSU crystal-stimulated GM-BMM. Importantly, TGFβ1 needs to be
present during the differentiation process for the development of the GM-CSF driven
hyper-inflammatory phenotype. This is consistent with the environment present in
vivo, where the MSU crystal-recruited monocytes differentiate in the presence of
GM-CSF and elevated TGFβ1. As such, TGFβ1 may contribute towards the devel-
opment of the M1-like macrophage phenotype observed in vivo allowing these cells
to respond with a faster enhanced pro-inflammatory response upon restimulation
[149]. This macrophage phenotype may well contribute towards the exacerbated
inflammatory responses often seen in recurrent gout attacks [149; 289; 290; 291].
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The data show that TGFβ1 increases the expression of CD14 by resting GM-
BMMs and M-BMMs. However, upon MSU crystal stimulation, only the M-CSF
macrophages significantly increased the expression of CD14. Although CD14 and
TLR2/4 have been shown to be involved in MSU crystal-mediated IL-1β produc-
tion by macrophages [96; 58], the data herein showed that the increased CD14 ex-
pression by MSU crystal-stimulated M-BMMs did not correlate with the observed
hypo-responsiveness of TGFβ1-differentiated M-BMMs. This indicates that IL-
1β signalling by MSU crystal-stimulated BMMs could be regulated via a CD14-
independent pathway and that CD14 expression is a poor predictor of inflammatory
responses by different macrophage populations to different stimuli.
Recent reports have shown that in response to different stimuli, macrophages and
DCs can process IL-1β through two independent signalling pathways: the canonical
pathway via caspase 1 and the non-canonical pathway via caspase 8 [245; 292; 246].
The data herein identify for the first time that MSU crystal-stimulated GM-CSF
macrophages require both caspase 1 and caspase 8 for the production of IL-1β, as
illustrated in Figure 6.1A. Furthermore, the TGFβ1-driven hyper-inflammatory re-
sponse by GM-BMM in response to MSU crystals also relies on a caspase 1/caspase
8-mediated interaction as well as on an enhanced NLRP3 inflammasome activity.
In contrast, although TGFβ1-treated M-CSF macrophages showed increased pro-
caspase 1 expression, the cleavage of pro-IL-1β into active IL-1β was blocked con-
sistent with the observed decrease in IL-1β production. It is possible that TGFβ1
blocks caspase 1 cleavage and the interaction between caspase 1/caspase 8, which
would negatively affect IL-1β cleavage by TGFβ1-differentiated M-BMMs, as illus-
trated in Figure 6.1B.
One possible mechanism involved in the differential association of caspase 1 and cas-
pase 8 in TGFβ1-treated macrophages may be the way in which caspase 8 associates
with RIP3. Although RIP3 has been linked to the ripoptosome [293; 251; 249; 294]
associated with apoptotic cell death [295; 296; 297] and to necrotic cell death
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[298; 299; 300], the data herein show that IL-1β production by TGFβ1-differentiated
GM-BMMs in response to MSU crystals was not a consequence of RIP3-mediated
cell death suggesting a cell death-independent role for RIP3. In this study, TGFβ1
caused the down-regulation of RIP3 by MSU crystal-stimulated GM-BMMs, which
could potentially increase the availability of caspase 8 to interact with caspase-1
to drive enhanced inflammasome activation and IL-1β release. In the same way,
upregulated RIP3 expression in MSU crystal-stimulated M-BMMs could result in
increased RIP3/caspase 8 association, thereby limiting the caspase 1/caspase 8 as-
sociation and decreasing IL-1β production.
Further investigations are needed to unravel possible interactions that are initi-
ated by TGFβ1, which contribute to the differentiation of the hyper-inflammatory
GM-BMM phenotype but shutting down the inflammatory functions of M-CSF
macrophages. One way to investigate associations between the inflammasome (such
as NLRP3, ASC), caspase 1, caspase 8 and the ripoptosome is to perform immuno-
precipitation experiments on TGFβ1-differentiated GM-BMMs and M-BMMs that
were stimulated with MSU crystals. This will provide further insight into the mech-
anisms by which TGFβ1 is regulating cellular signalling events by GM-BMMs and
M-BMMs in MSU crystal-induced inflammation.
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Figure 6.1: Proposed signalling pathway by TGFβ1-differentiated GM-
BMMs and M-BMMs in response to MSU crystal stimulation. Red arrows
indicate enhanced responses or upregulation, and blue lines represent inhibitory or sup-
pressive functions induced by TGFβ1.
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6.4 NK1.1 upregulation by macrophages
NK1.1 is a surface marker primarily used to identify NK cells and NKT cells
[253; 254; 255] but has not been previously reported to be expressed on macrophages.
The findings in chapter 5 showed that macrophages upregulated the surface marker
NK1.1 upon phagocytosis of either MSU crystals or apoptotic neutrophils, an event
that did not occur in response to other crystal types or LPS.
The activation of macrophages through phagocytosis of MSU crystals triggers the
production of pro-inflammatory cytokines including IL-1β and TNFα [74; 73; 103;
260; 106]. The observed upregulation of NK1.1 by MSU crystal-activated macrophages
was partially dependent on IL-1β and TNFα autocrine signalling. Although the in-
flammatory environment strongly influences macrophage phenotypes [301; 302; 303],
the absence of NK1.1 expression by LPS-activated macrophages indicates that pro-
inflammatory cytokine production alone is insufficient for triggering NK1.1 upreg-
ulation. Phagocytosis of crystals or beads, without pro-inflammatory cytokine pro-
duction, did not result in NK1.1 upregulation. This indicates that phagocytosis
alone is not sufficient for increasing surface marker expression of NK1.1.
Interestingly, NK1.1 upregulation by macrophages also occurred following non-
inflammatory phagocytosis of apoptotic neutrophils. In this way, phagocytosis-
driven NK1.1 expression by macrophages did not occur simply as a result of general
phagocytosis indicating that macrophage NK1.1 expression is more or less a physi-
ological phagocytosis-mediated process.
At this stage, the exact effect of the observed upregulation of NK1.1 on macrophage
function is unclear and data on the functional role of NK1.1 are limited. A recent
study has shown that signalling through NK1.1 can induce apoptosis by NK cells,
while triggering NKT cells to produce IL-4 [256]. In addition, NKDCs have been
described to exhibit NK cell-like cytotoxic activities [257; 304]. Furthermore, NK
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cells have the ability to kill immune cells, whereby their lytic activity depends on the
balance between killer cell activating (KAR) and killer cell inhibitory (KIR) recep-
tors [264; 265]. Interestingly, the results show that in vitro cultured macrophages
were also able to express KIR but not KAR, and that the expression of KIR by
macrophages was independent of their activation status.
There is limited information on whether macrophages can develop NK cell-like
functions through the expression of KIR [268]. However, in vitro differentiated
GM-CSF and M-CSF bone marrow-derived macrophages stimulated with IL-2 have
been shown to exhibit NK cell cytotoxicity directed against NK-sensitive target cells
[305; 306]. It is therefore possible that the NK1.1-expressing macrophages described
here could also display NK cell-like functions, including regulation of cytotoxic func-
tion by KIR similar to that observed by NK cells [307; 266; 267]. NK cells are found
in the inflamed joints of gout patients and have been linked with the regulation of
MSU crystal-induced inflammation [308; 83; 309; 85; 84].
Finally, these data provide further evidence of the variable expression of NK1.1 on
different immune cells. In addition to the current study showing that macrophages
readily express NK1.1 during inflammation, NKT cells can lose the expression of
NK1.1 upon stimulation with IL-2 [310]. Together, these findings highlight the need
to take extra care, and use multiple surface markers in combination with NK1.1, to
monitor NK or NKT cells in disease settings.
Further research is needed to answer the question of whether NK1.1+ macrophages
develop lytic activity against NK-sensitive target cells. One way to investigate
this is to co-culture MSU crystal-activated macrophages or macrophages that had
phagocytosed apoptotic neutrophils, with CFSE labelled NK-sensitive YAC-1 cells
in vitro. The levels of NK1.1 macrophage-mediated cytotoxicity/cell death could
be determined by flow cytometry using a blue-fluorescent reactive dye. If NK1.1+
macrophages do exhibit cytolytic activity, it would be of interest to investigate
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whether NK1.1+ macrophage-mediated killing is dependent on perforin, a cytolytic
mediator used by NK cells and cytolytic T lymphocytes (CTLs) to kill target cells
[311; 312]. Macrophages from perforin knockout mice could then be used to confirm
this killing pathway. This may provide insight into a possible functional role for
NK1.1 expression by macrophages.
Future studies could be undertaken to determine whether NK1.1 upregulation by
phagocytosing macrophages is associated with TGFβ1 production. The process
of phagocytosis of apoptotic neutrophils by macrophages [183; 313] and by neu-
trophils, as demonstrated in chapter 3, has been linked to the production of TGFβ1.
Therefore it is possible that NK1.1 expression by macrophages might be a TGFβ1-
mediated phagocytosis-driven event. To investigate this, macrophages could be
co-cultured with apoptotic neutrophils in the presence of the anti-TGFβ1 antibody
and the expression of NK1.1 by macrophages determined by flow cytometry. This
would provide insight of whether NK1.1 upregulation by phagocytosing macrophages
occurs via a TGFβ1 autocrine signalling loop.
6.5 Conclusion
The research presented within this thesis focussed on innate immune cells involved
in gouty inflammation, which provides new insights into mechanisms contributing to
the resolution of inflammation as well as the effect of TGFβ1 on the functional phe-
notype of monocyte-differentiated macrophages. A proposed model of acute gouty
inflammation is illustrated in Figure 6.2.
The deposition of MSU crystals within the joint triggers an acute inflammatory
response, which is associated with the generation of cytokines including TGFβ1
and IL-1β primarly produced by tissue resident macrophages referred to as M2-
like macrophages. These inflammatory mediators then trigger the upregulation of
NK1.1 expression by M2-like macrophages and the infiltration of neutrophils to the
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site of inflammation. As neutrophils infiltrate into the joint, their activation by MSU
crystals may further augments the inflammatory response through the production
of superoxide and IL-1β. In addition, circulating monocytes are also recruited to
the joint and over time, these MSU crystal-recruited monocytes differentiate into a
hyper-inflammatory macrophage phenotype (M1-like cells) driven by GM-CSF, a cy-
tokine mainly produced by synoviocytes, macrophages, endothelial cells and T cells.
The self-limiting inflammatory response is associated with the phagocytosis of apop-
totic neutrophils and the production of TGFβ1 by M1-like macrophages and cani-
balising neutrophils facilitating resolution of MSU crystal-induced inflammation.
Interestingly, phagocytosis-derived TGFβ1 has the ability to suppress neutrophil-
inflammatory functions and inflammatory functions of M2-like macrophages in re-
sponse to MSU crystals. While TGFβ1 contributes to the shutdown of neutrophils
and M2-like macrophages, it further primes the hyper-inflammatory GM-CSF macro-
phage phenotype to respond faster to recurring inflammatory insults.
Taken together, this research highlights the importance of the local inflammatory
environment in particular the role of TGFβ1 on the regulation of neutrophil and
macrophage functions during the initiation and resolution phase of acute gouty in-
flammation.
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Figure 6.2: Model of acute gouty inflammation. Red arrows indicate enhanced
responses or upregulation, and blue lines represent inhibitory or suppressive functions
induced by TGFβ1. IL-1β = interleukin-1β; O2
− = superoxide; TGFβ1 = transforming
growth factor β1.
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